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Abstract (300 words) 
Introduction 
Glucagon-like peptide-1 (GLP-1) is an incretin hormone essential for normal human glucose 
homeostasis. Expression of the GLP-1 receptor (GLP-1R) in the myocardium has fuelled 
growing interest in the direct and indirect cardiovascular effects of native GLP-1, its 
degradation product GLP-1(9-36), and the synthetic GLP-1R agonists. Preclinical studies 
have demonstrated cardioprotective actions of all three compounds in the setting of 
experimental myocardial infarction and left ventricular systolic dysfunction (LVSD). This has 
led to Phase 2 trials of native GLP-1 and incretin-based therapies in humans with and 
without Type 2 diabetes mellitus. These studies have demonstrated that GLP-1 is able to 
positively modulate the metabolic and haemodynamic parameters of individuals with 
coronary artery disease (CAD) and LVSD, independent of glycaemic control. 
 
Methods  
The Liraglutide to Improve coROnary haemodynamics during Exercise streSS (LIONESS) trial 
was an investigator-initiated single-centre randomised double-blind placebo-controlled 
crossover proof-of-principle physiological study designed to investigate whether 
Liraglutide, a subcutaneously injectable GLP-1 analogue, could improve exercise 
haemodynamics, as manifest by specific electrophysiological parameters measured through 




Of 105 patients screened, 26 patients were recruited to the trial. Two patients withdrew 
consent prior to trial commencement and two withdrew during the trial to have elective 
CABG surgery. In total 22 patients completed the 6-week crossover trial protocol. There 
was no significant difference between saline placebo versus 1.2 mg Liraglutide or 1.8 mg 
Liraglutide in the rate pressure product achieved at 0.1 mV ST-segment depression or the 
degree of ST-segment depression at peak exercise. Liraglutide did not cause symptomatic 
hypoglycaemia or any other significant adverse effects. 
 
Conclusion 
Liraglutide at 1.2 mg or 1.8 mg daily does not improve exercise haemodynamics when 
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1.1 The Diabetes Pandemic 
In 2012 an estimated 371 million people had diabetes and of those about a half were 
undiagnosed. By 2030 that number is set to expand to 552 million. Type 2 diabetes mellitus 
(T2DM) constitutes 85-95% of all diabetes in high-income nations and may account for an 
even greater proportion in their low- and middle-income counterparts (see Figure 1). As a 
global pandemic, diabetes claimed the lives of 4.8 million people in 2012, half of whom 
were below the age of 60.(1) The predominant cause of morbidity and mortality in diabetes 
is cardiovascular disease (CVD) with at least a two-fold excess risk of developing a multitude 
of vascular pathologies including ischaemic heart disease, different stroke subtypes, 
peripheral arterial disease and heart failure.(2,3) Indeed as many as 80% of T2DM patients 
will develop and possibly die of macrovascular complications.(3) Such stark findings have 
led many to regard diabetes as a coronary heart disease (CHD) risk equivalent, to a level at 
which non-diabetic individuals with a previous history of acute coronary syndrome (ACS) 
would reside. 
 
For many years this enhanced cardiovascular risk was thought to be a solely 
atherosclerosis-driven process characterised by endothelial cell dysfunction, oxidative 
stress, vessel remodelling, impaired vasodilatation and subendothelial plaque formation. 
More recently however the concept of the vulnerable patient has emerged to highlight the 
complex interplay between a constellation of deleterious processes spearheaded by, not 
only the vulnerable vessel/plaque, but also vulnerable blood constituents and a vulnerable 
myocardium; that together shift an individual towards a greater susceptibility to developing 
cardiovascular complications (see Figure 2).(4,5) It is therefore incumbent upon 
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cardiologists to recognise the pathophysiological intersection running through diabetes and 
CVD and thereafter aim to institute timely management of the glycaemic control and 
heightened cardiovascular risk dichotomy. 
 
Figure 1 The International Diabetes Federation Diabetes Atlas 2012 Update(1) 
Diabetes has become a truly global pandemic. Urbanisation, changes in lifestyle and developing health systems 
combine to increase individual risk for developing diabetes. 
 
Intensified glucose-lowering therapy to curtail major adverse cardiovascular and 
cerebrovascular events (MACCE) would seem the obvious place to start. Trial data however 
have been inconsistent. Tight maintenance of blood glucose concentrations close to the 
normal range was shown to delay the onset and slow the progression of microvascular 
complications in Type 1 and T2DM in the DCCT/EDIC and UKPDS trials respectively.(6,7) 
Results from the latter did go on to demonstrate a reduction, albeit less pronounced 
relative to microvascular sequelae, in the incidence of macrovascular complications after 10 
years of post-trial follow-up as more events occurred.(8) The PROactive Study of 
pioglitazone versus placebo in T2DM patients at high risk of macrovascular events did 
demonstrate a significant reduction of the secondary composite endpoint of all-cause 
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mortality, non-fatal myocardial infarction (MI) and stroke.(9) It did not however reach its 
primary composite endpoint from the time to randomisation to all-cause mortality, non-
fatal MI, stroke, ACS, endovascular/surgical intervention or amputation above the knee. 
Conversely large contemporary multicentre randomised trials of intensive glucose control 
such as ACCORD, ADVANCE and VADT have not shown a significant reduction in the rates of 
macrovascular events. Indeed the strategy was shown to increase mortality in 
ACCORD.(10–12) Overall a meta-analysis of the 33040 participants recruited to UKPDS, 
PROactive, ADVANCE, VADT and ACCORD found a 17% reduction in non-fatal MI and a 15% 
reduction in CHD but no significant changes in stroke or all-cause mortality.(13) An 
extended follow-up (median 9.8 years) of the VADT trial did reveal a significantly lower risk 
of time to first major cardiovascular event (p=0.04) but intensive glucose lowering did not 
reduce cardiovascular mortality.(14) Moreover the very drugs commonly used to intensify 
glucose control in these trials, such as rosiglitazone and first- and second-generation 
sulphonylureas, have themselves been independently associated with adverse 
macrovascular sequelae.(15,16) As such current European recommendations support an 
individualised approach to intensive glycaemic control taking in to account age, duration of 
T2DM and history of CVD.(17) Of late the therapeutic goal of alleviating MACCE as an 
adjunct to glycaemic control has been put to one side in favour of a shift in emphasis 
towards first demonstrating the cardiovascular safety of any novel antidiabetic agent. 
Incretin hormone-based therapies are a case in point. Emerging evidence over the last 
decade has indicated a signal of not only cardiovascular safety but also direct and indirect 
cardiovascular benefit emanating from native glucagon-like peptide-1 (GLP-1), its receptor 
agonists and the dipeptidyl peptidase-4 (DPP-4) inhibitors. This relatively new class of 
antihyperglycaemic agent is already well established as adjunctive therapy for optimal 







Endothelial dysfunction caused by: 
• hyperglycaemia 
• adipose tissue-derived inflammatory cytokines 
• CV risk factors  
Chemotaxis of monocytes and lymphocytes in to the 
activated endothelium provokes an inflammatory cascade 
leading to fatty streak deposition and ultimately plaque 
formation. Based on the study of culprit plaques, a vulnerable 
plaque can be defined according to: 
Major criteria 
• active inflammation (monocyte/macrophage +/- T-cell 
infiltration) 
• thin cap + large lipid core 
• endothelial denudation + superficial platelet 
aggregation 
• fissured plaque 
• stenosis >90% 
Minor criteria 
• superficial calcified nodule 
• glistening yellow 
• intraplaque haemorrhage 
• endothelial dysfunction 
• outward (positive) remodeling 
Note the associated reduction in the release of NO as a 
consequence of endothelial dysfunction. NO is beneficial: 
• mediates endothelium-dependent vasodilatation 
• reduces LDL levels 
• suppresses platelet aggregation 
Vulnerable blood 
• Activated visceral adipose tissue produces inflammatory 
cytokines such as PAI-1, IFN-γ and IL-6 
• Systemic prothrombotic milieu created through 
interaction of increased levels of fibrinogen with PAI-1 
• PAI-1 levels upregulated in diabetes and is 
independently associated with cardiovascular risk – a 
hypofibrinolytic state 
• Platelets are hyper-reactive in diabetes leading to 
accelerated susceptibility to activation and aggregation 
• Diabetes elevates TF levels leading to an increased 
propensity to thrombus formation – a hypercoagulable 
state 
• TF-bearing microparticles, vesicles released from 
various cell lines, are increased in diabetes 
Vulnerable myocardium 
• Certain myocardial factors can influence the development 
of ACS, heart failure and ultimately sudden cardiac death 
• Sympathetic hyperactivity can lead to life-threatening 
ventricular tachyarrhythmias 
• Increased vagal tone has an antifibrillatory effect 
• Note the autonomic neuropathy of T2DM 
• Metabolic modulation from glucose to fatty acid oxidation 
in the diabetic heart increases myocardial oxygen demand 
• Diabetes associated with hypertrophy, ventricular stiffness, 
diastolic dysfunction and microangiopathy 
The Vulnerable Patient 
Figure 2 The Vulnerable Patient at High Risk of 
Cardiovascular Complications 
The vulnerable patient is an individual who is at a 
heightened risk of suffering an acute coronary syndrome 
or sudden cardiac death based on the interaction 
between a constellation of deleterious processes 
emanating from vessel/plaque, blood and myocardial 
vulnerability. There are excellent articles in the medical 
literature that provide a far more detailed description of 
this pathophysiologcial interplay.(3–5) 
Key: NO=nitric oxide; LDL=low-density lipoprotein; PAI-
1=plasminogen activator inhibitor-1; IFN-γ=interferon 
gamma; IL-6=interleukin-6; TF=tissue factor; ACS=acute 
coronary syndrome 
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1.2 The Incretin Concept 
The incretin concept has evolved from the observation that an oral load of glucose can 
provoke a two- to three-fold more potent insulinotropic stimulus when compared to an 
isoglycaemic intravenous administration of glucose.(18) This led to the discovery of the 
incretin (INtestinal seCRETion of INsulin) hormones, which form part of the glucagon 
superfamily and are released from the intestine in response to enteral nutrition (Figure 3). 
Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin hormone to be 
identified from purified porcine intestinal extracts.(19) It is a 42-amino acid peptide made 
by duodenal and jejunal enteroendocrine K cells in the proximal small bowel. Glucagon-like 
peptide-1 (GLP-1) was next isolated, a 30-amino acid cleavage product of proglucagon 
produced by the enteroendocrine L cells of the distal ileum and colon, present in two 
equipotent molecular forms: GLP-1(7-37) and GLP-1(7-36), the latter moiety being most 
abundant in the circulation postprandially. Despite their origin, plasma levels of GLP-1 and 
GIP rise within minutes of eating pointing to a combination of neural and endocrine signals 
stimulating their secretion.(20)  
 
Both GLP-1 and GIP are fundamental to maintaining glucose homeostasis in humans. 
Together they account for 50-70% of total insulin secreted following an oral glucose load. 
They act via structurally independent G-protein coupled receptors (GPCR).(20) The GLP-1 
receptor (GLP-1R) is a heptahelical GPCR expressed widely in several tissue beds (Figure 3). 
It is found in pancreatic islet α and β cells together with sites in the central and peripheral 
nervous systems, alimentary canal, kidney, lung and heart.(21) Previously there had been 
debate over GLP-1R expression in liver, adipose tissue and skeletal muscle but recent 
evidence suggests this does in fact take place.(22–27) Binding of GLP-1 to the GLP-1R on 
 22 
islet β cells stimulates the production of adenylate cyclase leading to an increase in 
intracellular cyclic adenosine monophosphate (cAMP) and activation of the protein kinase A  
Figure 3 The Physiology of Glucagon-Like Peptide-1 
In line with the ubiquity of the GLP-1 receptor, GLP-1 mediates several pleiotropic physiological effects outside 
of those actions directly related to normal body glucose homeostasis. Incretin-based therapies either provide 
pharmacologic levels of an exogenous GLP-1R stimulus or preserve physiologic levels of endogenous GLP-1. 
Key: GLP-1=glucagon-like peptide-1; GLP-1R=glucagon-like peptide-1 receptor.(20,21,25,26) 
 
(PKA) signalling pathway. This is followed ultimately by an increase in cytosolic calcium 
levels and insulin exocytosis immediately thereafter.(26,28) GLP-1 and GIP contribute 
almost equally to, and have an additive effect on, enhancing insulin exocytosis at the start 
of a meal, although the effect of GLP-1 tends to predominate at higher glucose levels.(29) 
The sustained dual action of GIP and GLP-1 is also associated with stimulation of β-cell 
proliferation (whereas T2DM is characterised by a progressive decline in β-cell function), 




























































biosynthesis.(20) In parallel with the ubiquity of the GLP-1R, GLP-1 also strongly inhibits 
glucagon secretion (pancreatic islet α cells); delays gastric emptying and reduces food 
intake (stomach); induces satiety (brain); and increases glucose uptake peripherally (muscle 
and adipose tissue) (Figure 3).(26,30) Both compounds are rapidly degraded by the enzyme 
dipeptidyl peptidase-4 (DPP-4), which cleaves 2 amino terminal peptides from GLP-1(7-36) 
to form the GLP-1(9-36) metabolite (see Figure 3).(31) As a result GLP-1 has a half-life of <2 
minutes which means only 10-20% of total plasma GLP-1 is biologically active.(32) GLP-1 
and GIP are both cleared mainly by the kidneys. 
 
1.3 The Incretin Effect in Type 2 Diabetes Mellitus 
There is a defective incretin effect in both lean and obese T2DM patients.(33) Levels of GIP 
secretion can be increased after enteral nutrition, but its insulinotropic effect is severely 
depressed. As a result even supraphysiologic doses of GIP cannot further augment 
postprandial insulin secretion.(34,35) In contrast, meal-stimulated levels of GLP-1 secretion 
are significantly reduced. This is particularly the case in obese type 2 diabetics where the 
inherent insulin resistance of obesity may well be a contributing factor.(36) A continuous 
infusion of exogenous GLP-1 can however result in near normal insulin responses to a 
glucose load, suggesting preservation of insulinotropic activity (see Figure 4).(37,38) This 
fundamental difference between the predominant incretin hormones has meant that much 
of the focus has been drawn towards GLP-1. Furthermore GLP-1 does not cause 
hypoglycaemia, since its stimulatory effect on insulin secretion and its inhibitory action on 
glucagon release switch off when ambient glucose levels are <4 mmol/L.(39) Despite these 
benefits, the clinical utility of native GLP-1 as a therapeutic vehicle in T2DM is profoundly 
limited by its short half-life. As such novel treatment strategies to bypass this endogenous 
cul-de-sac have been engineered. Injectable GLP-1R agonists are an exogenous source of 
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degradation-resistant peptide with improved pharmacokinetic properties that act directly 
on the human GLP-1R and DPP-4 inhibitors are small molecules with clinically useful oral 
bioavailability that shield the endogenous peptide from degradation and thereby enhance 
its innate insulinotropic activity.(20) In essence GLP-1R agonists provide pharmacologic 
levels of a GLP-1R stimulus whereas DPP-4 inhibitors preserve physiologic levels of 
endogenous GLP-1 (see Figure 3).(40) The extent to which DPP-4 inhibitors elevate GLP-1 
and GIP levels is in the picomolar range whereas GLP-1R agonist-mediated augmentation is 
in the nanomolar range. 
 
Figure 4 A Comparison of the Incretin Effect in Healthy and Type 2 Diabetic Individuals 
In healthy subjects there is a two- to three-fold increase in insulin secretion following an oral glucose load 
compared with an isoglycaemic glucose infusion mediated by the action of the incretin hormones glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). In Type 2 diabetics this incretin 




1.4 Incretin Mimetics  
1.4.1 Glucagon-Like Peptide-1 Receptor Agonists 
In April 2005 Exenatide (trade name Byetta®) was the first GLP-1R agonist to be approved 
for use in T2DM by the Food and Drug Administration (FDA) and later by the European 
Medicines Agency (EMA) in November 2006. It is a 39-amino acid synthetic analogue of 
exendin-4 and a mimetic compound of endogenous GLP-1 with 53% homology. Exendin-4 is 
a naturally occurring peptide discovered during the search for biologically active 
compounds in the salivary secretions of the Gila monster lizard.(41) Exenatide is also DPP-4 
resistant and has a half-life of 2.4 hours necessitating a twice-daily subcutaneous injection 
formulation. Exendin-4 is exclusively cleared by the kidneys(42) and as such Exenatide is 
contraindicated in T2DM patients with severe renal impairment or end stage renal disease 
and used with caution in those post renal transplantation.(40,43)  
 
More recently Exenatide LAR (trade name Bydureon®), a longer-acting formulation 
administered once weekly has received European Union marketing authorisation in April 
2011 and FDA approval in January 2012. Its development has been stimulated by data that 
suggest the transient gastrointestinal side effects common to all GLP-1R agonists could be 
attenuated by achieving peak drug concentrations more slowly over time. Exenatide LAR 
has been developed using biodegradable polymeric microspheres that entrap the active 
agent and allow for gradual drug delivery at controlled rates. A plasma level of Exenatide 
>50 pg/mL, which is known to reduce fasting plasma glucose concentration, is observed 
after approximately 2 weeks of treatment.(44) 
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Liraglutide (trade name Victoza®), a synthetic analogue that shares 97% structural 
homology to native GLP-1, has been available in Europe since July 2009 and received FDA 
approval in January 2010. It avoids DPP-4 degradation via an amino acid substitution 
(arginine for lysine at position 34) and insertion of a fatty acid chain to the lysine at position 
26, allowing it to bind to albumin which also prevents renal elimination (Figure 5).(31) 
Indeed, since no single-organ system is primarily responsible for Liraglutide elimination, 
those patients with hepatic or renal impairment may not require dose adjustment.(30) 
Moreover Liraglutide is not directly nephrotoxic although there have been postmarketing 
reports of acute renal failure or exacerbation of underlying renal dysfunction, mainly as a 
result of those experiencing the known side effects of the drug such as nausea, vomiting 
and diarrhoea which in turn have presumably caused dehydration.(45) It can be used as an 
adjunct to diet, exercise, and in combination with standard oral antidiabetic medications to 
improve glycaemic control in T2DM. It has a half-life of approximately 10-14 hours after 
subcutaneous administration which allows its use as a once-daily preparation, potentially 
maximising drug compliance.(20)  
 
 
Figure 5 The Molecular Structure of Liraglutide (Victoza) Compared with Native Human GLP-1 
(Taken from Victoza Summary of Product Characteristics, NovoNordisk Ltd, UK, December 2010.) 
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Of note chronic Liraglutide administration in rodents has been linked with activation of 
GLP-1R-mediated calcitonin release, up-regulation of calcitonin gene expression, and 
subsequent C-cell hyperplasia.(46) With rats in particular, Liraglutide has been linked with 
C-cell adenomas and carcinomas such as medullary thyroid carcinoma (MTC).(47) This, 
however, has not been replicated in primates administered >60 times human exposure 
levels over a 20-month period(46) or in human T2DM subjects receiving Liraglutide over a 
2-year period when compared with non-diabetic obese controls.(47) These results probably 
indicate important inter-species differences in GLP-1R expression and effects on the thyroid 
gland. Nevertheless Liraglutide is contraindicated in patients with a personal or family 
history of MTC and in those with multiple endocrine neoplasia type 2 until the long-term 
effects of chronic therapy on the thyroid are known.(45) Both Exenatide and Liraglutide 
have also been associated with fatal and non-fatal haemorrhagic or necrotising pancreatitis 
during postmarketing surveillance.(43,45,48,49)  
 
Experimental data tells us GLP-1R agonists can expand β cell mass in rodents.(50,51) 
Although animal data cannot be conclusively extrapolated to human trials, there is the 
tantalising prospect that these agents could delay the progression of T2DM through 
increased β-cell proliferation, inhibition of β-cell apoptosis and enhanced differentiation of 
adult stem cells in the ductal pancreatic epithelium.(50,51) Conversely, the activation of the 
very same signalling pathways stimulated by the interaction of GLP-1R with its substrate 
could accelerate tumourigenesis in the pancreas.(49,51,52) Although a purely hypothetical 





Lixisenatide (trade name Lyxumia®) is derived from the first 39 amino acids of exendin-4 
and modified at its C-terminal by the addition of 6 lysine residues thereby affording 
resistance to DPP-4 degradation. It has greater affinity to the GLP-1R than native human 
GLP-1(7-36) in vitro.(53) Given once daily, it received a European Commission marketing 
authorisation for T2DM in February 2013. Despite this, a New Drug Application to the FDA 
was withdrawn in September 2013 and will not be resubmitted until the results of the 
ELIXA cardiovascular outcomes study published in December 2015 are fully analysed. 
 
Albiglutide (trade name Eperzan® in Europe and Tanzeum® in the United States) is a GLP-1 
dimer administered once weekly, which also has 97% homology to the native peptide. It is 
fused to human serum albumin thus extending its plasma half-life.(30) Albiglutide was 
approved for use by the European Medicines Agency in March 2015 and by the FDA in April 
2015. It is indicated as monotherapy or in combination therapy with metformin, 
glimepiride, pioglitazone, or insulin. Dulaglutide (trade name Trulicity®) received European 
marketing authorisation in November 2014 and was launched in the UK in January 2015. 
The FDA approved it in September 2014. It too comes as a once-weekly injectable 
preparation recommended as monotherapy when diet and exercise alone do not provide 
adequate glycaemic control in those intolerant of, or who have contraindications to, the 
use of metformin. It can also be used as add-on therapy to other glucose-lowering 
medications including insulin when these, together with diet and exercise, do not provide 
adequate glycaemic control. Taspoglutide is another long-acting GLP-1R agonist with 93% 
homology to endogenous GLP-1. It has since been discontinued however, due to 




Current National Institute for Health and Clinical Excellence (NICE) guidance recommends 
the use of incretin mimetics (such as Liraglutide and Exenatide) as either part of a triple 
therapy regimen when adequate glycaemic control is not achieved with metformin plus a 
sulphonylurea/thiazolidinedione or as a dual therapy package with metformin or 
sulphonylurea if the patient has had an adverse reaction to or is intolerant of metformin or 
a sulphonylurea, or thiazolidinediones and DPP-4 inhibitors.(56,57) The therapeutic niche 
for Lixisenatide has not yet been formalised by NICE until the publication of the clinical 
guideline for the management of T2DM update. The 2012 International Diabetes 
Federation (IDF) Global Guideline for T2DM recommends the use of GLP-1R agonists as a 
third-line agent to achieve appropriate glycaemic control.(58) A GLP-1R agonist may be 
recommended over a DPP-4 inhibitor when weight loss is a priority and if greater 
reductions in HBA1c are required. 
 
1.4.2 Dipeptidyl Peptidase-4 Inhibitors 
DPP-4 is a 766 amino acid cell surface serine aminopeptidase enzyme that cleaves N-
terminal dipeptides from proteins containing proline or alanine in the penultimate 
position.(30,59) DPP-4 can be found on the surface of epithelial, endothelial, immune and 
dendritic cells of the lung, pancreas, kidney, blood vessels, thymus, lymph nodes, spleen 
and brain respectively.(59) Monocytes, for instance, express high baseline levels of DPP-4 
that are further increased in pro-inflammatory states like obesity and T2DM. As such DPP-4 
is responsible for cleaving several peptides outside of the established GLP-1 biological 
perimeter, a variety of which mediate potentially beneficial actions on the myocardium and 
vasculature (see Table 1).(59–61) DPP-4 and aminopeptidase P are also responsible for the 
degradation of bradykinin, more so when the activity of angiotensin-converting enzyme 
(ACE), the predominant modulator of bradykinin and substance P activity, is being 
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attenuated by a pharmaceutical inhibitor.(62) Both bradykinin and substance P (see Table 
1) increase vascular permeability, which can lead to angioedema if allowed to accumulate, 
and their activity is left unchecked. ACE-inhibitors (ACEi) are commonly associated with 
angioedema. The theoretical premise of ACEi and DPP-4 inhibitors acting in tandem to 
further potentiate the risk of angioedema gains further credence when you consider a 
significant proportion of the T2DM population also suffer from hypertension and ACEi are 
indicated for renal protection. A combination of case report, retrospective cohort, FDA 
postmarketing and meta-analysis data confirm an increased risk of angioedema in patients 
taking both ACEi and DPP-4 inhibitor compared with DPP-4 inhibitor therapy alone; 
although the absolute risk remains small.(63–65) Healthcare providers must therefore be 
especially judicious when attributing a hypersensitivity reaction like angioedema solely to 
an ACEi, especially when the hypertensive diabetic patient may have been on the drug for 
several years, and overlook the presence of a DPP inhibitor in the therapeutic regimen, 
which may have been commenced only a few months before.(62) 
 
The level of biologically active GLP-1 made available by oral DPP-4 inhibitor therapy is 
typically 3- to 5-fold less than that provided by GLP-1R agonists.(20) Moreover, these 
agents lower glucose through both GLP-1R- and GIP receptor-mediated pathways,(66) and 
perhaps more significantly, pose the risk of modifying levels of other bioactive DPP-4 
substrates.(59–61) Therefore, an identical spectrum of adverse events should not be 
inferred upon both drug classes although, much like their GLP-1R agonist counterparts, 
DPP-4 inhibitors have also been linked with an increased risk of developing acute 
pancreatitis in postmarketing reports and a population-based matched case-control 
study.(48,49) Of greater concern is a tenuous link to pancreatic duct metaplasia with the 
use of Sitagliptin in particular and the immunomodulatory actions of DPP-4 inhibition 
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potentially upgrading the risk for all cancers in general.(49,52) This remains a theoretical 
concern with retrospective cohort and meta-analysis evidence demonstrating no excess risk 
of all cause hospital admission and death or cancer associated with DPP-4 inhibitors.(67,68) 
The quality of data from these latter studies are fraught with limitations. Nevertheless the 
FDA recommend continued licensed use of these agents until further long term prospective 
data is available.(69,70) 
 
Table 1 Other DPP-4 substrates and their cardiovascular effects (59–61) 
 
Key: GIP=glucose-dependent insulinotropic peptide; GLP-2=glucagon-like peptide-2; NPY=neuropeptide Y; 
PYY=peptide YY; SP=substance P; BNP=brain natriuretic peptide; SDF-1α=stromal cell-derived factor-1α 
 
Type and Name of Substrate DPP-4 Effect Target Tissue Cardiovascular Effect 
Regulatory 
peptides 
GIP(1-42) Inactivate Adipose tissue Promotes fatty acid metabolism 
 GLP-2(1-33) Inactivate Blood vessels Increased blood flow, heart rate 
and blood pressure 
Neuropeptides NPY(1-36) Altered receptor 
subtype specificity 
Myocardium Increased calcium current 
   Brain Increased appetite 
   Adipose tissue Increased adipocyte 
differentiation and decreased 
lipolysis 
 NPY(3-36) Altered receptor 
subtype specificity 
Blood vessel Increased angiogenesis 
   Adipose tissue Increased lipogenesis 
 PYY(1-36) Altered receptor 
subtype specificity 
Blood vessel Increased collateral blood flow 
   Adipose tissue Decreased lipolysis 
 SP(1-11) Inactivate Myocardium Reduced chronotropic and 
inotropic effect 
   Brain Altered cardiac adrenergic tone 
 BNP(1-32) Reduced activity Myocardium Attenuation of left ventricular 
remodelling 
   Blood vessel 
 
Increased vasodilatation 
   Kidney 
 
Increased natriuresis 
 BNP(3-32) Reduced activity Kidney 
 
Increased natriuresis 




There are several oral DPP-4 inhibitors currently licensed for the management of T2DM – 
Sitagliptin (trade name Januvia®), Saxagliptin (Onglyza®), Alogliptin (Nesina®), Linagliptan 
(Trajenta®) and Vildaglipitin (Galvus®). The DPP-4 inhibitors are weight neutral and prevent 
weight gain – this remains desirable in light of the generally observed weight gain 
associated with insulin therapy, glinides, sulphonylureas and thiazolidinediones.(60,71) 
They also demonstrate a negligible risk of hypoglycaemia.(71) DPP-4 inhibitors are currently 
recommended as second line therapy if glucose targets are not being achieved with 
metformin or a sulphonylurea according to the IDF Global Guideline for T2DM.(58) NICE 
2010 T2DM guidelines follow a similar path by recommending a DPP-4 inhibitor as second-
line therapy to first-line metformin or first-line sulphonylurea when glycaemic control 
remains or becomes inadequate.(56) NICE stipulate oral Sitagliptin might also be 
considered as a third-line agent to first-line metformin and second-line sulphonylurea if 
glucose control remains or becomes inadequate and insulin therapy is unacceptable to the 
patient or is inappropriate.(56) 
 
1.5 Indirect Cardiovascular Benefit: Effect on Cardiovascular Risk 
Incretin-based therapies at the least prevent weight gain, and in the case of GLP-1R 
agonists, actively stimulate body weight reduction.(72–74) This can in turn enhance insulin 
sensitivity, both of which can be of indirect cardiovascular benefit. In the Liraglutide Effect 
and Action in Diabetes (LEAD) Phase 3 clinical trials, Liraglutide monotherapy or in 
combination with one or two oral antidiabetic agents was associated with a mean weight 
loss of 1.0-3.2 kg.(75–80) Exenatide twice daily can promote weight loss of 0.9-3.6 kg and 
Exenatide once weekly 3.7-3.8 kg.(30,73) The weight loss observed with GLP-1R agonists 
tends to plateau after 4-6 months. Since GLP-1R agonists exclusively stimulate insulin 
secretion in the presence of elevated glucose levels; they have the added advantage of 
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conferring a relatively small risk of hypoglycaemia. Indeed the incidence of hypoglycaemia 
only tends to increase when they are combined with antidiabetic therapies known to cause 
it such as sulphonylureas.(40) GLP-1R agonists are also associated with dose-dependent 
nausea, vomiting and diarrhoea. Native GLP-1 delays gastric emptying, which provides an 
intuitive explanation as to perhaps why synthetic analogues may cause these 
gastrointestinal side effects. Since the nausea tends to be transient, the weight loss seen 
with these agents is unlikely to be related.(20,25) Indeed a trial of Liraglutide for the 
treatment of obesity in non-diabetics demonstrated significantly greater weight loss when 
compared with Orlistat or placebo and an absence of hypoglycaemic episodes. 
Gastrointestinal events were more common with Liraglutide but were mostly transient and 
of mild or moderate intensity in the study.(72) 
 
Despite their apparent weight loss neutrality, DPP-4 inhibitors also improve lipid profile via 
significant reductions in triglycerides, total cholesterol, low-density lipoprotein and high-
density lipoprotein cholesterols.(74,81–84) They have also been shown to modulate 
postprandial lipid levels.(60,81) The GLP-1R agonists instigate similar 
alterations.(73,74,78,80,85) The mechanism underlying these positive effects on lipid 
metabolism cannot, it appears, be solely attributed to weight loss. Alternative biochemical 
explanations remain to be explored, as does any confirmatory link with better 
cardiovascular outcome. 
 
Clinical trials studying the antidiabetic actions of incretin-based therapies have also 
demonstrated modest but significant reductions in blood pressure (BP).(74,86–89) In 
particular the cluster of LEAD and DURATION trials comparing the respective effects of 
Liraglutide and once-weekly Exenatide with other antidiabetic drugs have collectively 
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revealed systolic BP reductions of 2-6 mmHg and diastolic reductions of 1-2 
mmHg.(25,73,75–80,90–94) Again whether this will translate into tangible reductions in 
cardiovascular morbidity and mortality has yet to be established. Of note the BP reduction 
observed in the LEAD trials occurred within the first two weeks of therapy, which would 
suggest a mechanism of action independent of weight loss. Contrariwise a 20-week trial of 
Liraglutide for the treatment of obesity in non-diabetics saw reductions in systolic and 
diastolic BP run in tandem with weight loss.(72) A recent meta-analysis of 33 trials 
(n=12469) which assessed the efficacy of Exenatide and Liraglutide on glycaemic control 
confirmed that GLP-1 treatment achieved a greater SBP reduction than comparator therapy 
(weighted mean difference of 2.22 mmHg, 95% confidence interval [CI]: -2.97 to -1.47).(95) 
In a separate meta-regression analysis performed by the same investigators, the reduction 
in SBP was independent of baseline BP, weight loss, or tighter glycaemic control.(95) 
 
The method by which GLP-1 could potentially regulate BP is likely to be multifactorial and 
comprise: straightforward weight loss; augmentation of insulin biosynthesis leading to 
vasodilatation and directly inhibiting the noxious effect of hyperglycaemia on the 
endothelium(96); increased diuresis(97) and a GLP-1R and atrial natriuretic peptide co-
dependent axis directly mediating natriuresis(98); brainstem effects on medullary 
catecholamine neurons in the area postrema(99,100); and direct GLP-1-mediated 
vasodilatory actions on the peripheral vasculature via endothelium-dependent (nitric oxide 
– NO) and –independent pathways (cAMP).(96,101–104) There is a clear need for further 




Levels of biomarkers such as plasminogen activator inhibitor-1 (PAI-1), high sensitivity C-
reactive protein (hs-CRP) and brain natriuretic peptide (BNP) are all linked to increased 
cardiovascular risk and have all been shown to fall during Liraglutide therapy.(105) 
Sitagliptin therapy has also been seen to significantly reduce hs-CRP and vascular cell 
adhesion molecule-1 (VCAM-1) levels along with BP and albuminuria in 36 T2DM 
patients.(106) In the DURATION-2 trial of once weekly Exenatide versus Sitagliptin or 
Pioglitazone, levels of BNP, PAI-1, and hs-CRP were all consistently reduced by the incretin-
based therapies.(90) Various preclinical and clinical proof-of-concept studies have also 
shown an ability of DPP-4 inhibitors and GLP-1R agonists to potentially delay the 
progression of atherosclerosis through modulation of inflammatory cytokine expression, 
reduction in oxidative stress and direct inhibitory actions on macrophage foam cell 
formation in addition to reducing monocyte/macrophage accumulation in the arterial wall 
of murine aortas.(107–115) Albeit intriguing, translation of this anecdotal evidence in to 
long-term prognostic benefit remains to be elucidated in prospective randomised trials. 
 
1.6 Direct Cardiovascular Benefit: GLP-1-Mediated Cardioprotection 
Recent interest has focussed on the direct actions of GLP-1 on cardiac myocytes and 
endothelial cells. The ubiquity of the GLP-1R and, in particular, its presence in the heart has 
been known for some time.(96,116) Moreover knockout mice lacking the GLP-1R are 
characterised by a lower basal heart rate, increased left ventricular (LV) wall thickness, 
elevated LV end diastolic pressure (LVEDP), impaired LV contractility, diastolic dysfunction 
and attenuated cardiac reserve, which would suggest an endogenous role for GLP-1 in 
maintaining normal cardiac structure and function.(117) This haemodynamic effect in 
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rodent hearts, however, was not replicated in the porcine heart perhaps again highlighting 
inter-species differences.(118) 
 
1.7 Augmentation of Myocardial Glucose Uptake 
The heart has the ability to utilise a variety of different substrates to generate adenosine 
triphosphate (ATP) - the energy currency that is required continuously for it to maintain 
optimal performance. Under the strain of myocardial ischaemia and subsequent 
reperfusion injury, however, the heart’s metabolic flexibility is significantly compromised. 
The heart shifts its preference from using non-esterified fatty acids (NEFA) to using glucose 
in order to limit the production of reactive oxygen species (ROS) and to veer away from the 
greater need for molecular oxygen that comes with NEFA oxidation. Increased glucose 
uptake during myocardial ischaemia helps to: maintain cellular ultrastructure; promote 
myocardial recovery; reduce myocardial creatine phosphokinase depletion; slow 
mitochondrial injury; and sustain myocardial electrical and mechanical performance. 
Paradoxically, during an acute myocardial infarction (AMI), the circulation of free fatty acids 
(FFA) and secretion of catecholamines is increased which lead to acute glucose intolerance. 
FFA may also exert arrhythmogenic effects on the hypoxic myocardium, increase 
membrane damage and ultimately suppress cardiac function.(119) It follows, therefore, 
that therapeutic interventions that encourage glucose uptake and utilisation and/or 
minimize NEFA uptake and oxidation could prove hugely beneficial in attenuating the 
deleterious effects of myocardial I/R injury. Despite an overall acceptance of these 
rudimentary metabolic principles, strategies to augment glucose uptake by the injured 
myocardium have failed to yield the expected clinical benefits. The use of glucose-insulin-
potassium (GIK) infusion therapy (plus or minus intensive subcutaneous insulin therapy at 
discharge in the mid-term) post AMI is a case in point. As early as the 1960s Sodi-Pallares 
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pioneered the use of GIK as a ‘polarising’ solution to stabilise membranes and restore 
potassium to ischaemic cardiomyocytes.(120,121) As such the purported biochemical 
advantage centred upon correction of electrocardiographic abnormalities. A decade later, 
Opie proposed the idea of GIK reducing lipolysis (thereby reducing FFA concentrations) and 
promoting glycolysis.(122) Since then, and several randomised trials later (see Table 2), the 
theoretical advantages of GIK have not been realised in a robust and reproducible fashion. 
Along with the increased risk of hypoglycaemia, hyperkalaemia, the need for relatively 
intensive monitoring, severe phlebitis and fluid overload from continued intravenous 
administration, this therapeutic avenue has never gained widespread credence. And so the 
focus of attention has recently turned to GLP-1, a peptide hormone with insulinomimetic, 
insulinotropic, and glucagonostatic actions whose metabolic effects could potentiate 












Table 2 Randomised clinical trials of glucose-insulin-potassium infusion to improve 
outcome after acute myocardial infarction (123–130) 
 
Key: AMI=acute myocardial infarction; GIK=glucose-insulin-potassium; S/C=subcutaneous; VF=ventricular fibrillation; AV=atrioventricular; CHF=congestive heart failure; 
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 All cause mortality 
 Stroke 
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 Blood glucose <3 
mmol/L with and 
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was more frequent 
in the GIK infusion 
groups in the first 
24 hours  
 No significant 
difference in 
mortality between 
all three groups 
 No significant 
difference in 
stroke or non-fatal 
reinfarction 







Table 2 Randomised clinical trials of glucose-insulin-potassium infusion to improve 
outcome after acute myocardial infarction 
 
Key: AMI=acute myocardial infarction; GIK=glucose-insulin-potassium; S/C=subcutaneous; VF=ventricular fibrillation; AV=atrioventricular; CHF=congestive heart failure; 






Inclusion criteria Treatment 
Arms 


















30 days  Mortality 
 Cardiac arrest 
 Cardiogenic shock 
 Reinfarction 
 
 No difference 
between groups in 









often in the GIK 
group  
 No significant 
difference in 
mortality 
 No significant 
differences in the 










(diabetes vs. non 
diabetes; heart 
failure vs. no heart 
failure; early vs. 
late presentation; 
and reperfusion 





 STEMI patients 
without signs 
of heart failure 
presenting 









12 months  Mortality 
 Reinfarction 
 Revascularisation 
Not available  No significant 
difference in 
mortality 
 No significant 
difference in rates 






 Acute STEMI  GIK infusion 








 Heart failure 
 GIK therapy 
increased levels of 
glucose, potassium, 
and net fluid gain 






 No significant 
difference in 30-
day death, heart 
failure or the 
composite of 
death and heart 
failure between 
the two regimens 
 No significant 
differences in 6-
month clinical 





 Any patients 
aged 30 years 















 Progression to MI 
within 24 hours 
 Survival at 30d 
and 1 year 
 
 No significant 
difference in the 
rate of serious or 
non-serious adverse 
events between the 
two regimens 
 No statistical 
difference in 
progression to MI 
for GIK 
 No significant 
difference in 30d 
mortality 













1.8 GLP-1 in Myocardial Ischaemia and Heart Failure 
In the failing heart or the myocardium under threat of ischaemia/reperfusion (I/R) injury, 
the protective role of GLP-1 has come to light through several preclinical and human 
studies. The majority of preclinical studies have focussed on the actions of GLP-1 in 
ischaemic post-conditioning and reperfusion injury (see Table 3). Ex vivo models of isolated 
rodent Langendorff heart perfusion incorporating periods of ischaemia followed by 
reperfusion have all universally demonstrated that both GLP-1 and exendin-4 markedly 
reduce infarct size and enhance the recovery of myocardial contractility after transient 
coronary artery occlusion.(101,131–133) In vivo animal studies have also produced similar 
findings. In an experimental conscious canine model, a 24-hour infusion of GLP-1 was 
shown to ameliorate the effects of myocardial stunning induced by brief periods of 
coronary occlusion.(134) Of note isovolumic LV relaxation, an ATP-dependent process 
specifically influenced by myocardial substrate metabolism, improved significantly 
compared to controls. A recent in vivo I/R porcine model also demonstrated the benefit of 
an extended 3-day period of Exenatide, which subsequently reduced infarct size and 
accelerated the recovery of both systolic and diastolic function.(135) GLP-1 may also confer 
protection to the ischaemic heart outside of the diabetes setting. A 7-day pre-treatment 
period with Liraglutide given to both normoglycaemic and streptozotocin-induced diabetic 
mice was shown to reduce both infarct size and the incidence of cardiac rupture in addition 
to improving cardiac output and ultimately survival after experimental MI.(136) Here 
chronic Liraglutide therapy gave rise to cardioprotective and survival advantages over and 
above those observed for metformin, despite equivalent effects on glycaemic control and 
demonstrated the potential use of GLP-1R agonists in the non-diabetic population. 
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Some studies also point to a role for the metabolite GLP-1(9-36) generated by DPP-IV 
degradation, and pathways independent of the GLP-1R. Nikolaidis and colleagues 
demonstrated a GLP-1(9-36)-stimulated increase in myocardial glucose uptake and 
improvement in LV contractility in a canine model of pacing-induced dilated 
cardiomyopathy.(137) Following I/R injury, the enhancement of LV contractility mediated 
by both GLP-1(9-36) and exendin-4 seen in wild-type mice was observed to be resistant to 
exendin(9-39), a GLP-1R antagonist, and also persisted in gene-modified mice lacking a GLP-
1R.(101,133) Of note, acute treatment with GLP-1(9-36) at the point of reperfusion also 
resulted in better functional recovery independently of the GLP-1R. Furthermore, the 
improvement in functional recovery observed in hearts from GLP-1R mice was abolished 
when the DPP-4 inhibitor Sitagliptin was administered, again suggesting a pivotal role for 
the degradation product GLP-1(9-36) in mediating the beneficial effects.(101) These latter 
experiments point interestingly to the existence of possible receptor-independent 
pathways and/or an, as yet unidentified, alternative GLP-1R in the heart.(39) They also raise 
the question of whether it may be more advantageous, from a cardioprotective viewpoint, 
not to inhibit DPP-IV, thereby allowing the continued production of GLP-1(9-36). Although 
purely speculative, this would suggest currently available oral DPP-IV inhibitors, despite 
providing excellent glycaemic control might, in turn, be depriving the individual of 
protection from adverse cardiovascular sequelae. In a more recent study however, 
Goodwill and colleagues showed that systemic GLP-1(9-36) had no effect on coronary flow, 
blood pressure, heart rate or indices of cardiac function prior to or during regional 
ischaemia in a porcine model of experimental myocardial infarction.(138) In contrast, a 
short systemic infusion of GLP-1(7-36) significantly augmented cardiac output following 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The growing body of evidence in animal models has led to several Phase 2 trials of native 
GLP-1 in humans (see Table 4). In a small study involving 21 patients presenting with ST-
elevation myocardial infarction (STEMI) and LV systolic dysfunction (LVSD – ejection 
fraction <40%), a 72-hour GLP-1 infusion was shown to improve LV ejection fraction (LVEF) 
from 29% to 39% in both diabetic and nondiabetic patients after primary percutaneous 
coronary intervention (PPCI).(152) A further study randomised 20 patients to receive 
conventional therapy or standard therapy plus a GLP-1 infusion 12 hours prior to planned 
coronary artery bypass graft surgery. The infusion, which was then continued for 36 hours 
postoperatively, reduced inotrope and antiarrhythmic drug requirements and also resulted 
in better glycaemic control. There were, however, no significant differences in LVEF or 
cardiac index.(153) Addition of GLP-1 to standard therapy has also demonstrated significant 
improvements in LVEF, maximum myocardial ventilation oxygen consumption, 6-minute 
walk test indices, and quality of life measures in obese patients with LVSD (EF ≤40% and 
NYHA class III/IV). The drug, however, had to be administered continuously via a 
subcutaneous infusion over 5 weeks.(154) The widespread clinical application of 
endogenous GLP-1 is hampered by its short half-life and consequent need for a continuous 
infusion to allow therapeutic levels of the peptide to be maintained. This is of particular 
significance in patients with cardiomyopathy where strict fluid restrictions will often apply. 
Nonetheless these small, proof-of-concept, studies suggest that GLP-1, independent of its 
effect on glycaemic control, could potentially modulate the metabolic and haemodynamic 
outcomes of patients with coronary artery disease (CAD) and LVSD. Interestingly these 
effects were seen to occur in both diabetic and non-diabetic participants, reinforcing the 
safety aspect of GLP-1-based therapies during normoglycaemia.(152–157) 
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Read and colleagues have shown that Sitagliptin is able to improve myocardial response to 
ischaemia provoked by dobutamine stress and attenuate subsequent post-ischaemic LVSD 
(i.e. stunning) in patients with known CAD awaiting elective PCI.(156) Again the effect was 
seen in both diabetics and non-diabetics and was highly reproducible using standard 2D 
echocardiography and tissue Doppler techniques. Of particular interest was that Sitagliptin, 
and by virtue of its action on endogenous GLP-1(7-36), displayed a significantly greater 
beneficial effect on ischaemic, rather than non-ischaemic LV segments, already known to 
be supplied by a coronary artery with a stenosis >50%. This cardioprotective effect could be 
extended to and perhaps even improved by the GLP-1R agonists. Indeed in an identical trial 
format, but this time using a continuous infusion of GLP-1(7-36) given for 30 minutes prior 
to and 30 minutes into recovery from dobutamine stress, the same investigators 
demonstrated similar results.(155) Both studies confirm the cardioprotection was GLP-1R-
mediated and draw validity away from the idea that oral DPP-4 inhibitors may truncate the 
overall cardioprotective signal by reducing the amount of GLP-1(9-36) peptide available to 
act on alternative pathways.(101,133,137) In a pilot study of 20 patients with normal LV 
function and single CAD awaiting elective intervention, Read and colleagues have also 
demonstrated a reduction in ischaemic LV systolic and diastolic function caused by two 1-
minute intracoronary balloon occlusions separated by 30 minutes. GLP-1(7-36) was infused 
at the time of occlusion and continued until the PCI procedure was completed. Compared 
to saline placebo, GLP-1(7-36) improved recovery of function and mitigated LV 
stunning.(158)  
 
Perhaps the most convincing data currently available has emanated from a Danish trial of 
172 patients presenting with acute STEMI.(157) Patients (both diabetic and non-diabetic) 
were randomised in a 1:1 fashion to receive either an infusion of Exenatide 15 minutes 
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prior to coronary angioplasty, which was maintained for 6 hours, or saline placebo. There 
was a greater myocardial salvage index (as measured by cardiac magnetic resonance 
imaging) and a trend towards a smaller absolute infarct size in the Exenatide group. 
Importantly, no episodes of hypoglycaemia, pancreatitis, or any other adverse effect was 
reported with Exenatide. Although the sample size was too small to gain any leverage in 
hard endpoints such as mortality, heart failure (HF) or myocardial performance, the 
beneficial effect on surrogate endpoints is encouraging.(159) In a post-hoc analysis the 
investigators found that Exenatide treatment propagated a 30% decrease in final infarct 
size only when the system delay was ≤132 minutes.(160) If the system delay, defined as the 
time from first medical contact to intracoronary balloon deployment and a surrogate 
marker for duration of ischaemia was longer, no cardioprotective effect was seen. This 
neatly re-emphasises the fundamental importance of instigating reperfusion therapy within 
the first 2-3 hours of acute STEMI – a therapeutic window during which there is the most 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.9 What is the Mechanism of GLP-1-Mediated Cardioprotection?          
Several studies have suggested a possible link to pro-survival kinases such as 
phosphatidylinositol 3-kinase (PI3K)-Akt, glycogen synthase kinase-3 beta (GSK-3β), p70s6K, 
ERK1/2 and p38 mitogen-activated protein kinase (MAPK) along with activation of cyclic 
GMP- and adenylate cyclase-cAMP-protein kinase A (PKA)-dependent pathways (see Table 
3).(101,131–133,136,139,166) Other investigations have demonstrated positive GLP-1-
mediated actions on cardiomyocyte apoptosis, endogenous antioxidant defence 
mechanisms, oxidative stress and augmentation of myocardial glucose uptake during stress 
caused either by I/R injury or in the failing heart.(131,132,135–137,147,148,166–168) 
Potentially GLP-1 and its analogues thereof could well replicate or augment the 
cardioprotective effect of ischaemic preconditioning - the cardioprotection accumulated 
against subsequent MI through brief episodes of sub-lethal I/R injury. Bradykinin, 
angiotensin, endorphins and other short peptides have been shown to pre-condition the 
myocardium in the absence of an ischaemic stimulus in animal models. Binding of these 
ligands triggers an intracellular signalling cascade that eventually activates protein kinase C-
 (PKC-) and mitogen-activated protein kinases (MAPK: especially p38-MAPK). This 
process mediates the opening of K+ATP channels in cardiomyocyte and/or mitochondrial 
membranes which ultimately serves to delay cell death by inhibiting the mitochondrial 
permeability transition pore (mPTP). Glycogen synthase kinase-3 (GSK-3) lies 
immediately proximal to the mPTP in the signalling cascade and is thought to be the point 
of integration for converging cardioprotective signals in preconditioning. Its inactivation is 




Thus far definitive mechanisms underlying this beneficial effect remain unproven. If 
endogenous GLP-1, DPP-4 inhibitors and GLP-1R agonists promote cardioprotection via 
established signal transduction pathways then clearly this can be regarded as “run-of-the-
mill” protection (and therefore prone to tachyphylaxis) whether it be within an ischaemic 
pre- or post-conditioning framework.(169–171) It would, however, be important to 
establish whether a synergistic alliance exists, benefitting from both the activation of pro-
survival kinases and metabolic modulation inducing a shift towards glucose utilisation by 
the threatened myocardium.  
 
The current evidence base supporting the cardioprotective role of endogenous GLP-1, GLP-
1R agonists and DPP-4 inhibitors is compelling but we remain a long way from 
recommending these agents to a non-diabetic population at high cardiovascular risk or for 
administering these therapies for any purpose other than glycaemic control in T2DM 
patients. The role of the GLP-1R agonist Liraglutide in the management of hyperglycaemia 
in T2DM is established. In addition to promoting weight loss and improving glycaemia, the 
tantalising prospect of this agent also providing an avenue for the metabolic modulation of 
ischaemic and the failing myocardium is an emerging area of therapeutic interest and 
warrants further investigation. The majority of work thus far has focussed on the effect of 
GLP-1 on ischaemic preconditioning, postconditioning and reperfusion injury. Despite the 
numerous studies previously described, consensus is lacking on the underlying mechanism 
of action. Is Liraglutide-stimulated cardioprotection direct, incorporating standard signalling 
pathways involved in post-transcriptional gene modification of established pro-survival 
kinases or indirect, thereby indicating either significant alterations in the cardiac protein 
expression profile or the involvement of extra-cardiac receptor pathways? 
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There are currently no studies in the literature looking at the potential role of these agents 
in an anti-anginal capacity. This is an important prelude to the use of GLP-1 agonists in the 
setting of AMI since their use in those at risk of such events could potentially deliver 
benefits to those with silent MI, late presentation or early death before access to medical 
services. As such there is an opportunity to investigate the potential direct (or indirect) 
anti-ischaemic action of Liraglutide to reduce angina burden in a cohort of non-diabetic 
individuals with chronic stable angina and known coronary artery disease given the 
evidence detailed above. 
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2. Aims and Objectives 
Despite the improvements in survival mitigated by established therapies such as aspirin, 
clopidogrel, ticagrelor, prasugrel, angiotensin converting enzyme inhibitors, angiotensin II 
receptor blockers (ARBs), beta blockers, aldosterone antagonists and statins, coronary 
heart disease is still responsible for 1 in every 5 deaths in the Industrialised World. It is 
therefore imperative that we continue to investigate novel mechanisms that could 
potentially reduce morbidity and mortality arising from coronary atherosclerosis. The 
predominant focus of this MD(Res) thesis, therefore, was to add to the growing body of 
evidence on GLP-1-mediated cardioprotection by conceiving, designing, recruiting to and 
ultimately completing a single-centre clinical trial to investigate the effect of chronic GLP-1R 
activation on haemodynamics and exercise-induced ischaemia, as manifest by specific 
electrophysiological parameters, in a cohort of patients with chronic stable angina 
managed conservatively or awaiting revascularisation. Rather than study I/R injury 
following coronary occlusion, we set out to determine whether the putative anti-ischaemic 
properties of GLP-1 could translate into an anti-anginal action during sequential exercise 
stress testing. That is to say can Liraglutide reproduce the beneficial sequelae of the warm-




2.1 Hypothesis Under Investigation 
We hypothesise that Liraglutide, a stable GLP-1 mimetic, is able to improve the 
haemodynamic and electrocardiographic parameters of exercise-induced myocardial 
ischaemia in a cohort of patients with known obstructive coronary artery disease during 
serial exercise tolerance testing when compared with saline placebo.  
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3. Liraglutide to Improve corONary 
haemodynamics during Exercise streSS: 
The LIONESS Trial 
IRAS Reference: 78543 
REC Reference: 11/LO/1564  
NRES Committee London-Westminster Protocol Number: FS/11/70/28917 
NIHR UKCRN Portfolio Study ID: 11112 
Guy’s and St Thomas’ NHS Foundation Trust R&D Registration Number: RJ112/N131 
ClinicalTrials.gov Identifier: NCT02315001 
 
 
Emerging evidence from both animal and human studies suggest human GLP-1, an incretin 
hormone, and its synthetic analogues can protect the heart from myocardial ischaemia-
reperfusion injury and augment left ventricular contractile function, independent of 
glycaemic control and weight loss. Studies have thus far looked predominantly at 
cardioprotection in the context of ACS and LVSD. The aim of the LIONESS trial was to study 
the effects of chronic GLP-1R occupancy in a cohort of chronic stable angina patients with 
known obstructive coronary lesions either awaiting elective revascularisation or receiving 





3.1 Trial Design 
The Liraglutide to Improve coROnary haemodynamics during Exercise streSS (LIONESS) trial 
was an investigator-initiated single-centre randomised double-blind placebo-controlled 
crossover proof-of-principle physiological study designed to investigate the physiological 
basis of GLP-1R activation on exercise haemodynamics, as manifest by specific 
electrophysiological parameters, in those patients with significant coronary stenoses 
proven by a previous exercise test and delineated by coronary angiography. 
 
Both investigator and patient were blinded to the study drug. Patients were randomised to 
enter a GLP-1 treatment arm or matched-volume saline placebo arm. Following a 1-week 
run-in phase of daily 0.6 mg Liraglutide followed by a 1-week course of 1.2 mg Liraglutide, 
patients in the active intervention arm proceeded to their first exercise tolerance test (ETT) 
at the end of Week 2. Patients were then up-titrated to high-dose 1.8 mg Liraglutide for 
another week before performing a Week 3 ETT. A stepwise increase in Liraglutide dosage 
was factored into the trial protocol with the aim of observing a dose-response effect on 
haemodynamics during serial exercise stress testing. An initial 1-week run-in phase of once 
daily 0.6 mg Liraglutide was included to allow for improved gastrointestinal tolerability and 











Figure 6 LIONESS Trial Design  
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Those patients randomised to the placebo arm were given matched-volume saline 
injections for the first two weeks before the Week 2 ETT and then another week of saline 
injections before the Week 3 ETT. Patients then crossed over at this stage so that those 
who started on the treatment arm transferred to the placebo arm and vice versa (please 
refer to Figure 6 above). 
 
3.1.1 Rationale For Using Liraglutide 
Rather than use the endogenous peptide, a commercially available injectable GLP-1R 
agonist was selected to investigate the physiological role of GLP-1 on exercise-induced 
ischaemia. As such we could take advantage of a readily available and well-characterised 
pharmacological agent currently used by thousands of T2DM patients. Liraglutide (trade 
name Victoza manufactured by NovoNordisk, Bagsvaerd, Denmark), a synthetic analogue 
that shares 97% structural homology to native GLP-1 (Figure 5), received marketing 
authorisation from the European Commission in July 2009 to be used at doses of 1.2 mg or 
1.8 mg once daily. It binds to albumin in the circulation, protecting it from DPP-4 
degradation and preventing renal elimination. For these reasons Liraglutide is an 
appropriate surrogate for studying chronic GLP-1R activation in humans. Furthermore it has 
a half-life of approximately 10-14 hours following subcutaneous administration, which 
allows for use as a once-daily preparation. This permitted a crossover trial design to be 
applied, helped to maximise patient compliance and precluded the risk of fluid overload in 
individuals with established coronary heart disease. Moreover trial participants could avoid 
having to inject themselves more than once every day. The relatively small risk of 
hypoglycaemia associated with Liraglutide lent further support to it being used to study the 
effects of GLP-1 beyond glycaemic control in an all comers population of predominantly 
non-diabetic CAD patients. 
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What is of particular interest is the possibility of expanding the remit of incretin-based 
therapies to cover a non-diabetic population. Astrup and colleagues assessed the effect of 
Liraglutide compared with Orlistat or placebo on bodyweight in non-diabetic obese 
individuals (n=564) over a 20-week trial. Enrolled patients were randomly assigned to 
receive doses of Liraglutide at 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg once daily (the latter two 
doses higher than those previously studied/approved in individuals with T2DM). Adverse 
events associated with Liraglutide therapy were mainly nausea and vomiting. These 
symptoms were predominantly transient, tended to occur during the study run-in period 
when dose titration took place and were only of mild or moderate intensity. Altogether 8 
patients (2.2%) withdrew because of nausea and 5 (1.3%) because of vomiting from the 
Liraglutide cohort. Of note injection-site symptoms occurred in less than 7% of participants 
also. As a direct result of the LEAD trials described previously and the study by Astrup and 
colleagues, we felt Liraglutide, at doses of 0.6 mg, 1.2 mg and 1.8 mg, would be a generally 
safe and legitimate drug to use in a study population composed primarily of non-diabetics 
to determine the potential role of chronic GLP-1 receptor occupancy on the physiology of 
myocardial ischaemia. This data was presented to the Research Ethics Committee to 
support the use of Liraglutide for this unlicensed indication within a physiological study 
framework. 
 
Of note a much larger randomised controlled trial of weight management comparing 3.0 
mg Liraglutide versus placebo (2:1 randomisation) in 3731 non-diabetic patients with a 
body mass index (BMI) ≥30 (or BMI of at least 27 plus treated or untreated dyslipidaemia or 
hypertension) has since been published in July 2015.(172,173) All trial participants received 
counselling on lifestyle modification. Over the course of 56 weeks, patients in the 
Liraglutide group lost 8.4±7.3 kg of body weight versus 2.8±6.5 kg in the placebo group 
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(p<0.001). As expected the most common side effects of Liraglutide were related to the 
gastrointestinal system; 94% of which were only mild or moderate in severity. There were 
no cases of medullary thyroid carcinoma or C-cell hyperplasia, and Liraglutide treatment did 
not increase serum calcitonin concentrations. Of the 2481 patients in the Liraglutide group, 
only 10 cases of pancreatitis (0.4%) were reported, of which 9 were graded as mild. This 
data not only adds further credence to our decision to use Liraglutide as a surrogate of 
chronic GLP-1 receptor activation safely in a non-diabetic population but also led to FDA 
approval of Liraglutide in December 2014 as the first GLP-1 mimetic for weight loss 
treatment in adults with BMI ≥30 or a BMI of 27-29 plus one or more weight-related 
coexisting illnesses. 
 
It is important to note a fundamental principle underpinning the design of the LIONESS trial 
was based on the assumption that the 2-week period between the Week 3 ETT and the 
Week 5 ETT (see Figure 6 above), in those patients randomised to the active Liraglutide 
intervention first, would be sufficient to allow adequate washout of the drug and therefore 
minimise the impact of a potential carryover effect. Given that the half-life of Liraglutide is 
10-14 hours, this 2-week washout period far exceeds the generally accepted mark of ≥5 
half-lives. A washout period for those randomised to the placebo arm first would not apply 
per se, although this would be tested statistically nevertheless. 
 
3.1.2 Randomisation Procedure 
All randomisations were performed through a computer-generated randomisation 
programme (www.sealedenvelope.com) in a 1:1 randomisation ratio utilising a study-
specific ID assigned to each enrolled patient. Treatment allocation could be un-blinded in 
case of an emergency or serious adverse event if deemed necessary by the investigator. 
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3.1.3 Study Agent and Placebo Control (see also Section 4) 
Liraglutide was supplied to trial recruits in pre-filled single-use plastic syringes for once 
daily subcutaneous injection at doses of 0.6 mg, 1.2 mg and 1.8 mg (Figure 7). Matched-
volume saline placebo was also supplied in identical pre-filled syringes for subcutaneous 
injection. All study patients were taught how to safely inject themselves before study 
commencement. Study medication were produced and dispensed by the Aseptic Services 
Unit of St Thomas’ Hospital Pharmacy as a set of 7 separate disposable syringes at the 
beginning of each study week (see Figure 8). Patients were asked to store these in a 
refrigerator and to dispose of their used syringes in an empty sharps bin provided at the 
beginning of each study week. The sealed bin was brought to the next study visit to check 
for compliance with the trial agents. Patients were advised to administer their study agent 
at approximately the same time each day to reinforce compliance. We recommended that 
subcutaneous injections were made into the abdomen and that the injection site should be 






Figure 7 Pre-filled LIONESS 
Study Agent Syringe (left) 
and Original Victoza 
(NovoNordisk, Denmark) 




Figure 8 Official LIONESS Trial Prescription Proforma 
 
3.1.4 Concomitant Medication 
Once recruited, study participants had any heart rate-limiting drugs cautiously withdrawn 
prior to commencing the 6-week trial protocol. These included beta-blockers, rate-limiting 
calcium antagonists (e.g., diltiazem and verapamil), and ivabradine to ensure a normal 
chronotropic response to exercise stress testing. Long-acting oral nitrates and nicorandil 
were also stopped to avoid any potential interference with haemodynamic physiology and 
masking of angina burden. Patients were allowed to continue their antiplatelet therapy 
(e.g., aspirin, clopidogrel, prasugrel, and/or ticagrelor), ACE-inhibitors, ARBs, and statins. 
Patients were also permitted to continue their sublingual glyceryl trinitrate (GTN) spray or 
buccal GTN to relieve breakthrough angina. Those patients experiencing poor control of 
pre-existing hypertension following the cessation of the drugs listed previously were 
 60 
prescribed alternative antihypertensive medication during the course of the trial at the 
discretion of the investigator, or had their current medication they were allowed to 
continue up-titrated, and monitored closely for response. Once the patient had completed 
the trial they were recommenced on all their original medication. 
 
3.1.5 Exercise Stress Testing  
The host laboratory in the Rayne Institute at St Thomas’ Hospital has developed an 
established and reproducible exercise protocol for the study of warm-up angina in CHD 
patients, which will be adopted for this physiological study.(174–177) All exercise stress 
tests were performed using the standalone CASE Exercise Testing System (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). Twelve-lead electrocardiogram (ECG) tracings were 
obtained every 20 seconds and blood pressure recorded at baseline, peak exertion, 0.1 mV 
ST-segment depression, and every 3 minutes during exercise and 2 minutes during 
recovery. A standard BRUCE or modified BRUCE protocol was utilized dependent on patient 
physical condition. The same protocol was used for each individual’s serial exercise tests. 
The level of the ST-segment measured 0.08 seconds after the J point was calculated after 
signal averaging using the computer-assisted analysis on the CASE Exercise Testing System. 
Criteria for terminating an exercise stress test were as follows:  
 physical exhaustion,  
 severe chest pain,  
 attaining maximal age-related target heart rate (i.e. 220 – age),  
 ST-segment depression >0.4 mV, or  
 haemodynamically-significant dysrhythmia. 
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3.2 Trial Visits and Procedures 
3.2.1 Screening Visit 
Once a patient was deemed to have adequately fulfilled the inclusion and exclusion criteria 
(see Section 3.5), informed consent was obtained. Part of the inclusion criteria includes the 
demonstration of reversible ischaemia during an ETT. If a recent ETT was not available, the 
patient was asked to perform an ETT at the screening visit. The result of this ETT was not 
used in the final data analysis but was captured as part of the screening process. Those 
patients ineligible for trial participation were registered, and the reason for screening 
failure was recorded. Patients entering the trial received a tutorial on home blood glucose 
monitoring and the signs and symptoms of hypoglycaemia. A safety information card 
including contact details of the main investigator in case of side effects or general concern 
was issued (see Appendix). A full medical history and clinical examination was conducted. 
Baseline blood tests were taken at this stage (Table 5). Medications that needed to be 
withheld were identified at this visit and withdrawn cautiously (see Section 3.1.3 above). 
Those patients successfully recruited were randomised at this stage. 
 
3.2.2 Trial Visits (Week 0 to Week 6) 
Trial participants performed their first self-administration of study agent and first blood 
glucose measurement, which was recorded in their patient diary, at trial commencement 
(Week 0). An investigator supervised both at the first trial visit. Recruited patients attended 
a total of 7 trial visits and had procedures performed according to the schedule detailed in 
Table 7. Patients were asked to record twice daily home blood glucose measurements at 
approximately the same time in the morning and afternoon. Patients had blood tests 
performed at every study visit (Table 5). 
 62 
Table 5 Laboratory Tests 
The following blood tests were taken at every study visit unless otherwise stated: 
 Full blood count 
 Urea, creatinine and electrolytes 
 Estimated glomerular filtration rate 
 Liver function tests 
 Amylase 
 Corrected calcium 
 Random blood glucose 
 HBA1c (Week 0, Week 3 and Week 6 only) 
 Random lipid profile (serum total cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, and triglyceride) (Week 0, Week 3 and Week 6 only) 
 
3.2.3 Expected Duration of the Study 
From the point of administration of study drug on day 1 the total length of the study was 6 
weeks. There was no active follow-up of patients after completion of the 6-week trial 
protocol, at which point study drugs were terminated and patients had their pre-study 
medication recommenced immediately thereafter. 
 
3.2.4 Procedures for Recording and Reporting Adverse Events 
All study participants were issued a patient diary in which they were asked to record any 
adverse events, side effects, injection site reactions and angina burden. This diary was 
inspected at every study visit. Patients were also able to contact the Main Patient Liaison at 
all times for general enquiries and advice regarding any signs and symptoms they were 
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experiencing or concerned about pertaining to the study. The primary care physicians of all 
study participants were issued with an information sheet regarding the potential side 
effects of the GLP-1R agonist Liraglutide and the medication that a trial recruit may have 
had temporarily discontinued prior to commencing the trial. The fundamental importance 
of informing the Main Patient Liaison if any adverse events were to occur was reiterated at 
every trial visit.  
 
3.2.5 Withdrawal of Trial Participants 
Participants had the right to withdraw from the study at any time for any reason. Should a 
patient decide to withdraw from the study, all efforts were made to report the reason for 
withdrawal as thoroughly as possible. The investigator also had the right to withdraw 
patients from the study in the event of inter-current illness, adverse events or serious 
adverse events, protocol violations, administrative reasons or other reasons. The study 
drug would be discontinued and the participant withdrawn from the study if: 
 the participant missed 2 consecutive courses of treatment; 
 the participant decided they no longer wished to continue; 
 if the participant experienced an intolerable degree of angina as a result of withdrawing 
their pre-study heart rate-limiting or anti-anginal medications; 
 if the participant experienced significant side effects from their study medication, in 
particular excessive or intolerable nausea, vomiting or diarrhoea; or 
 it was recommended by the investigator. 
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The Sponsor or Chief Investigator was also allowed to prematurely discontinue the study on 
the basis of new safety information or for other reasons given by the Study Steering 
Committee or Research Ethics Committee concerned. 
 




















Exercise Test 4 
(Week 6) 
Obtain informed 
consent, issue safety 
information card and 
patient diary 
Yes - - - - - - - 
Randomisation to 
study agents 
Yes Perform first self-
administration of 
study agent 
- - - - - - 
Issue 7-day course of 
blinded study agent 
- Yes Yes Yes Yes Yes Yes Stop all study 
medication 
Check study drug 
compliance 











































Physical examination Yes Yes Yes Yes Yes Yes Yes Yes 
Height measurement Yes - - - - - - - 
Weight measurement Yes Yes Yes Yes Yes Yes Yes Yes 
Blood pressure 
measurement 
Yes Yes Yes Yes Yes Yes Yes Yes 
Electrocardiogram Yes - - - - - - - 
Pre-specified blood 
tests (Table 5) 
Yes Yes Yes Yes Yes Yes Yes Yes 
Perform supervised 
exercise tolerance test 
(ETT) 
Yes (if recent 
ETT 
unavailable) 
- - Yes Yes - Yes Yes 
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3.3 Patient Selection 
Potential trial participants fulfilling the inclusion and exclusion criteria listed below were 
recruited consecutively from the following patient groups: 
 Patients with known obstructive CAD on angiography and a previously abnormal 
exercise test, but who were currently stable on conservative medical management, 
were enrolled from general cardiology outpatient clinic. 
 Patients with known obstructive CAD on angiography and evidence of reversible 
myocardial ischaemia on exercise testing, awaiting elective percutaneous coronary 
intervention (PCI) or coronary artery bypass graft (CABG) surgery. 
 
3.3.1 Inclusion Criteria 
 Men and women aged 18-80 
 Patients must be able to walk confidently on an exercise treadmill 
 Patients must have a recent/baseline abnormal exercise tolerance test demonstrating 
>0.1 mV of planar or down-sloping ST-segment depression 
 Patients must have angiographic evidence of a >70% stenosis in a main epicardial 
coronary artery, with or without coronary stenoses elsewhere 
 Patients must have a normal resting ECG in sinus rhythm without bundle branch 
aberration or other conduction disturbance 
 Patients must have preserved left ventricular systolic function (ejection fraction ≥40%) 
 
3.3.2 Exclusion Criteria 
 An abnormal resting ECG including atrial fibrillation, bundle brunch aberration or other 
conduction disturbance 
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 Pre-existing significant left ventricular systolic dysfunction (ejection fraction <40%) 
 Pre-existing ischaemic or non-ischaemic cardiomyopathy 
 Pre-existing haemodynamically significant valvular heart disease 
 Inability to safely negotiate an exercise treadmill independently 
 Patients with Type 1 diabetes mellitus 
 Patients with Type 2 diabetes mellitus taking oral and/or subcutaneous anti-diabetic 
therapy 
 Patients with a personal or family history of medullary thyroid carcinoma   
 Patients with Multiple Endocrine Neoplasia syndrome type 2 
 Patients with acute renal failure or deteriorating renal function 
 
 
3.4 Outcome Measures 
3.4.1 Primary Endpoints 
 Change in rate pressure product at 0.1 mV ST-segment depression during sequential 
exercise tolerance testing performed over a 6-week study period 
 Change in degree of ST-segment depression at peak exercise during sequential exercise 
tolerance testing performed over a 6-week study period 
3.4.2 Secondary Endpoints 
 Change in total exercise time during sequential exercise tolerance testing performed 
over a 6-week study period 
 Change in time to 0.1 mV ST-segment depression during sequential exercise tolerance 
testing performed over a 6-week study period 
 Change in time to maximum ST-segment depression during sequential exercise 
tolerance testing performed over a 6-week study period 
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 Change in recovery time to 0.05 mV ST-segment depression during sequential exercise 
tolerance testing performed over a 6-week study period 
 Evidence of hypoglycaemia through twice-daily home blood glucose monitoring and 
once-weekly random serum glucose measurements 
 Evidence of renal dysfunction through once-weekly monitoring of serum creatinine and 
estimated glomerular filtration rate 
 Evidence of acute pancreatitis through once weekly monitoring of serum amylase 
alongside telephone and once-weekly face-to-face study visits. 
 
 
3.5 Sample Size Calculation 
The host department had previously shown that the time taken to 0.1 mV ST-segment 
depression (STD) (368±34418±36 seconds) and the rate pressure product at 0.1 mV STD 
(20500±75521907±764 mmHg/min) was significantly increased during the second of two 
serial exercise tests separated by 15 minutes in chronic CAD patients with known left 
anterior descending artery stenoses.(175,176) This effect has been attributed to warm-up 
angina, which is thought to augment the innate resistance of the myocardium to an 
ischaemic insult.(177,178) Following the premise of the original hypothesis we predicted 
the administration of Liraglutide to mimic the beneficial cardioprotective effects of warm-
up angina. A sample size of 26 patients, therefore, would need to be randomised in a 1:1 
fashion to each treatment arm (taking into consideration a >10% drop-out rate) followed by 
crossover to have 90% power to detect a difference between the means of approximately 
15% (2-sided =0.05). This calculation is predicated on the assumption that the washout 
phase is long enough to rule out carryover effects. Thereafter, the calculation of power and 
sample sizes for a crossover trial is essentially the same as that derived from a t-test for 
unpaired samples. 
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3.6 Data Management  
Data was recorded and collected prospectively using a customised paper LIONESS Trial Case 
Report Form. Investigators recorded adverse events, injection site reactions, angina 
episodes and clinical and laboratory parameters on the CRF at each study visit. 
 
3.7 Statistical Analysis 
The LIONESS Trial is effectively a simple two-period two-treatment crossover trial. That is to 
say, a trial where there are two treatments (Liraglutide versus saline placebo), each given 
once, in random order. It is also referred to as an AB/BA design, because patients are 
randomised to receive A then B or B then A. Comparison of these two sequence groups A-B 
and B-A will form the basis for confirmatory statistical analysis. Prior to this confirmatory 
analysis, we will perform the D’Agostino-Pearson test for normality on each of the sample 
population parameters under investigation. 
 
The assumption that the washout phase was long enough to rule out a carryover effect will 
be checked in a preliminary test. To this end, the sum of the values measured in the two 
periods is calculated for a particular variable in each subject and compared across the two 
sequence groups by means of another test for independent samples. This test for carryover 
effect will be performed using a parametric unpaired t-test, if the test for normality has 
indicated a normal distribution or a non-parametric Mann Whitney test, if the test for 
normality has indicated a non-normal distribution of some unspecified form common to 
both sequences. If the test yields a statistically significant result, this would indicate a 
significant carryover effect from one treatment sequence to the next. If this were the case 
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the accepted norm would be to analyse results from the first period only, before crossover, 
since this period is free of carryover effects, with the resultant diminution of statistical 
power. If the carryover effects are shown to be equal between treatment sequences it is 
then valid to proceed to assessing for a treatment effect. Again an unpaired two-sample t-
test (parametric, normal distribution) or a Mann Whitney test (non-parametric, non-normal 
distribution) for independent samples using the intra-individual differences between 
outcomes in both study periods as the raw data will be utilised.(179)  
 
A basic model of analysis in which outcome after Treatment A is compared directly with 
outcome after Treatment B (i.e. we ignore whether Treatment A is given in Period 1 or 
Period 2, given the fact that a significant carryover effect has already been ruled out) will 
also be calculated. A parametric paired t-test or a non-parametric Wilcoxon matched-pairs 
signed rank test will be adopted for this method of analysis, guided by the baseline test for 
normality. Linear regression will then be used to study the correlation between outcome 
parameters and baseline patient characteristics if a significant treatment effect is 
discovered. Overall, a p value <0.05 will be considered statistically significant. 
 
3.8 Ethics and Regulatory Approvals 
The LIONESS Trial was conducted in compliance with the principles of the Declaration of 
Helsinki (2008), the principles of Good Clinical Practice and in accordance with all applicable 
requirements laid down by the Co-Sponsors of the study, namely: King’s College London 




August 2011 LIONESS Trial confirmed as a physiological non-CTIMP study by the 
Medicines and Healthcare products Regulatory Agency (MHRA).  
 
September 2011 Formal submission of Version 1 of the trial protocol to NRES 
Committee London – Westminster. 
 
September 2011 REC Response requiring further information prior to award of a 
favourable ethical opinion. 
 
January 2012 Trial accepted to the NIHR UK Clinical Research Network portfolio 
(Study ID 11112).  
 
February 2012 Formal submission of Version 2 of the trial protocol to NRES 
Committee London – Westminster. 
 
April 2012 Favourable ethical opinion awarded by NRES Committee London – 
Westminster. 
 
May 2012 LIONESS Trial listed on the NIHR CRN trials database, which is 
accessible to the public at no charge, open to all prospective 
registrants, managed by a not-for-profit organization, has a 
mechanism to ensure the validity of the registration data, and is 
electronically searchable. 
 
May 2012 Guy’s and St Thomas’ NHS Foundation Trust R&D approval received. 
 
May 2012 Notice of Substantial Amendment Form formally submitted to NRES 
Committee London – Westminster: Trial agent changed from once 
daily Liraglutide to once weekly Exenatide. 
 
September 2012 Notice of Substantial Amendment retracted. 
 
October 2012 Minor Amendment to original Version 1 of trial protocol formally 
submitted and listed as Trial Protocol Version 1A. 
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October 2012 Favourable ethical opinion given by NRES Committee for Trial Protocol 
Version 1A since the changes made were not regarded as a Substantial 
Amendment. 
 
November 2012 Further Minor Amendment to Protocol Version 1A submitted to NRES 
Committee encouraged by R&D departments from both KCL and GSTT 
since the protocol was based on a CTIMP rather than a non-CTIMP 
template. New trial protocol listed as Version 1B. 
 
December 2012 Trial Protocol Version 1B accepted by NRES Committee. 
 
December 2012 Trial approval authorised by King’s College London R&D Theme Lead. 
 
December 2013 First patient recruited to the LIONESS Trial 
 
February 2014 Minor Amendment to Protocol Version 1B submitted to NRES 
Committee for addition of a new member of staff to the LIONESS Trial. 
New trial protocol listed as Version 1C. This is the current version of 
the trial protocol in use. 
 
March 2014 Trial Protocol Version 1C accepted by NRES Committee. 
 
May 2014 Annual Non-CTIMP Study Progress Report submitted to NRES 
Committee. 
 
October 2014 Last patient recruited to the LIONESS Trial 
 
November 2014 Last patient completed 6-week LIONESS Trial protocol 
 
November 2014 LIONESS Trial registered on clinicaltrials.gov (NCT02315001). 
 




May 2015 Declaration of the End of a Study form submitted to NRES Committee. 
 




4. Investigation of Liraglutide Stability 
for the LIONESS Trial 
In Version 1 (September 2011 – see Section 3.8) of the LIONESS Trial protocol we had 
planned to use pre-dosed Liraglutide injection pens and matching placebo pens containing 
pre-dosed normal saline. The only manufacturers of this matching placebo injection pen 
were the makers of Liraglutide itself – NovoNordisk. The company had initially agreed to 
provide these placebo pens. Had they fulfilled their initial offer, the trial could have started 
recruiting in April 2012 at which point a favourable ethical opinion had already been 
forthcoming from the NRES Committee London-Westminster. Unfortunately this was not 
the case. NovoNordisk did not honour their initial offer. As such the Guy’s and St Thomas’ 
NHS Foundation Trust Pharmacy Aseptic Services department were approached to produce 
pre-filled syringes containing Liraglutide or volume-matched normal saline as a placebo to 
maintain double-blinding in the trial (Figure 7). Each patient recruited required the 
following in identical 1mL plastic syringes: 
 7 x 0.6 mg pre-filled Liraglutide plus 7 x pre-filled matched-volume saline placebo 
 7 x 1.2 mg pre-filled Liraglutide plus 7 x pre-filled matched-volume saline placebo 
 7 x 1.8 mg pre-filled Liraglutide plus 7 x pre-filled matched-volume saline placebo 
 
Prior to producing these syringes for the trial, the aseptic services department requested 
we perform experiments to confirm the stability of Liraglutide when removed from its 
original pre-filled pen and transferred to a plastic syringe used over a 7-day course (Figure 
7). Again NovoNordisk were approached to provide their enzyme-linked immunosorbent 
assay (ELISA) kit for Liraglutide detection but this request was unsuccessful. To answer this 
question therefore, the CEK 0130-03 competitive enzyme immunoassay kit for Liraglutide 
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detection manufactured by AB Biolabs (Missouri, USA) was used. This was the only other 
Liraglutide assay available on the market. 
 
4.1 Principle Mechanism of the Competitive Enzyme Immunoassay Kit  
The assay kit was based on the competition between peptide (i.e. Liraglutide) and its tracer 
(biotinylated peptide) for a limited number of anti-peptide antibody binding sites. The 
antibody was a rabbit polyclonal which could recognise epitopes within intact Liraglutide 
that differed from those in endogenous GLP-1. Microwells were precoated with secondary 
goat anti-rabbit immunoglobulin G (IgG) antibodies. The concentration of the tracer was 
held constant while the concentration of peptide (standard or unknown sample) varied per 
well. Thus, the amount of tracer that was able to bind to the anti-peptide antibody would 
be inversely proportional to the concentration of the peptide in the well. The primary 
antibody and peptide (either peptide itself or its tracer) complexes bound the secondary 
antibodies attached to the well. The biotinylated peptides then interact with streptavidin-
horseradish peroxidase (SA-HRP), and the colourless solution of tetramethylbenzidine 
(TMB) and hydrogen peroxide mixture becomes blue via horseradish perioxidase (HRP) 
catalysis. Finally the blue coloured solution turns yellow when the reaction is stopped with 
hydrogen chloride (HCl). The intensity of the colour, determined spectrophotometrically, is 
proportional to the amount of peptide tracer and inversely proportional to the amount of 
peptide. A standard curve of a series of known concentrations of peptide would be 
established and the unknown concentrations in samples could be determined by 




4.2 Plan of Investigation 
The detection range of the CEK 0130-03 Liraglutide assay was 0.01 – 1000 ng/ml. As such 
Liraglutide, at an original stock solution concentration of 2 mg/ml or 2 x 106 ng/ml, was 
serially diluted to reach a target concentration of 2 ng/ml according to the protocol 
detailed below (Table 7). These serial dilutions were performed on Liraglutide solution 
taken from the original pre-filled pen as well as Liraglutide contained within the pre-filled 
plastic syringes to be used in the trial (Figure 7). 
 
 
To determine stability under varying conditions, we also tested each set of solutions 
(original pen and plastic syringe) stored at both room temperature (59°F to 86°F; 15°C to 
30°C) and at a refrigerated temperature (36°F to 46°F; 2°C to 8°C) according to the schedule 
detailed in Table 8 from Day 0 through to Day 9 to cover the potential 7-day shelf life of 
each batch of study agent syringes issued weekly during the trial. 
 
 
Table 7 Liraglutide serial dilution protocol for the CEK 0130-03 assay 
Vial Number Volume of Liraglutide  
(2 mg in 1ml) 




# 1 1000 µl ----------- 2 x 106 ng/ml 
# 2 100 µl of #1 9900 µl 2 x 104 ng/ml 
# 3 100 µl of #2 9900 µl 200 ng/ml 




 A control solution of Liraglutide provided with the assay was serially diluted according 
to the protocol below (Table 9). These provided the concentrations from which a 




Table 8 Concentration of Liraglutide tested from Day 0 to Day 9 
Day Liraglutide-O (Pen) 
(Original Pre-Filled Pen) 
Assay Liraglutide-P (Plastic) 
(Plastic Syringe) 
Assay 
 Liraglutide (2 mg/ml) stock solution  Liraglutide (2 mg/ml) stock solution   
0 1000 µl serially diluted to 2 ng/ml Yes 1000 µl serially diluted to 2 ng/ml Yes 
1 1000 µl serially diluted to 2 ng/ml Yes 1000 µl serially diluted to 2 ng/ml Yes 
3 1000 µl serially diluted to 2 ng/ml Yes 1000 µl serially diluted to 2 ng/ml Yes 
5 1000 µl serially diluted to 2 ng/ml Yes 1000 µl serially diluted to 2 ng/ml Yes 
7 1000 µl serially diluted to 2 ng/ml Yes 1000 µl serially diluted to 2 ng/ml Yes 
9 1000 µl serially diluted to 2 ng/ml Yes 1000 µl serially diluted to 2 ng/ml Yes 
Table 9 Serial dilution protocol for control Liraglutide solution 
Standard No. Volume of Variant Standard to 
add 
Volume of Assay 
Buffer to add 
Final Concentration 
# 1 1000 µl ----------- 1,000 ng/ml 
# 2 100 µl of #1 900 µl 100 ng/ml 
# 3 100 µl of #2 900 µl 10 ng/ml 
# 4 100 µl of #3 900 µl 1 ng/ml 
# 5 100 µl of #4 900 µl 0.1 ng/ml 
# 6 100 µl of #5 900 µl 0.01 ng/ml 
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 50 μl of standard was added to each well according to the example plate illustrated in 
the results section. Each concentration was assayed in duplicate. The standard 
concentrations from #6 to #1 (Table 10) corresponded to wells from A-1 and A-2 to F-1 
and F-2.    
 50 μl of assay buffer was added to wells G-1 and G-2, which represented Total Binding. 
 Wells H-1 and H-2 were left empty and regarded as Blank. 
 50 μl of Liraglutide-O (room temperature and refrigerated) and Liraglutide-P (room 
temperature and refrigerated) were added in duplicate to the remaining wells. 
 25 μl of reconstituted anti-peptide antibody solution was added to each well except the 
Blank wells. 
 25 μl of reconstituted biotinylated peptide solution was added to each well except the 
Blank wells. 
 The plate was then covered with a sealer and incubated at room temperature for 2 
hours. Orbital shaking at 300-400 rpm of the plate was conducted for the whole 
duration of the incubation. 
 After the first incubation the solution was decanted from the plate. Each well was 
washed with 350 μl of assay buffer, the buffer discarded, the plate then inverted and 
blotted dry. This procedure was repeated 3 times. 
 100 μl of SA-HRP solution was then added to each well. 
 The plate was covered and then incubated at room temperature for a further 1 hour 
with orbital shaking at 300-400 rpm.       
 Following incubation the solution was decanted from the plate, which was then washed 
and blotted dry as before 3 times. 
 100 μl of TMB mixture solution was then pipetted into each well. The plate was 
covered in aluminium foil to protect it from light degradation after the addition of TMB. 
 A final incubation was performed for a further 1 hour at room temperature with orbital 
shaking at 300-400 rpm. 
 The aluminium foil and plate cover were then removed. To stop the reaction 100 µl 2N 
HCl was added to each well.  
 The plate was then loaded onto a microtitre plate reader and absorbance read at 450 
nm to determine optical density. 
 This was performed from Day 0 to Day 9 on all Liraglutide samples under investigation. 




Following the addition of TMB to each well and the incubation thereafter, a blue colour 
would develop in the wells containing known standard concentrations of Liraglutide. The 
intensity of this blue colour is inversely proportional to increasing concentrations of 
standard Liraglutide. Once the reaction in each well is terminated by the addition of HCl, 
the colour changes from blue to yellow. Ultimately, the higher the concentration of 
standard Liraglutide, the lower the corresponding optical density when read at 450 nm. A 




Figure 9 A Standard Curve Provided as Demonstration Only for the CEK 0130-03 
Liraglutide ELISA (AB Biolabs, Missouri, USA). 
Concentration    ng / ml







CEK 0130-03 Liraglutide   StandardCurve Lot No. 1006147 
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
STD#1 (Standards: Conc vs AvgOD) 2.99 0.777 2.77 0.648 0.998
__________
Curve Fit Option - Fixed Weight Value
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Despite strictly adhering to the CEK 0130-03 assay instructions, the results achieved were 
completely haphazard and did not match what was expected or described by the 
manufacturer. The optical density did not consistently increase as an inverse function of 
standard (control) Liraglutide concentration. The ELISA did confirm the presence of 
Liraglutide in all samples tested from Day 0 to Day 9 but without a reliable standard curve, 
we could not accurately quantify the concentration of Liraglutide in the study samples on 
each day of testing. We could only presume there had to have been degradation of study 
reagents and relayed this information plus a copy of the results (Figure 10 – First Batch of 
ELISA Kit Results) to AB Biolabs. The kit manufacturers then sent a second batch of kits to 
repeat the study. Again, however, the results were inconsistent and unreliable (Figure 11). 
The second set of assays was therefore abandoned after Day 3. 
 
4.5 Discussion 
The results of the unsuccessful assays were reported back to St Thomas’ Hospital Pharmacy 
Aseptic Services. Having looked through the literature we also made them aware of the 
European Medicines Agency Evaluation of Medicines for Human Use of Victoza report from 
2009 which states that Liraglutide is contained within a High Density Polyethylene plastic 
container as part of the pre-filled injection pen device. The 1 mL syringes to be used for the 
LIONESS trial are manufactured by Becton Dickinson (New Jersey, USA) and consist of a 
clear plastic polycarbonate barrel (Product Number 309628). As such we would be 
transferring Liraglutide from a plastic container within the pen in to a plastic syringe. Given 
this information Pharmacy Aseptic Services were satisfied that the stability of Liraglutide 
would not be affected and agreed to provide the pre-dosed syringes for the LIONESS trial to 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5. LIONESS Trial Results 
5.1 Trial Recruitment 
We began actively recruiting to the LIONESS Trial in December 2013. From this point until 
October 2014, a total of 105 chronic stable angina patients were approached for entry in to 
the trial (Table 10 and Figure 12). Of these, 26 patients ultimately fulfilled the inclusion and 
exclusion criteria, attended a screening visit and signed a consent form to participate 
(Figure 13). 
Table 10 Breakdown of LIONESS Trial Recruitment 
Declined consent 44 
Normal ETT 11 
Patient breached 8 
Normal angiogram 2 
Unable to perform ETT 6 
Miscellaneous 8 
Withdrew consent 2 
Stopped trial early 2 

















The main barrier to patient recruitment was the duration of the study along with the 
distance patients would have to travel to attend a total of 7 trial visits on the same day of 
the week over a 6-week period. Many of the chronic stable angina patients that attend St 
Thomas’ Hospital general cardiology outpatient clinics or are awaiting elective coronary 
revascularisation are referred from district general hospitals in the Kent and Sussex regions. 
The vast majority of the 26 patients that signed a consent form to participate in the trial 
were awaiting elective coronary artery bypass graft (CABG) surgery (n=20). The remaining 
were either managed with conservative therapy (n=5) or awaiting elective percutaneous 






















Figure 13 LIONESS Trial Patient Recruitment by Month





Of the 26 patients that signed a consent form, 2 patients withdrew their consent prior to 
randomisation. Two patients (patient identifiers: LIONESS 21 and LIONESS 22) entered the 
trial but were then forced to withdraw from the trial prior to completion of the protocol. 
Prior to recruiting patients awaiting elective revascularisation we ensured there was at 
least a 6-week interval from the beginning of the trial to their planned intervention. A 
condition of the consent process however, meant that those patients awaiting elective 
CABG surgery or PCI would be allowed to leave the trial at any point if the date of their 
revascularisation procedure were to be brought forward. LIONESS 21 left the trial at the 
end of Week 2 and LIONESS 22 at the end of Week 3. Neither LIONESS 21 nor 22 left the 
trial early because of adverse events. A total of 22 patients, therefore, completed the trial 
protocol. Each of these patients had their rate-limiting and anti-anginal medication 
withheld for the duration of the trial protocol (Table 11). The trial was analysed on a per 
protocol basis (rather than an intention to treat basis). Please refer to the CONSORT 
diagram in Figure 15. 
 
Patients were randomised to Group A (Treatment A then Treatment B) or Group B 
(Treatment B then Treatment A). On un-blinding of the trial in November 2015 these 
treatment sequences represented the following: 
 
 Group A = saline placebo for 3 weeks followed by liraglutide therapy for 3 weeks and 
 Group B = liraglutide therapy for 3 weeks followed by saline placebo for 3 weeks. 
 
The remainder of this LIONESS Trial results section will be presented as per treatment 
sequence assignment Group A or Group B (Table 12 and Table 13 respectively) for all those 
patients who completed the entire 6-week protocol. 
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Table 11 LIONESS trial patient cardiovascular medication profile 
Group A Patients CV Medications Continued CV Medications Temporarily Withheld 
LIONESS01 Aspirin 75 mg od, Ramipril 5 mg od, Amlodipine 5 mg od, 
Atorvastatin 40 mg od 
Bisoprolol 5 mg od 
Atorvastatin 40 mg od 
LIONESS02 Aspirin 75 mg od, Losartan 25 mg od, Simvastatin 40 mg od, GTN 
spray 2 puffs PRN 
Atenolol 50 mg 
Isotard XL 30 mg od 
LIONESS04 Aspirin 75 mg od, Losartan 100 mg od, Indapamide 2.5 mg od, 
Atorvastatin 20 mg od, GTN spray 2 puffs PRN 
Bisoprolol 2.5 mg od 
Diltiazem 240 mg od 
LIONESS06 Aspirin 75 mg od, Clopidogrel 75 mg od, Enalapril 25 mg od, 
Amlodipine 5 mg od, Atorvastatin 40 mg od 
Atenolol 50 mg od 
Isosorbide mononitrate MR 120 mg od 
LIONESS09 Clopidogrel 75 mg od, Irbesartan/Hydrochlorothiazide 300/12.5 1 
tablet od, Atorvastatin 10 mg od, GTN spray 2 puffs PRN 
Bisoprolol 2.5 mg od 
LIONESS10 Aspirin 75 mg od, Irbesartan 300 mg od, Lercanidipine 10 mg od, 
Atorvastatin 10 mg od 
Bisoprolol 5 mg od 
LIONESS12 Aspirin 75 mg od, Ramipril 2.5 mg od, Atorvastatin 80 mg nocte, 
GTN spray 2 puff PRN 
Bisoprolol 1.25 mg od 
LIONESS13 Aspirin 75 mg od, Amlodipine 5 mg od, Simvastatin 20 mg od, GTN 
spray 2 puffs PRN 
Nebivolol 5 mg od 
Isosorbide mononitrate 40 mg (am) 20 mg (pm) 
LIONESS17 Aspirin 75 mg od, Atorvastatin 20 mg od, GTN spray 2 puffs PRN Monomil XL 30 mg od 
LIONESS20 Aspirin 75 mg od, Clopidogrel 75 mg od, Losartan 25 mg od, 
Amlodipine 10 mg od, Pravastatin 20 mg od 
Bisoprolol 1.25 mg od 
LIONESS23 Aspirin 75 mg od, Simvastatin 40 mg od, GTN spray 2 puffs PRN Nicorandil 10 mg bd 
LIONESS24 Aspirin 75 mg od, Ticagrelor 90 mg bd, Ramipril 2.5 mg od, 
Atorvastatin 10 mg od, GTN spray 2 puffs PRN  
Bisoprolol 2.5 mg od 
 
Group B Patients CV Medications Continued CV Medications Temporarily Withheld 
LIONESS03 Aspirin 75 mg od, Prasugrel 10 mg od, Ramipril 2.5 mg od, 
Atorvastatin 40 mg od, GTN spray 2 puffs PRN 
Bisoprolol 2.5 mg od 
LIONESS05 Aspirin 75 mg od, Ramipril 2.5 mg od, Atorvastatin 40 mg od, GTN 
spray 2 puffs PRN 
Bisoprolol 5 mg od 
Isosorbide mononitrate 10 mg bd 
LIONESS07 Aspirin 75 mg od, Clopidogrel 75 mg od, Ramipril 10 mg od, 
Indapamide 1.5 mg od, Atorvastatin 40 mg od 
Bisoprolol 10 mg od 
Isotard XL 25 mg od 
LIONESS08 Aspirin 75 mg od, Clopidogrel 75 mg od, Perindopril 2 mg od, 
Amlodipine 5 mg od, Simvastatin 40 mg nocte 
Bisoprolol 5 mg od 
Isotard XL 60 mg od 
LIONESS11 Aspirin 75 mg od, Simvastatin 20 mg od Bisoprolol 2.5 mg od 
Isotard XL 25 mg od 
LIONESS14 Aspirin 75 mg od, Irbasartan 150 mg od, Amlodipine 5 mg od, 
Bendroflumethiazide 2.5 mg od, Atorvastatin 80 mg od, GTN spray 2 
puffs PRN 
Bisoprolol 1.25 mg od 
Nicorandil 20 mg bd 
LIONESS15 Aspirin 75 mg od, Clopidogrel 75 mg od, Ramipril 2.5 mg od, 
Atorvastatin 40 mg od, GTN spray 2 puffs PRN 
Bisoprolol 2.5 mg od 
LIONESS16 Aspirin 75 mg od, Clopidogrel 75 mg od, Enalapril 10 mg od, 
Bendroflumethiazide 2.5 mg od, Atorvastatin 80 mg od, GTN spray 2 
puffs PRN 
Bisoprolol 2.5 mg od 
LIONESS18 Aspirin 75 mg od, Clopidogrel 75 mg od, Ramipril 1.25 mg od, 
Atorvastatin 80 mg od, GTN spray 2 puffs PRN 
Bisoprolol 5 mg od 
LIONESS19 Aspirin 75 mg od, Amlodipine 10 mg od None 
 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2 Exercise Stress Testing 
5.2.1 Guidelines employed to analyse exercise stress tests 
The following guidelines were employed to ensure uniformity of serial exercise stress test 
analysis following completion of the LIONESS Trial (please refer to Section 3.2.5 also): 
 
 Measure ST-segment depression relative to original baseline at start of the exercise test 
– not necessarily the isoelectric line. 
 Any ST-segment deviation in a positive direction should be excluded from the analysis. 
 The first time point at which recovery to 0.05 mV ST-segment depression is achieved 
should be taken as the time to recovery; irrespective of whether there is a biphasic 
pattern of ST-segment deviation occurring in the recovery phase. 
 If the ST-segment is already below the isoelectric line measure recovery to 0.05 mV 
relative to the original baseline. 
 If the ST-segment is below the isoelectric line at baseline and a return to 0.05 mV 
relative to that baseline is not achieved then use the time taken to get back to that 
original baseline. 
 If the ST-segment is above the isoelectric line at baseline take recovery as 0.05 mV 
relative to the original baseline – again not necessarily relative to the isoelectric line. 
 For those patients ultimately achieving their maximum ST-segment depression in 
recovery – use the peak exercise time as the time to max ST-segment depression. 
 For those patients not achieving 0.1 mV ST-segment depression  - use 0.05 mV ST-
segment depression as a cut-off. 
 
All exercise tests were analysed by two investigators independently of each other and 
results compared thereafter. All exercise tests were analysed and the results documented 
before the trial was un-blinded.  
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Given that an increase in Liraglutide dose from 1.2 mg once daily (for 1 week) to 1.8 mg 
once daily (for 1 week) was factored into the study design to determine whether there was 
a dose-response effect on exercise haemodynamics, the exercise tests performed after 
each week during the Liraglutide treatment period will be analysed independently and 
compared with the corresponding exercise test performed on saline placebo. Therefore the 
Week 2 ETT (ETT1) will be compared with the Week 5 ETT (ETT3) and the Week 3 ETT (ETT2) 
with the Week 6 ETT (ETT4) (please refer to Figures 6 and 15). 
 
5.2.2 Percentage of target heart rate achieved 
The rise in heart rate with exercise is universally accepted as an adjunct measure of 
exercise stress test adequacy; if a patient achieves 85% of their age-predicted maximum 
heart rate (i.e. 220 - age), the test is considered to be adequate for detection of myocardial 
ischaemia. Failure to reach this target heart rate (THR) can lead to a test being labelled as 
“nondiagnostic” or “submaximal” but not necessarily abnormal.(180) 
 
Percentage THR achieved by all trial participants at baseline before trial commencement 
and after each week of treatment (irrespective of treatment period) can be seen in Table 
14. Using a one-way ANOVA test with multiple comparisons, there was no significant 
difference in percentage of THR achieved by all trial participants during each of the 4 ETTs 
performed during the course of the trial (see Figure 16). Mean percentage of THR achieved 
across all ETTs performed during the trial was approximately 81 ± 10% which would suggest 
trial participants exercised sufficiently to allow inferences upon myocardial ischaemia to be 
made and would tend to exclude a supplemental training effect during each of the ETTs in 
the trial phase. 
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There was, however, a significant difference between the percentages of THR achieved 
during the baseline ETT prior to trial commencement compared with ETTs performed 
during the trial (p=0.0112) (Figure 16). This difference may reflect an increased familiarity 
and confidence with the exercise stress test procedure as patients progressed from the 
screening visit to the trial phase. 
 
Table 14 Percentage of target heart rate achieved by LIONESS trial participants during serial 
exercise tolerance testing 











ETT3 on  
Liraglutide 1.2 mg 
 
ETT4 on  
Liraglutide 1.8 mg 
 
LIONESS01 59 102 94 87 89 
LIONESS02 89 88 87 91 92 
LIONESS04 78 92 94 92 96 
LIONESS06 69 77 70 72 76 
LIONESS09 74 76 75 75 68 
LIONESS10 70 83 86 86 80 
LIONESS12 86 87 82 78 78 
LIONESS13 56 67 66 75 70 
LIONESS17 80 75 86 74 80 
LIONESS20 95 97 90 99 93 
LIONESS23 78 83 84 85 89 
LIONESS24 86 84 81 76 76 
Group B 
 
LIONESS03 83 96 92 98 101 
LIONESS05 62 63 64 69 68 
LIONESS07 101 92 95 93 92 
LIONESS08 74 76 79 74 83 
LIONESS11 62 79 73 71 77 
LIONESS14 63 80 78 74 76 
LIONESS15 62 70 66 87 71 
LIONESS16 74 64 66 71 60 
LIONESS18 70 77 81 78 75 
LIONESS19 78 78 80 80 80 
Mean 74.95 81.18 80.41 81.14 80.45 
SD 11.93 10.53 9.82 9.20 10.41 
Lower 95% CI 69.67 76.51 76.06 77.06 75.84 
Upper 95% CI 80.24 85.85 84.76 85.22 85.07 






5.3 Primary Endpoints 
5.3.1 Change in rate pressure product at 0.1 mV ST-segment depression 
The rate pressure product (RPP) is the product of heart rate and systolic blood pressure 
expressed as beats/minute mmHg. It is a recognised indicator of myocardial oxygen 
consumption (MVO2) and a valuable marker of cardiac function and overall physical 
fitness.(181) The RPP can be used to gauge haemodynamic response to exercise (Table 15) 
and can be used to titrate exercise intensity to remain below the angina threshold in those 
with chronic stable angina. 
 
Table 15 Rate pressure product as an indicator of haemodynamic response 
 
Haemodynamic Response Rate Pressure Product 
 
High >30000 
High Intermediate 25 - 30000 
Intermediate 20 - 25000 
Low Intermediate 15 - 20000 
Low 10 - 15000 
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The RPP at 0.1 mV STD for ETT1 versus ETT3 can be seen in Table 16. As mentioned 
previously in Section 3.7 (pages 59-60) a preliminary test to expose a carryover effect is first 
performed by comparing the sum of the values over both treatment periods between 
Groups A and B (Table 16: see column “ETT1 + ETT3”). A Mann Whitney test for a non-
parametric distribution was performed which confirmed no significant difference (p= 
0.1802) between the sum totals of Groups A and B (Figure 17). 
 
Table 16 Rate pressure product at 0.1 mV ST-segment depression for ETT1 versus ETT3 
(*denotes RPP at peak exercise when 0.1 mV ST-segment depression was not observed)  
 
GROUP A PATIENT 
 
ETT1 Placebo RPP 
 
ETT3 Lira1.2 RPP 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS01 32856 19600 52456 13256 
LIONESS02 22572 21809 44381 763 
LIONESS04 34100 29376 63476 4724 
LIONESS06 16872* 15301* 32173 1571 
LIONESS09 22000* 20608* 42608 1392 
LIONESS10 22698 23353 46051 -655 
LIONESS12 23975 18327 42302 5648 
LIONESS13 17472* 17066* 34538 406 
LIONESS17 23728 20909 44637 2819 
LIONESS20 19404 17956 37360 1448 
LIONESS23 20900 18139 39039 2761 
LIONESS24 24120* 19920* 44040 4200 
  
 
Average = 43588.42 3194.42 
  
 
SD = 8292.79 3672.68 
 
GROUP B PATIENT 
 
ETT1 Lira1.2 RPP 
 
ETT3 Placebo RPP 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS03 20286 25192 45478 -4906 
LIONESS05 20453 19186* 39639 1267 
LIONESS07 30000* 26344* 56344 3656 
LIONESS08 22260* 21942* 44202 318 
LIONESS11 16650* 18300* 34950 -1650 
LIONESS14 14868 13209 28077 1659 
LIONESS15 16688 16008 32696 680 
LIONESS16 18297 16638 34935 1659 
LIONESS18 19320 17854 37174 1466 
LIONESS19 17545 16402 33947 1143 
  
 













Absence of a carryover effect permits us to determine whether there is a treatment effect. 
As described in Section 3.7 the delineation of a treatment effect can be calculated both as 
unpaired and paired samples. The former is tested by comparing the difference between 
period 1 and period 2 for Groups A and B (Table 16: see column “ETT1 – ETT3”). Based on a 
non-parametric distribution, a Mann Whitney test demonstrated no significant difference 
between the two treatments (p=0.0897). 
 
By adopting a basic model of analysis, RPP at 0.1 mV STD after the first ETT on placebo is 
compared directly with RPP at 0.1 mV STD after Liraglutide 1.2 mg (i.e. we ignore whether 
placebo or Liraglutide 1.2 mg is given in Period 1 or Period 2), a Wilcoxon matched-pairs 
signed rank test (non-parametric distribution; p=0.0968) showed no significant treatment 
effect. In summary Liraglutide 1.2 mg for 1 week did not significantly increase RPP at 0.1 
mV ST-segment depression when compared with saline placebo (Figure 18). 
 
 
The RPP at 0.1 mV ST-segment depression for ETT2 versus ETT4 can be seen in Table 17. 
There was no significant carryover effect from ETT2 to ETT4 for either group of trial 
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participants as evidenced by a Mann Whitney test (p=0.381) of the sum of RPP values (ETT2 
+ ETT4) from both treatment sequences (Figure 19). This result also allows for a treatment 
effect to be analysed. 
 
Table 17 Rate pressure product at 0.1 mV ST-segment depression for ETT2 versus ETT4 
(*denotes RPP at peak exercise when 0.1 mV ST-segment depression was not observed) 
 
GROUP A PATIENT 
 
ETT2 Placebo RPP 
 
ETT4 Lira1.8 RPP 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS01 24871 25929 50800 -1058 
LIONESS02 22127 21774 43901 353 
LIONESS04 35802 25800 61602 10002 
LIONESS06 16478* 16385* 32863 93 
LIONESS09 20680 16320* 37000 4360 
LIONESS10 23115 21692* 44807 1423 
LIONESS12 25740 19264 45004 6476 
LIONESS13 16625* 16728* 33353 -103 
LIONESS17 20844 12672 33516 8172 
LIONESS20 19312 17666 36978 1646 
LIONESS23 18437 20790 39227 -2353 
LIONESS24 23875* 21538* 45413 2337 
  
Average = 42038.67 2612.33 
  
SD = 8431.38 3847.95 
 
GROUP B PATIENT 
 
ETT 2 Lira1.8 RPP 
 
ETT 4 Placebo RPP 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS03 19856 17316 37172 2540 
LIONESS05 20010* 18144 38154 1866 
LIONESS07 27448 18352 45800 9096 
LIONESS08 25155* 22890* 48045 2265 
LIONESS11 20880* 19372* 40252 1508 
LIONESS14 13668 13081 26749 587 
LIONESS15 17710 13312 31022 4398 
LIONESS16 15540 17100 32640 -1560 
LIONESS18 17741 20740 38481 -2999 
LIONESS19 16698 22264 38962 -5566 
  












     
 
 
Comparing the difference between period 1 and period 2 for Groups A and B (Table 17: see 
column “ETT2-ETT4”) there was no significant difference between the treatments (Mann 
Whitney test p=0.7223). By comparing the RPP at 0.1 mV STD directly between the second 
ETT on placebo with the ETT on Liraglutide 1.8 mg (irrespective of trial period), no 
significant treatment effect was discovered (Wilcoxon matched-pairs signed rank test 
p=0.4826). In summary Liraglutide 1.8 mg for 1 week did not significantly increase RPP at 
0.1 mV ST-segment depression when compared with saline placebo (Figure 20). 
 
 
5.3.2 Change in degree of ST-segment depression at peak exercise  
The degree of STD at peak exercise for ETT1 versus ETT3 can be seen in Table 18. There was 
no significant carryover effect from ETT1 to ETT3 comparing the sum of the values over 
both treatment periods between Groups A and B (Mann Whitney test p=0.759) (Figure 21). 






Table 18 ST-segment depression at peak exercise for ETT1 versus ETT3 
 
GROUP A PATIENT 
 
ETT1 Placebo STD (mm) 
 
ETT3 Lira1.2 STD (mm) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS01 1.30 0.00 1.30 1.30 
LIONESS02 1.95 1.75 3.70 0.20 
LIONESS04 1.65 1.20 2.85 0.45 
LIONESS06 0.80 0.75 1.55 0.05 
LIONESS09 0.00 0.00 0.00 0.00 
LIONESS10 0.40 1.10 1.50 -0.70 
LIONESS12 3.30 4.55 7.85 -1.25 
LIONESS13 0.50 0.45 0.95 0.05 
LIONESS17 1.30 1.80 3.10 -0.50 
LIONESS20 1.50 0.70 2.20 0.80 
LIONESS23 2.90 2.80 5.70 0.10 
LIONESS24 0.40 0.45 0.85 -0.05 
  
Average = 2.63 0.04 
  
SD = 2.24 0.67 
 
GROUP B PATIENT 
 
ETT1 Lira1.2 STD (mm) 
 
ETT3 Placebo STD (mm) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS03 1.85 2.25 4.10 -0.40 
LIONESS05 1.45 0.80 2.25 0.65 
LIONESS07 0.70 0.70 1.40 0.00 
LIONESS08 0.00 0.00 0.00 0.00 
LIONESS11 0.60 0.60 1.20 0.00 
LIONESS14 1.50 2.70 4.20 -1.20 
LIONESS15 1.30 1.00 2.30 0.30 
LIONESS16 1.05 0.90 1.95 0.15 
LIONESS18 1.60 1.40 3.00 0.20 
LIONESS19 1.60 2.10 3.70 -0.50 
  










   
 105 
Comparing the difference between period 1 and period 2 for Groups A and B (Table 18: see 
column “ETT1-ETT3”) there was no significant difference between the treatments (Mann 
Whitney test p=0.7829). By comparing the STD at peak exercise directly between the first 
ETT on placebo with the ETT on Liraglutide 1.2 mg (irrespective of trial period), no 
significant treatment effect was discovered (Wilcoxon matched-pairs signed rank test 
p=0.6836). In summary there was no significant difference in the degree of ST-segment 
depression seen at peak exercise when a 1-week period of daily Liraglutide 1.2 mg 
therapy was compared with a 1-week period of daily saline placebo injections (Figure 22). 
 
The degree of STD at peak exercise for ETT2 versus ETT4 can be seen in Table 19. There was 
no significant carryover effect from ETT2 to ETT4 comparing the sum of the values over 
both treatment periods between Groups A and B (Mann Whitney test p=0.6878) (Figure 
23). This permits a treatment effect to be calculated. 
 
Comparing the difference between period 1 and period 2 for Groups A and B (Table 19: see 
column “ETT2-ETT4”) there was no significant difference between the treatments (Mann 
Whitney test p=0.5938). By comparing the STD at peak exercise directly between the 
second ETT on placebo with the ETT on Liraglutide 1.8 mg (irrespective of trial period), no 
significant treatment effect was found (Wilcoxon matched-pairs signed rank test p=0.5709). 
In summary there was no significant difference in the degree of ST-segment depression 
seen at peak exercise when a 1-week period of daily Liraglutide 1.8 mg therapy was 






Table 19 ST-segment depression at peak exercise for ETT2 versus ETT4 
 
GROUP A PATIENT 
 
ETT2 Placebo STD (mm) 
 
ETT4 Lira1.8 STD (mm) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS01 1.50 1.10 2.60 0.40 
LIONESS02 1.85 2.15 4.00 -0.30 
LIONESS04 1.60 1.65 3.25 -0.05 
LIONESS06 0.80 0.50 1.30 0.30 
LIONESS09 1.40 0.50 1.90 0.90 
LIONESS10 1.15 0.95 2.10 0.20 
LIONESS12 1.40 2.50 3.90 -1.10 
LIONESS13 0.30 0.15 0.45 0.15 
LIONESS17 2.60 3.30 5.90 -0.70 
LIONESS20 0.90 1.85 2.75 -0.95 
LIONESS23 2.70 2.80 5.50 -0.10 
LIONESS24 0.30 0.40 0.70 -0.10 
  
Average = 2.86 -0.11 
  
SD = 1.74 0.58 
 
GROUP B PATIENT 
 
ETT2 Lira1.8 STD (mm) 
 
ETT4 Placebo STD (mm) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS03 2.35 2.35 4.70 0.00 
LIONESS05 0.90 0.90 1.80 0.00 
LIONESS07 1.00 0.60 1.60 0.40 
LIONESS08 0.00 0.00 0.00 0.00 
LIONESS11 0.60 0.80 1.40 -0.20 
LIONESS14 2.50 3.40 5.90 -0.90 
LIONESS15 1.40 1.10 2.50 0.30 
LIONESS16 1.30 1.20 2.50 0.10 
LIONESS18 1.20 1.30 2.50 -0.10 
LIONESS19 1.90 1.60 3.50 0.30 
  













5.4 Secondary Endpoints 
5.4.1 Change in total exercise time during sequential exercise tolerance testing performed 
over a 6-week study period 
Total exercise time during ETT1 versus ETT3 can be seen in Table 20. There was no 
significant carryover effect from ETT1 to ETT3 comparing the sum of the values over both 
treatment periods between Groups A and B (Mann Whitney test p=0.7223) (Figure 25). This 
permits a treatment effect to be calculated. 
 
Table 20 Change in total exercise time for ETT1 versus ETT3 
 
GROUP A PATIENT 
 
ETT1 Placebo Total  
Exercise Time (secs) 
 
ETT3 Lira1.2 Total  
Exercise Time (secs) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS01 367 372 739 -5 
LIONESS02 306 409 715 -103 
LIONESS04 233 223 456 10 
LIONESS06 496 550 1046 -54 
LIONESS09 531 469 1000 62 
LIONESS10 518 524 1042 -6 
LIONESS12 243 295 538 -52 
LIONESS13 554 558 1112 -4 
LIONESS17 199 268 467 -69 
LIONESS20 526 465 991 61 
LIONESS23 506 458 964 48 
LIONESS24 240 251 491 -11 
  
Average = 796.75 -10.25 
  
SD = 256.55 52.13 
 
GROUP B PATIENT 
 
ETT1 Lira 1.2 Total  
Exercise Time (secs) 
 
ETT3 Placebo Total  
Exercise Time (secs) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS03 646 687 1333 -41 
LIONESS05 167 201 368 -34 
LIONESS07 459 538 997 -79 
LIONESS08 245 531 776 -286 
LIONESS11 247 659 906 -412 
LIONESS14 523 647 1170 -124 
LIONESS15 505 521 1026 -16 
LIONESS16 402 565 967 -163 
LIONESS18 260 313 573 -53 
LIONESS19 230 253 483 -23 
  











   
 
Comparing the difference between period 1 and period 2 for Groups A and B (Table 20: see 
column “ETT1-ETT3”) there was a significant difference between the treatments (Mann 
Whitney test p=0.0071) suggesting a longer duration of exercise on placebo versus 
Liraglutide 1.2 mg. 
 
By comparing the total exercise time directly between the first ETT on placebo with the ETT 
on Liraglutide 1.2 mg (irrespective of trial period), no significant treatment effect was found 
(Wilcoxon matched-pairs signed rank test p=0.06034) although there did appear to be a 
trend towards a greater duration of exercise on placebo (mean total exercise time 438 ± 
161 seconds) when compared to Liraglutide 1.2 mg (mean total exercise time 388 ± 137 
seconds) (Figure 26). In summary there was a trend towards a longer total exercise time 
after a 1-week course of daily saline placebo injections compared with a 1-week course of 
daily Liraglutide 1.2 mg. This trend appeared to be significant when Groups A and B were 





Total exercise time during ETT2 versus ETT4 can be seen in Table 21. There was no 
significant carryover effect from ETT2 to ETT4 comparing the sum of the values over both 
treatment periods between Groups A and B (Mann Whitney test p=0.4562) (Figure 27). This 
permits a treatment effect to be calculated. 
 
 
Table 21 Change in total exercise time for ETT2 versus ETT4 
GROUP A PATIENT 
 
 
ETT2 Placebo Total  
Exercise Time (secs) 
 
ETT4 Lira1.8 Total  
Exercise Time (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS01 378 389 767 -11 
LIONESS02 341 410 751 -69 
LIONESS04 231 264 495 -33 
LIONESS06 473 443 916 30 
LIONESS09 559 561 1120 -2 
LIONESS10 519 454 973 65 
LIONESS12 431 398 829 33 
LIONESS13 478 616 1094 -138 
LIONESS17 236 360 596 -124 
LIONESS20 546 526 1072 20 
LIONESS23 510 485 995 25 
LIONESS24 242 251 493 -9 
  
Average = 841.75 -17.75 
  
SD = 224.93 63.20 
GROUP B PATIENT 
 
ETT 2 Lira1.8 Total  
Exercise Time (secs) 
 
ETT 4 Placebo Total  
Exercise Time (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS03 690 711 1401 -21 
LIONESS05 192 216 408 -24 
LIONESS07 499 570 1069 -71 
LIONESS08 275 547 822 -272 
LIONESS11 636 598 1234 38 
LIONESS14 587 596 1183 -9 
LIONESS15 557 452 1009 105 
LIONESS16 512 554 1066 -42 
LIONESS18 261 264 525 -3 
LIONESS19 290 246 536 44 
  










Comparing the difference between period 1 and period 2 for Groups A and B (Table 21: see 
column “ETT2-ETT4”) there was no significant difference between the treatments (Mann 
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Whitney test p=0.9361). By comparing the total exercise time directly between the second 
ETT on placebo with the ETT on Liraglutide 1.8 mg (irrespective of trial period), no 
significant treatment effect was found (Wilcoxon matched-pairs signed rank test p=0.9937). 
In summary a 1-week exposure to Liraglutide 1.8 mg daily did not significantly increase 
the total exercise time performed by patients compared with a 1-week regimen of daily 





5.4.2 Change in time to 0.1 mV ST-segment depression during sequential exercise 
tolerance testing performed over a 6-week study period 
Time to 0.1 mV STD during ETT1 versus ETT3 can be seen in Table 22. Of the 22 patients 
who completed the trial protocol, 16 patients demonstrated STD ≥0.1 mV during serial 
exercise stress testing and were entered into this particular analysis. There was no 
significant carryover effect from ETT1 to ETT3 comparing the sum of the values over both 
treatment periods between Groups A and B (Mann Whitney test p=0.2786) (Figure 29). This 
permits a treatment effect to be calculated. 
 
 111 
Table 22 Change in time to 0.1 mV ST-segment depression for ETT1 versus ETT3 
 
GROUP A PATIENT 
 
ETT1 Placebo Time to 1mm STD (secs) 
 
ETT3 Lira1.2 Time to 1mm STD (secs) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS01 301 426 727 -125 
LIONESS02 174 187 361 -13 
LIONESS04 220 200 420 20 
LIONESS10 460 440 900 20 
LIONESS12 120 101 221 19 
LIONESS17 160 220 380 -60 
LIONESS20 260 509 769 -249 
LIONESS23 200 190 390 10 
  
Average = 521 -47.25 
  
SD = 242.14 96.21 
 
GROUP B PATIENT 
 
ETT1 Lira1.2 Time to 1mm STD (secs) 
 
ETT3 Placebo Time to 1mm STD (secs) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS03 353 462 815 -109 
LIONESS05 150 201 351 -51 
LIONESS07 539 588 1127 -49 
LIONESS14 420 398 818 22 
LIONESS15 375 390 765 -15 
LIONESS16 400 520 920 -120 
LIONESS18 240 260 500 -20 
LIONESS19 140 100 240 40 
  










Comparing the difference between period 1 and period 2 for Groups A and B (Table 22: see 
column “ETT1-ETT3”) there was no significant difference in time to 0.1 mV STD between 
the treatments (Mann Whitney test p>0.9999). By comparing the time to 0.1 mV STD 
directly between the first ETT on placebo with the ETT on Liraglutide 1.2 mg irrespective of 
trial period (Table 23), no significant treatment effect was discovered (Wilcoxon matched-
pairs signed rank test p=0.7818). In summary Liraglutide 1.2 mg for 1 week did not 
significantly change the time to 0.1 mV ST-segment depression when compared with 




Table 23 Direct comparison of time to 0.1 mV ST-segment depression on saline placebo 
versus Liraglutide 1.2 mg 
 
Patient Placebo (seconds) Liraglutide 1.2 mg (seconds) 
LIONESS01 301 426 
LIONESS02 174 187 
LIONESS04 220 200 
LIONESS10 460 440 
LIONESS12 120 101 
LIONESS17 160 220 
LIONESS20 260 509 
LIONESS23 200 190 
LIONESS03 462 353 
LIONESS05 201 150 
LIONESS07 588 539 
LIONESS14 398 420 
LIONESS15 390 375 
LIONESS16 520 400 























   
 
 
Time to 0.1 mV STD during ETT2 versus ETT4 can be seen in Table 24. Of the 22 patients 
who completed the trial protocol, 16 patients demonstrated STD ≥0.1 mV during serial 
exercise stress testing and were entered into this particular analysis. There was no 
significant carryover effect from ETT2 to ETT4 comparing the sum of the values over both 
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treatment periods between Groups A and B (Mann Whitney test p=0.2786) (Figure 31). This 
permits a treatment effect to be calculated. 
 
Table 24 Change in time to 0.1 mV ST-segment depression for ETT2 versus ETT4 
 
GROUP A PATIENT 
 
ETT 2 Placebo Time to 1mm STD (secs) 
 
ETT 4 Lira1.8 Time to 1mm STD (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS01 345 354 699 -9 
LIONESS02 188 187 375 1 
LIONESS04 201 210 411 -9 
LIONESS10 400 454 854 -54 
LIONESS12 340 140 480 200 
LIONESS17 142 222 364 -80 
LIONESS20 510 321 831 189 
LIONESS23 225 220 445 5 
  
Average = 557.38 30.38 
  
SD = 204.80 105.45 
 
GROUP B PATIENT 
 
ETT 2 Lira1.8 Time to 1mm STD (secs) 
 
ETT 4 Placebo Time to 1mm STD (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS03 443 460 903 -17 
LIONESS05 192 231 423 -39 
LIONESS07 500 601 1101 -101 
LIONESS14 354 300 654 54 
LIONESS15 380 354 734 26 
LIONESS16 419 490 909 -71 
LIONESS18 250 255 505 -5 
LIONESS19 160 160 320 0 
  










Comparing the difference between period 1 and period 2 for Groups A and B (Table 24: see 
column “ETT2-ETT4”) there was no significant difference in time to 0.1 mV STD between 
the treatments (Mann Whitney test p=0.4881). By comparing the time to 0.1 mV STD 
directly between the second ETT on placebo with the ETT on Liraglutide 1.8 mg irrespective 
of trial period (Table 25), no significant treatment effect was seen (Wilcoxon matched-pairs 
signed rank test p=0.4717). In summary Liraglutide 1.8 mg for 1 week did not significantly 
change the time to 0.1 mV ST-segment depression when compared with saline placebo 
(Figure 32). 
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Table 25 Direct comparison of time to 0.1 mV ST-segment depression on saline placebo 







Liraglutide 1.8 mg (seconds) 
 
LIONESS01 345 354 
LIONESS02 188 187 
LIONESS04 201 210 
LIONESS10 400 454 
LIONESS12 340 140 
LIONESS17 142 222 
LIONESS20 510 321 
LIONESS23 225 220 
LIONESS03 460 443 
LIONESS05 231 192 
LIONESS07 601 500 
LIONESS14 300 354 
LIONESS15 354 380 
LIONESS16 490 419 
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5.4.3 Change in time to maximum ST-segment depression during sequential exercise 
tolerance testing performed over a 6-week study period 
Time to maximum ST-segment depression during ETT1 versus ETT3 can be seen in Table 26. 
There was no significant carryover effect from ETT1 to ETT3 comparing the sum of the 
values over both treatment periods between Groups A and B (Mann Whitney test 
p=0.2613) (Figure 33). This permits a treatment effect to be calculated. 
 
Table 26: Change in time to maximum ST-segment depression ETT1 versus ETT3 
 
GROUP A PATIENT 
 
ETT1 Placebo Time to max STD (secs) 
 
ETT3 Lira1.2 Time to max STD (secs) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS01 345 372 717 -27 
LIONESS02 300 389 689 -89 
LIONESS04 233 223 456 10 
LIONESS06 496 550 1046 -54 
LIONESS09 480 40 520 440 
LIONESS10 480 449 929 31 
LIONESS12 244 295 539 -51 
LIONESS13 554 558 1112 -4 
LIONESS17 199 240 439 -41 
LIONESS20 450 465 915 -15 
LIONESS23 500 410 910 90 
LIONESS24 225 240 465 -15 
  
Average = 728.08 22.92 
  
SD = 245.76 139.08 
 
GROUP B PATIENT 
 
ETT1 Lira1.2 Time to max STD (secs) 
 
ETT3 Placebo Time to max STD (secs) 
 
ETT1 + ETT3 
 
ETT1 - ETT3 
 
LIONESS03 569 630 1199 -61 
LIONESS05 167 201 368 -34 
LIONESS07 459 538 997 -79 
LIONESS08 245 531 776 -286 
LIONESS11 458 654 1112 -196 
LIONESS14 480 647 1127 -167 
LIONESS15 505 390 895 115 
LIONESS16 402 565 967 -163 
LIONESS18 261 313 574 -52 
LIONESS19 230 253 483 -23 
  












Comparing the difference between period 1 and period 2 for Groups A and B (Table 26: see 
column “ETT1-ETT3”) there was a significant difference in time to maximum STD between 
the treatments (Mann Whitney test p=0.0161) such that the time to maximum STD was 
longer after a 1-week regimen of saline placebo compared to a 1-week course of 1.2 mg 
Liraglutide. 
 
By performing a paired comparison of the time to maximum STD directly between the first 
ETT on placebo with the ETT on Liraglutide 1.2 mg irrespective of trial period, there was 
however no significant treatment effect seen (Wilcoxon matched-pairs signed rank test 
p=0.111). In summary a 1-week course of Liraglutide 1.2 mg did not significantly prolong 
the time to maximum ST-segment depression and may indeed have shortened the time 




Time to maximum ST-segment depression during ETT2 versus ETT4 can be seen in Table 27. 
There was no significant carryover effect from ETT2 to ETT4 comparing the sum of the 
values over both treatment periods between Groups A and B (Mann Whitney test p=0.381) 
(Figure 35). This permits a treatment effect to be calculated. 
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Table 27: Change in time to maximum ST-segment depression ETT2 versus ETT4 
 
GROUP A PATIENT 
 
ETT2 Placebo Time to max STD (secs) 
 
ETT4 Lira1.8 Time to max STD (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS01 378 389 767 -11 
LIONESS02 341 410 751 -69 
LIONESS04 231 264 495 -33 
LIONESS06 467 443 910 24 
LIONESS09 460 560 1020 -100 
LIONESS10 510 455 965 55 
LIONESS12 432 389 821 43 
LIONESS13 479 616 1095 -137 
LIONESS17 236 360 596 -124 
LIONESS20 510 526 1036 -16 
LIONESS23 465 480 945 -15 
LIONESS24 220 223 443 -3 
  
Average = 820.33 -32.17 
  
SD = 215.86 62.99 
 
GROUP B PATIENT 
 
ETT2 Lira1.8 Time to max STD (secs) 
 
ETT4 Placebo Time to max STD (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS03 689 711 1400 -22 
LIONESS05 193 216 409 -23 
LIONESS07 500 570 1070 -70 
LIONESS08 90 547 637 -457 
LIONESS11 636 570 1206 66 
LIONESS14 587 596 1183 -9 
LIONESS15 557 452 1009 105 
LIONESS16 512 530 1042 -18 
LIONESS18 261 265 526 -4 
LIONESS19 290 240 530 50 
  











Comparing the difference between period 1 and period 2 for Groups A and B (Table 27: see 
column “ETT2-ETT4”) there was no significant difference in time to maximum STD between 
the treatments (Mann Whitney test p=0.5824). By performing a paired comparison of the 
time to maximum STD directly between the second ETT on placebo with the ETT on 
Liraglutide 1.8 mg irrespective of trial period, there was again no significant treatment 
effect seen (Wilcoxon matched-pairs signed rank test p=0.4826). In summary there was no 
significant difference in the time to maximum STD between a 1-week course of 
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Liraglutide 1.8 mg compared with a 1-week regimen of saline placebo in the same 





5.4.4 Change in recovery time to 0.05 mV ST-segment depression during sequential 
exercise tolerance testing performed over a 6-week study period 
Recovery time to 0.05 mV ST-segment depression during ETT1 versus ETT3 can be seen in 
Table 28. There was no significant carryover effect from ETT1 to ETT3 comparing the sum of 
the values over both treatment periods between Groups A and B (Mann Whitney test 
p=0.5387) (Figure 37). This permits a treatment effect to be calculated. 
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Table 28: Change in recovery time to 0.05 mV ST-segment depression ETT1 versus ETT3 
GROUP A PATIENT ETT1 Placebo Recovery time (secs) ETT3 Lira1.2 Recovery time (secs) ETT1 + ETT3 ETT1 - ETT3 
LIONESS01 530 475 1005 55 
LIONESS02 380 374 754 6 
LIONESS04 60 107 167 -47 
LIONESS06 85 20 105 65 
LIONESS09 40 19 59 21 
LIONESS10 60 39 99 21 
LIONESS12 59 70 129 -11 
LIONESS13 141 68 209 73 
LIONESS17 41 76 117 -35 
LIONESS20 520 320 840 200 
LIONESS23 520 370 890 150 
LIONESS24 60 60 120 0 
  
Average = 374.50 41.50 
  
SD = 373.42 73.17 
GROUP B PATIENT ETT1 Lira1.2 Recovery time (secs) ETT3 Placebo Recovery time (secs) ETT1 + ETT3 ETT1 - ETT3 
LIONESS03 523 500 1023 23 
LIONESS05 381 433 814 -52 
LIONESS07 379 175 554 204 
LIONESS08 360 362 722 -2 
LIONESS11 27 53 80 -26 
LIONESS14 350 500 850 -150 
LIONESS15 51 40 91 11 
LIONESS16 60 106 166 -46 
LIONESS18 294 70 364 224 
LIONESS19 74 120 194 -46 
  
Average = 485.80 14.00 
  
SD = 351.53 115.76 
  
 
Comparing the difference between period 1 and period 2 for Groups A and B (Table 28: see 
column “ETT1-ETT3”) there was no significant difference in recovery time to 0.05 mV STD 
between the treatments (Mann Whitney test p=0.2754). A paired comparison of the 
recovery time to 0.05 mV STD directly between the first ETT on placebo with the ETT on 
Liraglutide 1.2 mg irrespective of trial period, also confirmed no significant treatment effect 
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(Wilcoxon matched-pairs signed rank test p=0.1682). In summary there was no significant 
difference in recovery time to 0.05 mV ST-segment depression when a 1-week course of 
Liraglutide 1.2 mg was compared with a 1-week regimen of saline placebo (Figure 38). 
 
Recovery time to 0.05 mV ST-segment depression during ETT2 versus ETT4 can be seen in 
Table 29. There was no significant carryover effect from ETT2 to ETT4 comparing the sum of 
the values over both treatment periods between Groups A and B (Mann Whitney test 




Comparing the difference between period 1 and period 2 for Groups A and B (Table 29: see 
column “ETT2-ETT4”) there was no significant difference in recovery time to 0.05 mV STD 
between the treatments (Mann Whitney test p=0.3055). A paired comparison of the 
recovery time to 0.05 mV STD directly between the second ETT on placebo with the ETT on 
Liraglutide 1.8 mg irrespective of trial period, also confirmed no significant treatment effect 
(Wilcoxon matched-pairs signed rank test p=0.2649). In summary there was no significant 
difference in recovery time to 0.05 mV ST-segment depression when a 1-week course of 
Liraglutide 1.8 mg was compared with a 1-week regimen of saline placebo (Figure 40). 
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Table 29: Change in recovery time to 0.05 mV ST-segment depression ETT2 versus ETT4 
 
GROUP A PATIENT 
 
ETT2 Placebo Recovery time (secs) 
 
ETT4 Lira1.8 Recovery time (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS01 470 410 880 60 
LIONESS02 300 433 733 -133 
LIONESS04 61 60 121 1 
LIONESS06 61 40 101 21 
LIONESS09 40 40 80 0 
LIONESS10 55 40 95 15 
LIONESS12 80 50 130 30 
LIONESS13 60 40 100 20 
LIONESS17 91 171 262 -80 
LIONESS20 33 340 373 -307 
LIONESS23 490 405 895 85 
LIONESS24 42 40 82 2 
  
Average = 321.00 -23.83 
  
SD = 324.44 106.30 
 
GROUP B PATIENT 
 
ETT2 Lira1.8 Recovery time (secs) 
 
ETT4 Placebo Recovery time (secs) 
 
ETT2 + ETT4 
 
ETT2 - ETT4 
 
LIONESS03 420 540 960 -120 
LIONESS05 180 120 300 60 
LIONESS07 340 510 850 -170 
LIONESS08 15 0 15 15 
LIONESS11 14 112 126 -98 
LIONESS14 458 594 1052 -136 
LIONESS15 70 80 150 -10 
LIONESS16 100 136 236 -36 
LIONESS18 117 105 222 12 
LIONESS19 110 84 194 26 
  












5.4.5 Evidence of hypoglycaemia through twice-daily home blood glucose monitoring and 
once-weekly random serum glucose measurements 
Endogenous GLP-1 does not cause hypoglycaemia, since its stimulatory effect on insulin 
secretion and its inhibitory action on glucagon release switch off when ambient glucose 
levels are <4 mmol/L. Liraglutide too has a relatively small risk of causing hypoglycaemia 
when used in isolation and tends to only cause significant hypoglycaemia when used in 
combination with an insulin secretagogue (e.g. sulphonylurea) or insulin.(75–80) However, 
given that the predominant core of LIONESS Trial participants completing the 6-week 
protocol were non-diabetics (n=20) we felt it was important to monitor random blood 
glucose regularly in all study recruits. This was accomplished by asking patients to take 
twice-daily home blood glucose measurements before and after midday and all before a 
meal. If at all possible patients were asked to take these measurements at roughly the 
same time every day and to record said measurements in a patient diary. Patients were 
trained to use a home blood glucose monitor at their screening visit. At each trial visit an 
investigator took a note of all daily recordings and a random plasma glucose was also 
checked as part of the overall blood work up. 
 
According to the American Diabetes Association (ADA) hypoglycaemia can be defined as the 
following (182): 
 
 Alert value for hypoglycemia: ≤3.9 mmol/L plasma glucose concentration   
 Severe hypoglycemia: 
o Requires assistance of another person to actively administer carbohydrates, 
glucagon, or take other corrective actions  
o Plasma glucose concentrations may not be available during an event 
o Neurological recovery following plasma glucose levels returning to normal 
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considered sufficient evidence that event was induced by low plasma glucose 
concentration 
 Documented symptomatic hypoglycemia: 
o Typical hypoglycemia symptoms accompanied by measured plasma glucose 
 ≤3.9 mmol/L 
 Asymptomatic hypoglycemia: 
o Not accompanied by typical hypoglycemia symptoms but with measured 
plasma glucose ≤3.9 mmol/L 
 Probable symptomatic hypoglycemia: 
o Typical hypoglycemia symptoms not accompanied by plasma glucose 
determination but likely caused by plasma glucose ≤3.9 mmol/L   
 Pseudo-hypoglycemia: 
o Reports of typical hypoglycemia symptoms with measured plasma glucose >3.9 
mmol/L but approaching that threshold 
 
Out of a theoretical 1848 home blood glucose monitoring (HBGM) measurements (i.e. 44 
possible measurements per day from 22 patients multiplied by 42 days), 1818 recordings 
were entered in patient diaries: a return rate of 98.4%. Of those patients randomised to 
Group A (treatment sequence: placebo then Liraglutide) there were 5 (0.3%) blood glucose 
measurements ≤3.9 mmol/L in the placebo phase and 5 (0.3%) measurements ≤3.9 mmol/L 
in the Liraglutide phase. In Group B patients (treatment sequence: Liraglutide then placebo) 
there were 7 (0.4%) blood glucose measurements ≤3.9 mmol/L in the Liraglutide phase and 
2 (0.1%) blood glucose measurements ≤3.9 mmol/L in the placebo phase. None of these 
episodes were accompanied by typical symptoms and as such can be defined as 































































































































































































































































































































































































































































































































































































































We then compared Group A and Group B patients’ HBGM recordings by treatment 
sequence. In Group A there was a significantly lower average BM in the morning (Wilcoxon 
matched-pairs signed rank test p=0.002) and in the afternoon (paired t-test p=0.0025) in 




In Group B there was also a significantly lower average BM in the morning (paired t-test 
0.0003) and in the afternoon (paired t-test p<0.0001) in the Liraglutide trial period versus 
the placebo trial period (see Figures 47 and 48). 
 
   
 
When comparing HBGM recordings in the entire trial cohort blood sugar was again seen to 
be significantly lower both in the morning (Wilcoxon matched-pairs signed rank test 
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p<0.0001) and in the afternoon (paired t-test p<0.0001) during the Liraglutide trial period 
as opposed to the placebo trial period (Figures 49 and 50). 
 
   
 
These results help to confirm and/or strongly indicate the following: 
 Liraglutide has a relatively low risk of hypoglycaemia 
 Liraglutide does lower blood sugar significantly compared with saline placebo but not 
to a dangerously low level 
 Patient compliance to study agents appears to be very high 
 Patient compliance to HBGM measurements appears to be very high 
 Bioactivity/stability of Liraglutide has been retained following transfer from an 
injectable pen to a plastic syringe used by our pharmacy department to maintain 
blinding of study agents 
 
To further confirm these results we also measured random plasma glucose (RPG) at the 





Table 30 Random plasma glucose measurements from trial visits 
Patient Random Plasma Glucose (mmol/L) 
Group A Baseline 
 
Week 1 Week 2 Week 3 Average 
 
Week 4 Week 5 Week 6 Average 
LIONESS01 5.3 
 
6.3 4.8 6.5 5.9 
 
4.5 5.3 5.1 5.0 
LIONESS02 4.9 
 
5.2 4.6 5.8 5.2 
 
4.6 3.8 5.1 4.5 
LIONESS04 5.1 
 
5.8 5.8 4.6 5.4 
 
6.6 6.0 5.8 6.1 
LIONESS06 4.3 
 
5.5 5.4 4.4 5.1 
 
4.3 4.1 5.8 4.7 
LIONESS09 10.4 
 
5.5 8.5 7.5 7.2 
 
8.0 5.9 5.5 6.5 
LIONESS10 6.7 
 
7.7 5 7.1 6.6 
 
5.4 6.0 4.5 5.3 
LIONESS12 6.5 
 
5.4 5.5 7.3 6.1 
 
6.1 4.8 4.8 5.2 
LIONESS13 7.9 
 
7.1 6.8 5.5 6.5 
 
4.7 7.4 5.9 6.0 
LIONESS17 4.6 
 
4.6 4.5 4.5 4.5 
 
4.3 4.7 5.1 4.7 
LIONESS20 5.0 
 
6.4 4.9 4.7 5.3 
 
5.0 4.9 5.4 5.1 
LIONESS23 5.2 
 
7.4 5.2 5.0 5.9 
 
6.0 4.8 4.8 5.2 
LIONESS24 5.5 
 
6.1 6.1 6.2 6.1 
 
5.8 5.5 6.1 5.8 
Group B Baseline 
 
Week 1 Week 2 Week 3 Average 
 
Week 4 Week 5 Week 6 Average 
LIONESS03 4.5 
 
4.5 5.1 4.8 4.8 
 
5.5 5.1 5.4 5.3 
LIONESS05 6.4 
 
5.5 4.3 4.1 4.6 
 
4.8 4.6 5.1 4.8 
LIONESS07 6.6 
 
7.1 5.8 6.3 6.4 
 
7.3 6 6.2 6.5 
LIONESS08 4.1 
 
4.2 3.7 3.8 3.9 
 
4.3 4.4 4.1 4.3 
LIONESS11 5.3 
 
5.2 4.4 4.6 4.7 
 
5.6 5.7 6.1 5.8 
LIONESS14 5.6 
 
5.1 4.8 6.7 5.5 
 
5.4 5.1 6.3 5.6 
LIONESS15 5.1 
 
5.2 4.7 4.1 4.7 
 
4.0 4.8 4.3 4.4 
LIONESS16 5.7 
 
5.9 6.2 3.5 5.2 
 
6.2 5.4 4.8 5.5 
LIONESS18 8.2 
 
4.9 5 6.7 5.5 
 
8.8 8.1 6.5 7.8 
LIONESS19 5.0 
 
4.8 3.5 3.8 4.0 
 
6.3 5.7 5.0 5.7 
  
A repeated measures one-way ANOVA demonstrated a significant difference (p=0.0034) 
when mean RPG at baseline (5.8 ± 1.5 mmol/L) was compared with mean RPG after 
Liraglutide (5.2 ± 0.7 mmol/L) or when mean RPG after placebo (5.7 ± 0.9 mmol/L) was 
compared with mean RPG after Liraglutide. There was no significant difference when mean 





Liraglutide has been shown to significantly lower glycated haemoglobin (HBA1c) in the 
LEAD trials.(75–80) Although trial participants were predominantly non-diabetic we felt 
monitoring HBA1c would be a useful surrogate of Liraglutide activity. HBA1c levels were 
checked at baseline, Week 3 and Week 6 (Table 31). A repeated measures one-way ANOVA 
revealed a significantly lower mean HBA1c after Liraglutide (5.61 ± 0.32 %) compared with 
baseline (5.80 ± 0.45 %) and after placebo (5.76 ± 0.37 %) (p=0.0026) but no significant 
difference in HBA1c when baseline was compared with placebo (Figure 52). This result 
again helps to confirm Liraglutide activity during the course of the trial and supports the 






Table 31 LIONESS Trial HBA1c measurements 
Patient HBA1c (%) 
Group A Baseline Week 3 Week 6 
LIONESS01 5.0 5.3 5.3 
LIONESS02 5.8 5.5 5.5 
LIONESS04 5.4 5.6 5.3 
LIONESS06 5.7 6 6.1 
LIONESS09 5.8 6 5.7 
LIONESS10 5.8 5.9 5.8 
LIONESS12 5.7 5.8 5.5 
LIONESS13 6.2 6.4 6.2 
LIONESS17 5.5 5.6 5.4 
LIONESS20 5.5 5.3 5.6 
LIONESS23 5.9 5.7 5.3 
LIONESS24 5.8 5.8 5.6 
Group B Baseline Week 3 Week 6 
LIONESS03 5.8 5.4 5.7 
LIONESS05 5.4 5.4 5.3 
LIONESS07 7.0 6.4 6.5 
LIONESS08 5.4 5.3 5.5 
LIONESS11 5.3 5.3 5.4 
LIONESS14 5.9 5.7 5.9 
LIONESS15 6.3 5.7 5.8 
LIONESS16 5.7 5.6 5.6 
LIONESS18 6.7 6.0 6.6 
LIONESS19 5.9 5.3 5.5 
    
 
   
 133 
5.4.6 Evidence of renal dysfunction through once-weekly monitoring of serum creatinine 
and estimated glomerular filtration rate 
Renal impairment following Liraglutide therapy has been reported in post-marketing 
studies, usually in association with nausea, vomiting, diarrhea, or dehydration, which may 
sometimes require hemodialysis. For this reason we also monitored weekly creatinine and 
estimated glomerular filtration rate (eGFR) in all patients at baseline and at each trial visit, 
as markers of renal function (Tables 32 and 33). According to the National Kidney 
Foundation normal eGFR ranges from between 90 – 120 mL/min/1.73 m2. 
 




Serum Creatinine (μmol/L) 
 
Group A Baseline 
 
Week 1 Week 2 Week 3 Average 
 
Week 4 Week 5 Week 6 Average 
LIONESS01 90 
 
77 80 83 80 
 
80 86 87 84 
LIONESS02 105 
 
100 86 87 91 
 
86 83 84 84 
LIONESS04 74 
 
72 73 72 72 
 
69 74 72 72 
LIONESS06 82 
 
79 78 74 77 
 
76 79 83 79 
LIONESS09 46 
 
52 54 48 51 
 
51 49 50 50 
LIONESS10 96 
 
99 95 91 95 
 
107 105 99 104 
LIONESS12 71 
 
70 78 70 73 
 
75 83 76 78 
LIONESS13 72 
 
69 71 69 70 
 
66 66 71 68 
LIONESS17 89 
 
83 85 88 85 
 
90 85 87 87 
LIONESS20 161 
 
194 145 154 164 
 
138 135 134 136 
LIONESS23 87 
 
81 85 81 82 
 

















































96 90 91 92 
 
98 83 111 97 
LIONESS05 70 
 
73 75 72 73 
 
66 68 72 69 
LIONESS07 103 
 
90 105 103 99 
 
106 106 111 108 
LIONESS08 81 
 
74 81 76 77 
 
79 83 81 81 
LIONESS11 101 
 
96 104 105 102 
 
108 102 105 105 
LIONESS14 112 
 
112 119 113 115 
 
102 98 113 104 
LIONESS15 81 
 
81 86 86 84 
 
87 82 82 84 
LIONESS16 93 
 
74 81 75 77 
 
74 74 75 74 
LIONESS18 133 
 
129 128 128 128 
 
131 126 128 128 
LIONESS19 115 
 
117 112 112 114 
 
110 117 107 111 








Estimated glomerular filtration rate (mL/min/1.73 m2) 
 
Group A Baseline 
 
Week 1 Week 2 Week 3 Average 
 
Week 4 Week 5 Week 6 Average 
LIONESS01 73 
 
88 84 80 84 
 
84 77 76 79 
LIONESS02 60 
 
64 76 75 72 
 
76 79 78 78 
LIONESS04 97 
 
101 99 101 100 
 
106 97 101 101 
LIONESS06 81 
 
85 86 91 87 
 
89 85 80 85 
LIONESS09 117 
 
101 97 111 103 
 
104 109 106 106 
LIONESS10 66 
 
64 67 71 67 
 
59 60 64 61 
LIONESS12 99 
 
100 89 100 96 
 
93 83 91 89 
LIONESS13 93 
 
97 94 97 96 
 
102 102 94 99 
LIONESS17 75 
 
81 79 76 79 
 
74 79 77 77 
LIONESS20 37 
 
30 42 39 37 
 
44 46 46 45 
LIONESS23 75 
 
81 77 81 80 
 


















































71 77 76 75 
 
69 84 60 71 
LIONESS05 104 
 
99 96 100 98 
 
111 107 100 106 
LIONESS07 64 
 
75 63 64 67 
 
62 62 59 61 
LIONESS08 80 
 
89 80 86 85 
 
83 78 80 80 
LIONESS11 65 
 
69 63 62 65 
 
60 64 62 62 
LIONESS14 60 
 
60 56 60 59 
 
67 70 60 66 
LIONESS15 88 
 
88 82 82 84 
 
81 87 87 85 
LIONESS16 52 
 
67 61 66 65 
 
67 67 66 67 
LIONESS18 46 
 
48 48 48 48 
 
47 49 48 48 
LIONESS19 56 
 
55 57 57 56 
 
59 55 61 58 




A repeated measures one-way ANOVA was used to compare both serum creatinine and 
eGFR parameters at baseline versus placebo trial period versus Liraglutide trial period 
(Figures 53 and 54). There was no significant difference in serum creatinine at baseline 
(91.6 ± 24.6 μmol/L) versus placebo trial period (89.6 ± 24.4 μmol/L) versus Liraglutide trial 
period (88.8 ± 21.0 μmol/L) (p=0.4638). Likewise, there was no significant difference in 
eGFR at baseline (76.2 ± 21.1 mL/min/1.73 m2) versus placebo trial period (77.7 ± 18.8 
mL/min/1.73 m2) versus Liraglutide trial period (77.7 ± 18.6 mL/min/1.73 m2) (p=0.4505). 
Aside from confirming the safety of Liraglutide administration in this particular cohort of 
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chronic stable angina patients, this result also reaffirms the utility of incorporating a 0.6 mg 
Liraglutide run-in phase during the active agent trial period (see Figure 6). This low-dose 
Liraglutide enhances gastrointestinal tolerability thereby reducing the incidence of nausea, 
vomiting and diarrhoea; side effects endemic to the early stages of GLP-1R agonist therapy. 
The benefits of this are twofold. It serves to limit early patient withdrawal from the trial 











5.4.7 Evidence of acute pancreatitis through once weekly monitoring of serum amylase 
alongside telephone and once-weekly face-to-face study visits. 
In the first five LEAD trials, a total of 3978 patients with T2DM participated in double-blind, 
randomised controlled clinical studies to evaluate the glycaemic efficacy and safety of 
Liraglutide as monotherapy and in combination with one or two oral anti-diabetic 
medications.(75–79) During the course of these trials there were 7 cases of pancreatitis in 
patients on Liraglutide compared with 1 case in a patient using an alternative anti-diabetic 
medication. As such the risk of pancreatitis is listed under the “Warnings and Precautions” 
section of standard Liraglutide prescribing information. Although there were too few cases 
to establish a causal relationship, we felt it was important to monitor for pancreatitis in the 
LIONESS Trial population. This was implemented via weekly measurements of serum 
amylase (Table 34), emphasising the need for patients to report symptoms of pancreatitis 
such as abdominal pain, nausea, vomiting, diarrhoea, anorexia, fever, and rigors to the 
Main Patient Liaison during the week between trial visits and directly enquiring about the 
symptoms of pancreatitis at every trial visit.  
 
There were no documented cases of acute pancreatitis during the trial. A repeated 
measures one-way ANOVA of serum amylase at baseline (68.1 ± 27.4 IU) versus mean 
amylase during the placebo phase of the trial (75.1 ± 34.4 IU) versus mean amylase during 
the Liraglutide phase (77.6 ± 41.5 IU) of the trial found no significant difference in serum 
amylase levels between the treatment periods (p=0.0248) (Figure 55). There was a trend 
towards slightly higher amylase levels following Liraglutide therapy compared to baseline 
and placebo but this did not reach significance. This only serves to confirm exogenous GLP-
1 activity rather than any adverse side effect. 
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Table 34 LIONESS Trial serum amylase measurements 
Patient Serum Amylase (IU) 
Group A Baseline 
 
Week 1 Week 2 Week 3 Average 
 
Week 4 Week 5 Week 6 Average 
LIONESS01 NA 
 
47 NA 45 46 
 
45 48 50 48 
LIONESS02 72 
 
73 80 73 75 
 
72 87 92 84 
LIONESS04 131 
 
145 137 153 145 
 
152 159 149 153 
LIONESS06 51 
 
43 40 44 42 
 
55 52 47 51 
LIONESS09 35 
 
43 37 40 40 
 
37 24 31 31 
LIONESS10 83 
 
82 85 73 80 
 
79 96 81 85 
LIONESS12 65 
 
62 57 67 62 
 
62 58 45 55 
LIONESS13 51 
 
54 54 54 54 
 
51 51 61 54 
LIONESS17 47 
 
46 44 43 44 
 
44 45 46 45 
LIONESS20 84 
 
116 98 103 106 
 
123 172 201 165 
LIONESS23 81 
 
88 96 85 90 
 

















































57 55 58 57 
 
64 55 51 57 
LIONESS05 48 
 
56 48 68 57 
 
132 76 56 88 
LIONESS07 42 
 
48 46 46 47 
 
46 46 45 46 
LIONESS08 108 
 
107 102 101 103 
 
122 126 108 119 
LIONESS11 48 
 
47 47 57 50 
 
56 45 45 49 
LIONESS14 54 
 
55 47 51 51 
 
52 48 46 49 
LIONESS15 40 
 
49 51 50 50 
 
54 45 40 46 
LIONESS16 82 
 
85 72 63 73 
 
91 96 97 95 
LIONESS18 69 
 
79 78 68 75 
 
84 70 70 75 
LIONESS19 129 
 
129 148 255 177 
 
192 151 142 162 





The LEAD trials along with those of Astrup et al. and Pi-Sunyer et al. have all demonstrated 
the ability of Liraglutide to stimulate significant weight loss independent of glycaemic 
control.(72,75–80,172) Native GLP-1 slows down gastric emptying which promotes a feeling 
of fullness. This is also the likely substrate for the nausea, vomiting and diarrhoea 
associated with incretin-based therapies. GLP-1 also provokes a sense of satiety centrally. 
Altogether these factors result in weight loss. During the course of the trial we documented 
weight (in kilograms) at baseline and at every trial visit thereafter (Table 35). 
 






Group A Baseline 
 
Week 1 Week 2 Week 3 Average 
 
Week 4 Week 5 Week 6 Average 
LIONESS01 103.0 
 
103.5 101.0 102.1 102.2 
 
101.8 100.0 100.8 100.9 
LIONESS02 93.9 
 
92.6 91.5 92.1 92.1 
 
91.0 91.5 92.3 91.6 
LIONESS04 98.3 
 
99.0 97.7 97.5 98.1 
 
98.5 97.6 97.5 97.9 
LIONESS06 102.5 
 
103.6 104.3 104.5 104.1 
 
103.9 103.6 102.1 103.2 
LIONESS09 62.3 
 
61.9 62.1 61.8 61.9 
 
61.7 60.2 60.1 60.7 
LIONESS10 78.7 
 
77.8 78.0 77.5 77.8 
 
76.8 77.6 76.4 76.9 
LIONESS12 70.6 
 
71.0 69.7 70.4 70.4 
 
70.5 68.8 67.7 69.0 
LIONESS13 68.3 
 
67.8 67.6 67.8 67.7 
 
67.6 67.3 66.6 67.2 
LIONESS17 105.9 
 
106.1 106.5 106.8 106.5 
 
106.1 106.5 105.5 106.0 
LIONESS20 94.3 
 
94.4 93.5 93.6 93.8 
 
93.7 92.2 92.6 92.8 
LIONESS23 89.4 
 
89.2 89.4 89.4 89.3 
 

















































101.8 101.5 100.1 101.1 
 
100.2 100.2 100.0 100.1 
LIONESS05 81.5 
 
79.9 78.3 78.6 78.9 
 
79.2 80.3 81.5 80.3 
LIONESS07 126.4 
 
126.1 126.0 124.6 125.6 
 
122.0 122.4 122.0 122.1 
LIONESS08 68.6 
 
68.9 67.9 68.1 68.3 
 
68.6 68.1 67.9 68.2 
LIONESS11 87.8 
 
87.2 86.0 85.7 86.3 
 
86.4 87.3 87.5 87.1 
LIONESS14 78.2 
 
78.4 77.6 77.0 77.7 
 
77.5 77.3 77.4 77.4 
LIONESS15 102.6 
 
102.8 101.9 101.7 102.1 
 
102.0 102.3 103.1 102.5 
LIONESS16 58.7 
 
57.6 56.5 56.1 56.7 
 
57.5 57.9 57.9 57.8 
LIONESS18 95.7 
 
95.7 95.0 94.2 95.0 
 
94.2 95.5 94.4 94.7 
LIONESS19 96.8 
 
95.6 95.9 95.2 95.6 
 
95.0 95.3 94.9 95.1 
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A repeated measures one-way ANOVA comparing weight at baseline (88.75 ± 16.5 kg) 
versus mean weight after the placebo phase (88.11 ± 16.27 kg) versus mean weight after 
the Liraglutide phase (87.78 ± 16.86 kg) confirmed a significant difference (p=0.0008). On 
multiple comparisons the significant difference lay between mean weight at baseline versus 
mean weight after Liraglutide. There was no significant difference between mean weight at 
baseline versus mean weight after placebo as expected. Neither was there a significant 
difference between mean weight after placebo versus mean weight after Liraglutide (Figure 
56). This again tentatively helps to confirm patient compliance with study agents along with 
the stability of Liraglutide in the plastic syringes used to administer the drug. It is important 
to note the specific weight loss trials by Astrup and Pi-Sunyer were performed over a 20-
week and 56-week period respectively.(72,172) As such the incremental weight loss seen 
during the LIONESS Trial cannot be expected to be as impressive as those trials. 





5.6 Blood Pressure 
Liraglutide has been shown to positively modulate BP. Whether this beneficial effect 
ultimately confers an improvement in cardiovascular morbidity and mortality is yet to be 
determined. Of note the BP reduction observed in the LEAD trials occurred within the first 
two weeks of therapy, which would suggest a mechanism of action independent of weight 
loss.(75–80) Here, BP was recorded at the screening visit and during each trial visit. Four 
measurements separated by 5 minutes each were taken at all the trial visits and the 
average of these recordings was documented. Patients were kindly asked to refrain from 
drinking any caffeine-containing drinks within 2 hours of the trial visit. Results for systolic 
and diastolic BP can be seen in Tables 36 and 37 respectively. 
Table 36 Changes in systolic blood pressure during the LIONESS Trial 
Patient Systolic Blood Pressure (mmHg) 
Group A BASELINE 
 
WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS01 150 
 
175 151 153 160 
 
142 129 137 136 
LIONESS02 165 
 
140 159 156 152 
 
144 151 155 150 
LIONESS04 169 
 
186 194 193 191 
 
201 186 179 189 
LIONESS06 150 
 
149 149 145 148 
 
147 129 142 139 
LIONESS09 158 
 
149 136 137 141 
 
138 154 147 146 
LIONESS10 148 
 
151 156 164 157 
 
143 122 132 132 
LIONESS12 121 
 
159 142 117 139 
 
135 142 122 133 
LIONESS13 149 
 
151 161 140 151 
 
139 146 123 136 
LIONESS17 147 
 
122 132 112 122 
 
125 127 119 124 
LIONESS20 107 
 
121 126 122 123 
 
128 130 136 131 
LIONESS23 139 
 
133 147 124 135 
 
137 125 136 133 
LIONESS24 128 
 
156 155 144 152 
 
152 131 140 141 
Group B BASELINE 
 
WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS03 132 
 
125 122 115 121 
 
138 152 110 133 
LIONESS05 100 
 
159 149 143 150 
 
134 134 127 132 
LIONESS07 128 
 
163 146 136 148 
 
138 151 143 144 
LIONESS08 129 
 
166 163 142 157 
 
133 131 140 135 
LIONESS11 115 
 
109 124 129 121 
 
107 127 135 123 
LIONESS14 120 
 
107 108 106 107 
 
109 104 109 107 
LIONESS15 120 
 
120 120 121 120 
 
117 121 115 118 
LIONESS16 128 
 
155 121 148 141 
 
137 119 132 129 
LIONESS18 120 
 
128 134 129 130 
 
133 133 130 132 
LIONESS19 134 
 
129 126 142 132 
 
142 138 138 139 
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Table 37 Changes in diastolic blood pressure during the LIONESS Trial 
Patient Diastolic Blood Pressure (mmHg) 
Group A BASELINE 
 
WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS01 67 
 
84 78 82 81 
 
75 81 80 79 
LIONESS02 93 
 
93 94 88 92 
 
92 101 95 96 
LIONESS04 92 
 
109 129 128 122 
 
132 117 119 123 
LIONESS06 90 
 
79 74 79 77 
 
81 81 78 80 
LIONESS09 89 
 
77 82 78 79 
 
75 97 86 86 
LIONESS10 62 
 
57 63 72 64 
 
63 56 60 60 
LIONESS12 78 
 
100 87 81 89 
 
79 90 85 85 
LIONESS13 86 
 
74 74 71 73 
 
70 69 77 72 
LIONESS17 78 
 
84 65 65 71 
 
60 79 64 68 
LIONESS20 63 
 
73 77 75 75 
 
78 74 76 76 
LIONESS23 72 
 
67 74 64 68 
 
67 68 77 71 
LIONESS24 88 
 
89 91 89 90 
 
87 84 86 86 
Group B BASELINE 
 
WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS03 84 
 
71 87 89 82 
 
85 107 82 91 
LIONESS05 68 
 
93 91 96 93 
 
79 83 81 81 
LIONESS07 86 
 
114 93 96 101 
 
94 100 89 94 
LIONESS08 67 
 
98 98 78 91 
 
74 76 81 77 
LIONESS11 76 
 
74 77 81 77 
 
66 87 78 77 
LIONESS14 77 
 
68 76 62 69 
 
70 66 57 64 
LIONESS15 79 
 
79 75 72 75 
 
71 79 74 75 
LIONESS16 65 
 
71 62 71 68 
 
74 66 67 69 
LIONESS18 79 
 
81 73 83 79 
 
75 73 81 76 
LIONESS19 73 
 
75 76 81 77 
 
82 79 73 78 
            
 
A repeated measures one-way ANOVA of mean systolic BP at baseline (134.4 ± 18.3 mmHg) 
versus mean systolic BP after placebo (139.2 ± 17.7 mmHg) versus mean systolic BP after 
Liraglutide (137.1 ± 16.5 mmHg) showed no significant differences after multiple 
comparisons (p=0.2284) (Figure 57). 
 
A repeated measures one-way ANOVA of mean diastolic BP at baseline (77.8 ± 9.8 mmHg) 
versus mean diastolic BP after placebo (80.1 ± 12.8 mmHg) versus mean diastolic BP after 
Liraglutide (81.6 ± 13.6 mmHg) also revealed no significant differences after multiple 








5.7 Lipid Profile 
GLP-1R agonists have been shown to positively modulate lipid profile.(73,74,78,80,85) For 
this reason we checked lipid profiles in all trial patients at baseline, before crossover after 
Week 3 and at the end of the trial after Week 6. These were non-fasting samples looking at 
total cholesterol (TC) (Table 38), low density lipoprotein-cholesterol (LDL-C) (Table 39) and 
high density lipoprotein-cholesterol (HDL-C) (Table 40). 
 
Table 38 Changes in total cholesterol during the LIONESS Trial 
Patients Baseline total cholesterol (mmol/L) Total cholesterol after placebo (mmol/L) Total cholesterol after Liraglutide (mmol/L) 
LIONESS01 3.2 3.0 2.7 
LIONESS02 3.0 2.4 2.2 
LIONESS04 2.9 3.8 3.4 
LIONESS06 4.9 4.7 4.3 
LIONESS09 4.6 4.8 4.3 
LIONESS10 4.7 4.7 4.0 
LIONESS12 4.0 5.0 4.5 
LIONESS13 2.6 3.1 3.4 
LIONESS17 5.8 5.4 4.8 
LIONESS20 4.0 5.0 3.9 
LIONESS23 3.1 3.5 2.8 
LIONESS24 3.9 4.0 3.5 
LIONESS03 3.3 3.0 2.7 
LIONESS05 4.3 4.5 3.1 
LIONESS07 3.5 3.3 3.0 
LIONESS08 3.8 3.8 3.5 
LIONESS11 5.5 4.6 4.0 
LIONESS14 4.4 5.0 4.2 
LIONESS15 3.7 3.9 3.4 
LIONESS16 3.7 4.4 3.1 










Mean 3.97 4.14 3.56 







Table 39 Changes in low density lipoprotein-cholesterol during the LIONESS Trial 
Patients Baseline LDL-C (mmol/L) LDL-C after placebo (mmol/L) LDL-C after Liraglutide (mmol/L) 
LIONESS01 1.58 1.39 1.21 
LIONESS02 0.88 0.55 0.47 
LIONESS04 1.63 2.39 2.02 
LIONESS06 2.26 2.32 1.91 
LIONESS09 2.01 1.92 1.95 
LIONESS10 2.41 2.33 1.95 
LIONESS12 1.71 3.17 3.02 
LIONESS13 1.13 1.35 1.73 
LIONESS17 3.82 3.43 3.04 
LIONESS20 2.39 3.23 2.22 
LIONESS23 1.39 1.81 1.12 
LIONESS24 1.87 1.95 1.47 
LIONESS03 1.41 1.17 0.94 
LIONESS05 2.16 2.57 1.63 
LIONESS07 1.83 1.63 1.41 
LIONESS08 1.29 1.26 1.24 
LIONESS11 3.00 2.39 1.88 
LIONESS14 2.40 2.55 2.22 
LIONESS15 1.80 2.08 1.79 
LIONESS16 1.83 2.12 1.45 










Mean 1.99 2.14 1.77 






Table 40 Changes in high density lipoprotein-cholesterol during the LIONESS Trial 
Patients Baseline HDL-C (mmol/L) HDL-C after placebo (mmol/L) LDL-C after Liraglutide (mmol/L) 
LIONESS01 0.99 0.95 0.99 
LIONESS02 1.13 1.09 1.14 
LIONESS04 0.78 0.84 0.91 
LIONESS06 1.20 0.97 1.06 
LIONESS09 2.07 2.35 1.95 
LIONESS10 1.33 1.30 1.36 
LIONESS12 0.81 1.04 1.01 
LIONESS13 0.84 0.82 0.84 
LIONESS17 1.22 1.12 1.09 
LIONESS20 1.30 1.47 1.37 
LIONESS23 1.38 1.33 1.37 
LIONESS24 1.77 1.77 1.70 
LIONESS03 1.18 1.30 1.31 
LIONESS05 0.85 1.08 0.80 
LIONESS07 1.14 1.09 1.09 
LIONESS08 1.88 1.87 1.67 
LIONESS11 1.53 1.49 1.42 
LIONESS14 1.04 1.13 1.04 
LIONESS15 1.34 0.96 1.12 
LIONESS16 1.30 1.51 1.25 










Mean 1.24 1.26 1.21 







Repeated measures one-way ANOVA of TC measurements throughout the trial 
demonstrated a significant difference (p<0.0001). After multiple comparisons there was a 
significant difference between baseline TC versus TC after Liraglutide therapy and a 
significant difference between TC after placebo versus TC after Liraglutide (Figure 59). 
There was no significant difference between baseline TC versus TC after placebo. 
 
Repeated measures one-way ANOVA of LDL-C measurements throughout the trial also 
revealed a significant difference (p=0.0025). After multiple comparisons there was a 
significant difference between LDL-C after placebo versus LDL-C after Liraglutide only 
(Figure 60). There were no significant differences elsewhere. Repeated measures one-way 
ANOVA of HDL-C measurements throughout the trial demonstrated no significant 
differences (p=0.3635 (Figure 61). 
 
Whether the significant differences found in the lipid profile were due simply to biological 
variation or a direct result of biochemical modulation by Liraglutide is difficult to say given 
the small sample size and limited study duration. 
 147 
5.8 Symptoms 
5.8.1 Angina episodes 
Trial participants were given a patient diary and asked to note down all episodes of angina 
occurring throughout the study duration. These episodes were then documented in the 
Case Report Form at every trial visit. We felt this exercise was all the more pertinent given 
that we had temporarily discontinued all rate-limiting and anti-anginal medications patients 
had been taking prior to entering the trial (see Table 11 page 85). The frequency of angina 
episodes were, however, relatively low (Table 41). There was also no significant difference 
in frequency of angina on placebo when compared with Liraglutide (Wilcoxon matched-
pairs signed rank test p=0.1433) (Figure 62). 
Table 41 Frequency of angina episodes during the LIONESS Trial 
Group A WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS01 2 0 0 1 
 
1 2 1 1 
LIONESS02 0 0 1 0 
 
0 0 0 0 
LIONESS04 1 2 1 1 
 
1 1 2 1 
LIONESS06 2 0 0 1 
 
0 0 0 0 
LIONESS09 0 0 0 0 
 
1 2 0 1 
LIONESS10 0 0 0 0 
 
0 0 0 0 
LIONESS12 5 4 2 4 
 
0 0 0 0 
LIONESS13 1 1 0 1 
 
1 0 2 1 
LIONESS17 1 0 0 0 
 
1 0 0 0 
LIONESS20 0 0 0 0 
 
0 1 1 1 
LIONESS23 0 0 0 0 
 





















Group B  WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS03 0 0 1 0 
 
2 2 0 1 
LIONESS05 1 0 1 1 
 
0 0 0 0 
LIONESS07 1 0 0 0 
 
0 0 0 0 
LIONESS08 0 0 0 0 
 
0 0 2 1 
LIONESS11 2 2 1 2 
 
0 0 1 0 
LIONESS14 1 0 0 0 
 
0 0 0 0 
LIONESS15 0 0 0 0 
 
1 2 1 1 
LIONESS16 0 0 0 0 
 
1 0 2 1 
LIONESS18 4 0 3 2 
 
9 3 5 6 
LIONESS19 3 1 0 1 
 
7 2 5 5 





5.8.2 Gastrointestinal symptoms 
Gastrointestinal (GI) upset is fairly common on commencing GLP-1R agonist therapy. As 
such we thought it prudent to monitor for this side effect. As with angina frequency, we 
asked all trial recruits to note down any episodes of nausea, vomiting, abdominal 
discomfort and diarrhoea in their diaries. The incorporation of a run-in phase of low dose 
Liraglutide in the trial design has ultimately led to a relatively low incidence of GI symptoms 
(Table 42). As expected, however, there was a significantly higher incidence of GI symptoms 
after Liraglutide therapy when compared with placebo (Wilcoxon matched-pairs signed 
rank test p=0.0078) (Figure 63). These GI symptoms did not lead to the premature 
withdrawal of any patients from the trial. They also serve to help confirm the stability of 







Table 42 Frequency of gastrointestinal symptoms during the LIONESS Trial 
Group A WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS01 0 0 0 0 
 
0 0 0 0 
LIONESS02 0 0 0 0 
 
0 0 0 0 
LIONESS04 0 0 0 0 
 
0 0 2 1 
LIONESS06 0 0 0 0 
 
0 0 0 0 
LIONESS09 2 2 0 1 
 
0 5 0 2 
LIONESS10 0 0 0 0 
 
8 0 0 3 
LIONESS12 0 0 0 0 
 
0 0 0 0 
LIONESS13 0 0 1 0 
 
1 3 0 1 
LIONESS17 0 0 0 0 
 
0 0 0 0 
LIONESS20 0 0 0 0 
 
0 0 0 0 
LIONESS23 0 0 0 0 
 





















Group B WEEK 1 WEEK 2 WEEK 3 Average 
 
WEEK 4 WEEK 5 WEEK 6 Average 
LIONESS03 1 0 0 0 
 
0 0 0 0 
LIONESS05 1 1 1 1 
 
0 0 0 0 
LIONESS07 0 0 0 0 
 
0 0 0 0 
LIONESS08 0 0 1 0 
 
0 0 0 0 
LIONESS11 1 4 0 2 
 
0 0 0 0 
LIONESS14 2 0 0 1 
 
0 0 0 0 
LIONESS15 0 1 0 0 
 
0 0 0 0 
LIONESS16 0 0 1 0 
 
0 0 0 0 
LIONESS18 0 2 0 1 
 
0 0 0 0 
LIONESS19 0 0 0 0 
 
0 0 0 0 





5.9 Summary of Results from the LIONESS Trial 
 Mean percentage of THR achieved across all ETTs performed during the LIONESS Trial 
was approximately 81 ± 10%. 
 Liraglutide 1.2 mg for 1 week did not significantly increase the RPP at 0.1 mV ST-
segment depression when compared with a 1-week course of saline placebo. 
 Liraglutide 1.8 mg for 1 week did not significantly increase the RPP at 0.1 mV ST-
segment depression when compared with a 1-week course of saline placebo. 
 There was no significant difference in the degree of ST-segment depression seen at 
peak exercise when a 1-week period of daily Liraglutide 1.2 mg therapy was compared 
with a 1-week period of daily saline placebo injections. 
 There was no significant difference in the degree of ST-segment depression seen at 
peak exercise when a 1-week period of daily Liraglutide 1.8 mg therapy was compared 
with a 1-week period of daily saline placebo injections. 
 There was a trend towards a longer total exercise time after a 1-week course of daily 
saline placebo injections compared with a 1-week course of daily Liraglutide 1.2 mg. 
This trend appeared to be significant when Groups A and B were analysed in an 
unpaired fashion although we suspect this is likely to be a random effect. 
 A 1-week exposure to Liraglutide 1.8 mg daily did not significantly increase the total 
exercise time performed by patients compared with a 1-week regimen of daily saline 
placebo injections. 
 Liraglutide 1.2 mg for 1 week did not significantly change the time to 0.1 mV ST-
segment depression when compared with saline placebo. 
 Liraglutide 1.8 mg for 1 week did not significantly change the time to 0.1 mV ST-
segment depression when compared with saline placebo. 
 A 1-week course of Liraglutide 1.2 mg did not significantly prolong the time to 
maximum ST-segment depression and may indeed have shortened the time to 
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maximum STD according to an unpaired analysis of treatment effect, although this 
again could be a random effect. 
 There was no significant difference in the time to maximum STD between a 1-week 
course of Liraglutide 1.8 mg compared with a 1-week regimen of saline placebo in the 
same individuals. 
 There was no significant difference in recovery time to 0.05 mV ST-segment depression 
when a 1-week course of Liraglutide 1.2 mg was compared with a 1-week regimen of 
saline placebo. 
 There was no significant difference in recovery time to 0.05 mV ST-segment depression 
when a 1-week course of Liraglutide 1.8 mg was compared with a 1-week regimen of 
saline placebo. 
 Mean home blood glucose measurements were significantly lower in the Liraglutide 
phase of the trial compared with the placebo phase of the trial in all patients. This did 
not, however, result in any symptomatic episodes of hypoglycaemia. 
 Random plasma glucose was also significantly lower during the Liraglutide phase of the 
trial versus both RPG at baseline and RPG during placebo. 
 HBA1c was significantly lower during the Liraglutide phase versus baseline and versus 
the placebo phase. 
 There was no evidence of deterioration of renal function throughout the study. 
 There were no episodes of acute pancreatitis during the entire course of the trial. 
 There was a significant reduction in weight after Liraglutide therapy when compared 
with weight at baseline. 
 There were no significant changes in systolic or diastolic blood pressure throughout the 
study. 
 There were significant reductions in total cholesterol and LDL-cholesterol after the 
Liraglutide phase of the study when compared with baseline and the placebo phase. 
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 There were no significant differences in the frequency of angina when patients were on 
Liraglutide or placebo. 
 There were significantly higher cases of gastrointestinal symptoms when patients were 
taking Liraglutide although the overall incidence of events was low. 
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6. Retrospective Audit of LIONESS Trial 
Patients Proceeding to Elective CABG 
Surgery 
By virtue of its crossover design the LIONESS Trial did not have a formal follow-up period 
and ended once the last ETT was completed after week 6. Thereafter all patients were 
asked to recommence their pre-trial medication and continue with whatever management 
plan had already been in place for their chronic stable angina. Of the 22 patients that 
completed the 6-week trial, 17 patients went on to have elective CABG surgery. We 
thought it would be of interest to perform a retrospective audit of the interval from 
LIONESS Trial completion up to the time of CABG surgery and 1-year thereafter, to look at 
clinical course along with all-cause and cardiovascular mortality (Table 43). This was not a 
pre-specified analysis of the LIONESS Trial. Patients waited an average of 24 ± 27 days for 
elective surgery after the trial. All 17 patients survived to hospital discharge. There has 
been no all-cause or cardiovascular mortality at 1-year. There was no significant difference 
in days spent on the high dependency unit (Mann-Whitney test p=0.81); days to hospital 
discharge (Mann Whitney test p=0.72); cardiopulmonary bypass time (Mann Whitney test 
p=0.78) or aortic cross clamp time (Mann Whitney test p=0.87) between those trial patients 
randomised to Group A (placebo then Liraglutide) versus those in Group B (Liraglutide then 
placebo) (see Figures 64-67). Clearly there are a multitude of factors that could affect these 
variables but it appears participation in the LIONESS Trial had no bearing on patient 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To the best of our knowledge we have shown for the first time in the literature that 
Liraglutide, acting as a surrogate for chronic GLP-1R activation, does not act as an anti-
anginal agent in a cohort of chronic stable angina patients with known obstructive coronary 
artery disease and does not positively enhance any parameters of haemodynamic 
performance measured during serial exercise stress testing. Liraglutide did not significantly 
augment indices of cardiac function such as the rate pressure product and did not 
attenuate the degree of ST-segment depression seen at peak exercise. There was no dose-
response effect seen either, such that both the standard dose of 1.2 mg of Liraglutide and a 
higher dose of 1.8 mg Liraglutide did not provoke a significant anti-anginal or anti-ischaemic 
effect during serial exercise stress testing. Furthermore, Liraglutide did not significantly 
reduce the number of angina episodes when compared with placebo, although the overall 
incidence of angina in the patient cohort was relatively low. 
 
In contrast we did demonstrate the safety of using Liraglutide in a predominantly non-
diabetic population, further emphasising the fact that GLP-1-mediated stimulation of 
insulin secretion and inhibition of glucagon release switches off when ambient glucose 
levels are <4 mmol/L. There were no symptomatic episodes of hypoglycaemia recorded 
throughout the duration of the trial. As is already known from the literature, Liraglutide 
does have beneficial effects on lipid profile and weight loss. This positive modulation of 
cardiovascular risk was seen again in the LIONESS Trial with significant reductions in weight, 
total cholesterol and LDL-cholesterol occurring during the Liraglutide phase of treatment. 
The changes seen in lipid profile could simply be due to biological variation as opposed to a 
direct (or indirect) GLP-1-mediated effect. It should be borne in mind that 21 out of 22 
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patients in the trial (see Table 11, page 85) were taking statins and were allowed to 
continue their statins throughout the trial. This perhaps makes the significant changes in 
seen in lipid profile slightly more impressive. We did not see any positive effects on BP. 
Again the short duration of active agent may have been a factor here along with the fact 
that 20 out of 22 patients did have beta-blocker therapy withheld across the 6 weeks (see 
Table 11 page 85) and so may have had a rebound rise in their BP at trial initiation. This 
may have countered any potential GLP-1-mediated gains in BP control. Ultimately we 
should be clear that the trial was not powered (or designed for that matter) to detect 
differences in weight, lipid profile or BP.  
 
These findings above do, however, go some way to overcoming one of the major limitations 
of the study design. We were unable to definitively prove the stability of Liraglutide 
transferred from its original injection pen to a 1 mL plastic syringe, over a proposed shelf 
life of at least 7 days. The only ELISA kit available on the open market to detect Liraglutide 
proved to be faulty on two separate occasions. The ELISA kit did confirm the presence of 
Liraglutide over a 9-day course (see Figure 10 pages 73-78) but did not allow quantification 
of the peptide or reliable elucidation of potential degradation of activity to be performed. 
Moreover the manufacturers of Liraglutide, NovoNordisk, were also not forthcoming in 
providing identical saline placebo injection pens required to maintain the double-blinded 
design of the trial, despite earlier promises. The significant reductions in random plasma 
glucose, daily home blood glucose measurements, HBA1c, total cholesterol, LDL-
cholesterol, and body weight along with an increased incidence of gastrointestinal side 
effects during the active agent period of therapy constitute reasonably overwhelming 
evidence that the stability and bioactivity of Liraglutide were preserved despite transfer to 
the plastic syringes used in the trial. We cannot, however, reliably quantify that stability or 
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bioactivity such that Liraglutide administered via its original injection pen may have 
provoked tangible improvements in exercise haemodynamics. Since NovoNordisk are the 
only manufacturers of the matching saline placebo injection pen, we may never know. 
Clearly a parallel open-label trial could be performed using original Liraglutide injection 
pens but the data would be exposed to significant bias and confounding. 
 
The duration of therapy may also be a limiting factor. Perhaps a more sustained period of 
active agent could have stimulated greater improvements in exercise haemodynamics. 
Logistical constraints prevented us from extending the trial duration. It was already quite a 
challenge persuading non-diabetic patients to agree to take an antidiabetic medication (and 
saline placebo) given via injection over a 6-week period. Patients were also required to 
attend a trial visit, often miles away from home, on the same day for 6 weeks, which is 
quite an undertaking. In addition, trial recruits were also asked to lance themselves twice a 
day for 42 days to monitor blood glucose at home. The return rate of 98.4% of home blood 
glucose measurements is testament to the willingness, motivation and enthusiasm of our 
trial recruits for the clinical research process. I cannot thank each and every one of them 
enough. 
 
Another potential limitation of the trial is the severity of baseline ischaemia displayed by 
the trial recruits. In total 16 out of the 22 patients who completed the trial demonstrated 
≥0.1 mV of ST-segment depression during exercise testing. Could we have detected more 
significant improvements in exercise haemodynamics had we restricted the trial to just 
those with ≥0.1 mV of ST-segment depression? Given the fact neither Liraglutide 1.2 mg nor 
1.8 mg could prolong the time to 0.1 mV STD, even in those with the greatest degree of 
electrophysiological ischaemia, suggests this is unlikely. 
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The validity of exercise tolerance testing to detect myocardial ischaemia also comes in to 
question. Exercise stress testing has a sensitivity (true positive rate) of 45-50% and 
specificity (true negative rate) of 85-90%; suggesting a higher efficacy for exclusion rather 
than confirmation of stable CAD. In the context of the LIONESS Trial this is appropriate 
given that all patients were known to have established CAD via angiography.  
 
Pharmacological agents used to replicate exercise stress can better guarantee achievement 
of ≥85% of target heart rate during stress echocardiography, stress perfusion cardiac 
magnetic resonance (MR) imaging and nuclear myocardial perfusion scanning. These 
imaging modalities study left ventricular function and regional wall motion (so can 
therefore better localise the distribution of ischaemia) but not the exercise haemodynamics 
via specific electrophysiological parameters we were investigating. Moreover exercise 
stress is preferred over pharmacological testing because exercise can provide higher 
physiological stress and better correlation between a patient’s symptoms and physical work 
capacity than what would be achieved by pharmacological testing. Moreover, the fact 
recruits to the LIONESS Trial did achieve >81% of their target heart rate does add validity to 
the ability of serial exercise stress testing to detect myocardial ischaemia in this study. 
 
It would be useful to validate the findings of the LIONESS Trial by superimposing the same 
6-week crossover design on serial stress echocardiography (sensitivity 80-85% and 
specificity 80-88%) or perfusion CMR. Dobutamine stress CMR detects ischaemia-induced 
wall motion abnormalities and has an estimated sensitivity and specificity of 79-88% and 
81-91% respectively. Perfusion (vasodilator stress) CMR measures myocardial perfusion and 
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has a sensitivity and specificity of 67-94% and 61-85% - comparable to nuclear perfusion 
imaging. Indeed the AddHope2 study is currently recruiting patients with CAD and newly 
diagnosed T2DM to intervention with Liraglutide plus Metformin versus placebo plus 
Metformin in a 12 plus 12 weeks crossover intervention study with a 2-week washout 
period. The primary cardiovascular endpoint will be change in left ventricular ejection 
fraction during stress echocardiography.(183)  
 
We used a crossover design for the LIONESS Trial because it suits the chronic nature of the 
condition under investigation – stable angina. Each patient serves as his/her own control. 
The crossover design therefore avoids problems associated with the comparability of study 
and control groups and confounding variables such as age and gender since intra-individual 
rather than inter-individual differences are studied. A comparison of treatments on the 
same subject is also expected to be more precise which means a smaller sample size can 
often be utilised. Moreover, crossover can be advantageous with respect to the power of 
the statistical test carried out to confirm the existence of a treatment effect. To exploit 
these advantages it is imperative to factor in a washout phase that is sufficiently long 
enough to rule out a carryover effect. We are confident this was the case in the LIONESS 
Trial. Had a patient been randomised to Group A in the trial they would be on placebo prior 
to crossover, hence no carryover. Had they started in Group B, they would have had two 
weeks of placebo injections post crossover before their third ETT (please see Figure 6, page 
47). This 2-week period is well over the accepted mark of ≥5 half-lives of the active agent in 
question. In addition to this we also measured for a carryover effect statistically before 
assessing for a treatment effect during the analysis of all the haemodynamic endpoints, 
which underpin the LIONESS Trial.(179) We also analysed the data based on both 
parametric and nonparametric distributions, following a test for normality, to ensure wide-
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ranging validity of the results. There remains some controversy over how best to analyse 
crossover trials. Some favour a two-stage process in which a preliminary test for carryover 
effect is first ascertained statistically and, if absent, a treatment effect can be calculated. 
Indeed a carryover effect was not detected for any of the haemodynamic primary and 
secondary endpoints measured in the trial, which would also suggest that an appropriate 
washout period had been incorporated. Alternatively the validity of results emanating from 
a crossover trial can solely be attributed to the quality and feasibility of the washout period. 
If the washout period can reliably eliminate a carryover effect pharmacologically then the 
data from an AB/BA design can be assessed in a matched pairs fashion; that matched pair 
being the same individual. We have applied both schools of thought to the analysis of the 
LIONESS Trial. 
 
So what of the future? Following a mandate issued by the FDA in 2008, all novel 
antidiabetic agents will have to undergo a rigorous cardiovascular safety evaluation within 
a phase 2/3 clinical study programme.(184) This guidance has been applied to all new 
T2DM drugs, even in the absence of any preclinical or clinical signal of cardiovascular risk. 
The EMA followed suit with a draft guideline in 2010, later revised in 2012.(185) Cue a raft 
of pharmaceutical industry funded large prospective multicentre randomised placebo-
controlled trials investigating the effect of GLP-1R agonists and DPP-4 inhibitors on 
cardiovascular endpoints: EXSCEL (Exenatide – NCT01144338); LEADER (Liraglutide – 
NCT01179048); ELIXA (Lixisenatide – NCT01147250); TECOS (Sitagliptin – NCT00790205); 
SAVOR-TIMI 53 (Saxagliptin – NCT01107886); EXAMINE (Alogliptin – NCT00968708); and 
CAROLINA (Linagliptin – NCT01243424).  
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The LEADER trial followed more than 9000 adults with T2DM at high risk for major adverse 
CV (MACE) events for up to 5 years. On March 4th 2016 Novo Nordisk announced the top 
line results. The trial compared addition of either Liraglutide or placebo to standard of care 
and met the primary endpoint of non-inferiority for the composite outcome of the first 
occurrence of CV death, nonfatal MI, or nonfatal stroke. Preliminary reports also indicate a 
superior reduction of MACE derived from all three endpoint components. The full dataset 
will be represented at the American Diabetes Association meeting in June 2016. 
 
Both SAVOR-TIMI 53 and EXAMINE have now reported their full results. In SAVOR-TIMI 53 
16,492 T2DM patients, with a history of or at risk for cardiovascular events, were randomly 
assigned to Saxagliptin versus placebo and followed up for a median 2.1 years.(186) The 
overall hazard ratio (HR) for the primary endpoint (a composite of cardiovascular death, MI, 
or ischaemic stroke) was 1.00 (95% confidence interval - CI: 0.89-1.12) giving rise to a p-
value for non-inferiority of <0.001. Although not related to excess mortality, there was an 
unexpected and statistically significant increase in the incidence of hospitalisation for HF in 
the Saxagliptin arm (3.5% vs. 2.8%, hazard ratio [HR] 1.27, 95% CI 1.07-1.51, p=0.007). It 
should be noted however that this only represented a 0.7% excess risk in absolute terms 
over the two-year follow-up period. In a post hoc analysis by the FDA the composite of CV 
death and hospitalised HF (6.0% vs. 5.3%, HR 1.14, 95% CI 1.00-1.30) and the composite of 
all cause mortality and hospitalised HF (7.6% vs. 6.7%, HR 1.16, 95% CI 1.03-1.30) were both 
higher on Saxagliptin therapy. Clinical factors at baseline that were associated with 
hospitalised HF included a history of HF, elevation of N-terminal pro-B-type natriuretic 
peptide, and reduced kidney function. There was also a small increase in hypoglycaemic 
events on Saxagliptin, which was most often seen in patients with baseline HBA1c <7.0% 
and in those taking long-acting sulphonylureas during the trial. 
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In EXAMINE 5,380 T2DM patients with a history of AMI or unstable angina in the previous 
15-90 days were randomly assigned to receive Alogliptin or placebo on top of conventional 
diabetic and cardioprotective therapy. Over a median follow up of 18 months the overall 
HR for the primary endpoint (a composite of cardiovascular death, nonfatal MI, nonfatal 
stroke) was 0.96 with a p value for non-inferiority of <0.001.(187) Although not revealed in 
the original publication, a post hoc analysis of the EXAMINE trial presented at the European 
Association for the Study of Diabetes in September 2013 revealed a numerically higher 
incidence of heart failure hospitalisations (HR 1.19; p=0.220) in the Alogliptin arm too.(188) 
Is this a class effect of DPP-4 inhibitors? Results from the Vildagliptin in Ventricular 
Dysfunction Diabetes (VIVIDD) trial, recently presented as a late-breaking trial at the Heart 
Failure Congress in May 2013, only serve to muddy the waters yet further.(189) Here 254 
T2DM patients with known ventricular dysfunction (New York Heart Association class I-III) 
were randomised to receive Vildagliptin or placebo. The trial met its primary endpoint of 
noninferiority in terms of change in LVEF from baseline to 52 weeks. Alarmingly, however, 
there was a statistically significant increase in LV end diastolic volume and a trend towards 
an increase in LV end systolic volume associated with the oral DPP-4 inhibitor. This change 
in LV dimensions was not associated with an increase in BNP levels. Indeed BNP levels fell 
28% after Vildagliptin relative to baseline compared with 14% in the placebo arm 
suggesting no deleterious change in LV wall stress. Clearly ongoing and future trials of 
antidiabetes drugs will need to pre-specify and adjudicate heart failure as an endpoint to 
clarify the observations seen in SAVOR-TIMI 53, EXAMINE and VIVIDD. 
 
There have since been a number of studies specifically investigating the association 
between hospitalisation for heart failure and management with incretin-based therapies. A 
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post-hoc analysis of the EXAMINE data found that Alogliptin did not increase the risk of 
heart failure outcomes in T2DM patients with recent ACS.(190) A retrospective cohort 
study involving >19000 adult diabetics was used to assess for the association of GLP-1 
agents with time to HF hospitalisation. A cohort of 1426 GLP-1 users were identified from 
this database and matched in a 1:2 fashion with controls. Here GLP-1 agents were 
associated with a reduced risk of HF hospitalisation (adjusted HR 0.51; p=0.002).(191) A 
much larger retrospective registry study of 127555 patients also found that DPP-4 inhibitors 
were associated with a reduced risk of HF hospitalisation when compared with 
sulphonylureas.(192)  
 
In contrast analysis of a US claims database of 7620 diabetic patients with incident HF 
found that Sitagliptin increased the risk of HF-related hospitalisation.(193) It should be 
remembered that the population studied had pre-existing HF so the link between DPP4-
inhibitor therapy and HF appears tenuous at best. Indeed the TECOS study prospectively 
randomised 14671 T2DM patients with cardiovascular disease to add either Sitagliptin or 
placebo to existing therapy. During a median follow-up of 3 years there was no significant 
difference between the two groups in terms of HF hospitalisation (p=0.98). More 
pertinently, Sitagliptin was noninferior to placebo for the primary cardiovascular outcome 
of cardiovascular death, nonfatal MI, nonfatal stroke or hospitalisation for unstable angina. 
As such Sitagliptin did not confer a cardiovascular benefit but did not confer a significant 
risk either.(194) The rate of hospitalization for heart failure in the Sitagliptin group was 
similar to those in the placebo group. The composite of CV death and hospitalised HF was 
also the same on Sitagliptin versus placebo. 
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Finally on the topic of heart failure, a multicentre observational study of incretin-based 
drugs and heart failure from the CNODES Investigators was recently published in the New 
England Journal of Medicine in March 2016.(195) Here a nested case-control analysis of 
multiple cohorts from Canada, the United States and the United Kingdom was applied in 
which each patient hospitalised for HF was matched with up to 20 controls based on sex, 
age, cohort entry date, duration of treated diabetes, and follow-up time. From a cohort of 
1499650 patients, 29741 were hospitalised for heart failure. The rate of HF did not increase 
with the use of incretin-based drugs as compared with oral antidiabetic drug combinations 
in those with (HR 0.86, 95% CI 0.62 to 1.19) and without (HR 0.82, 95% CI 0.67 to 1.00) a 
history of HF. Results were similar for both DPP-4 inhibitors and GLP-1 analogues. 
 
Neither SAVOR-TIMI 53 or EXAMINE indicated an excess of pancreatitis or pancreatic 
cancer associated with DPP-4 inhibitor therapy which is of course reassuring. And 
ultimately both Saxagliptin and Alogliptin met the FDA 2008 guidance for cardiovascular 
safety for which their respective trials were powered to ascertain. Disappointingly, 
however, neither revealed a reduction in cardiovascular events. In the case of SAVOR-TIMI 
53, perhaps two years of additional Saxagliptin therapy was insufficient to allow regression 
of an atherosclerotic process that had been endemic for several years in a population at the 
wrong end of the cardiovascular risk spectrum.(186) Many of the patients enrolled in to 
both arms of SAVOR-TIMI 53 were already on multiple cardioprotective therapies, which 
may have masked any beneficial impact on macrovascular events emanating from the study 
groups. Moreover these results may lend further weight to the theory that stricter 
glycaemic control does not necessarily lead to a reduction in cardiovascular events. Of note, 
a recent preclinical study by Hausenloy and colleagues found that chronic pretreatment 
with either Vildagliptin or Sitagliptin was able to ameliorate infarct size in mice both ex vivo 
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and in vivo. Interestingly, the cardioprotection was only seen at elevated glucose 
concentrations of 7, 9 and 11 mmol/L but not at 5 mmol/L. This glucose-sensitive 
cardioprotection by endogenous GLP-1 might in part explain why intensive glycaemic 
control has been associated with increased, or at least a plateau, in cardiovascular 
risk.(196) In the LIONESS Trial there was no evidence of deterioration in LV systolic function 
as evidenced by the preserved perioperative LV function noted in those patients 
proceeding to planned CABG surgery (Table 43, Page 149). One patient did have moderate 
LVSD but this had already been noted prior to trial recruitment and therefore prior to 
surgery also. The LIONESS Trial was not, however, designed or powered to investigate for a 
signal of heart failure associated with Liraglutide therapy. 
 
The ELIXA trial of Lixisenatide in 6068 patients with T2DM and ACS has also recently 
reported.(197) Much like Liraglutide, Lixisenatide was not associated with a higher rate of 
serious adverse events or severe hypoglycaemia, pancreatitis, pancreatic neoplasms, or 
allergic reactions compared with placebo. The addition of Lixisenatide to usual care did not 
significantly alter the rate of major cardiovascular events or other serious events. 
Importantly, there were no significant between-group differences in the rate of 
hospitalisation for heart failure or the rate of death. There were also no significant changes 
in blood pressure or heart rate on Lixisenatide versus placebo. 
 
Encouragingly a retrospective analysis of the LifeLink database of medical and 
pharmaceutical insurance claims in the United States (from June 2005 through to March 
2009) did reveal a significant reduction in cardiovascular events in 39,275 T2DM patients 
taking Exenatide compared with 381,218 non-Exenatide treated individuals (HR 0.81; 
p=0.01).(198) Is there a faint suggestion that GLP-1R agonists might provide greater 
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cardioprotection than DPP-4 inhibitors? In the meantime we certainly need a deeper 
knowledge of DPP-4 biology, the relative importance of GLP-1(9-36) pharmacology and the 
biochemical endpoints of GLP-1R-dependent versus -independent pathways before we can 
fully understand the cardiovascular effects of GLP-1 beyond glycaemic control. Only then 
will we appreciate to what degree the GLP-1R agonists and DPP-4 inhibitors are benevolent 
or maleficent towards the cardiovascular risk continuum. At present much of the data 
linking incretin-based therapy to positive cardiovascular outcomes lies within the preclinical 
domain. Now that much of the long-term cardiovascular outcomes studies of GLP-1 therapy 
have ruled out any adverse cardiovascular risk it is incumbent upon us to identify specific 
cohorts of both diabetic and non-diabetic patients that may benefit from the putative 
cardioprotective properties of the GLP-1 peptide. 
 
This MD(Res) degree has been an enriching and fascinating process filled with the highs of 
conceiving, designing and completing a single-centre randomised study to the lows of 
having to abandon preclinical studies in murine hearts (see Appendix) due to the slow 
progression of the LIONESS Trial. Please accept my sincere gratitude for your kind 
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PATIENT CONSENT FORM 
 
Title of project: The Physiological Effects of GLP-1 on Haemodynamics during 
Exercise in Patients with Ischaemic Heart Disease 
 
Name of Chief Investigators: Professor Michael Marber and  








One copy for patient, one for researcher, one to be kept with hospital notes. 
 
 








Name of Person taking consent.  





















 Please initial box 
1.  I confirm that I have read and understood the information sheet for the above study and have had 
the opportunity to ask questions. 
 
 
2.  I understand that sections of any of my medical notes may be looked at by members of the research 
team and authorised personnel within the NHS Trust where it is relevant to the research or to 
assess that appropriate research standards are being maintained within the study. I give permission 
for these individuals to have access to my records. I understand that the information about me will 
be held in the strictest confidence and that my results will not be available to a third party. 
 
 
3.  I give my consent to the transfer of non-identifiable (anonymous) data and samples to countries 
having a lower standard of Data Protection than the UK.  
 
 
4.  I understand that images collected will be stored on a computer system, and, after my name and 
address have been removed, may be available to researchers at other institutions. 
 
 
5.  I understand that my participation is voluntary; and that I am free to withdraw at anytime, without 
giving any reason, and without my medical care or legal rights being affected. 
 
 
6.  I agree to take part in the study and that the general results of the study will be made available to 
the medical community most likely through publication in a reputable medical journal. 
 
 




8. I consent to the Chief Investigators of the trial contacting my GP and alerting him/her of my 




                        
 
Research Study: Participant Information Sheet 
The Physiological Effects of GLP-1 on Haemodynamics during  
Exercise in Patients with Ischaemic Heart Disease 
 
We would like to invite you to take part in a research study. Your doctor will explain 
the study to you but in addition, please take time to read the following information 
carefully and decide whether or not you wish to take part. Before you decide, it is 
important for you to understand why the research is being conducted and what it will 
involve.  Please feel free to ask questions if anything is at all unclear to you, or if you 
would like any more information, whatever it may be. 
 
What is the purpose of the study? (The scientific question being asked) 
We are specifically looking at the actions of a hormone called glucagon-like peptide-
1 (GLP-1) to see if it affects exertional angina. The human gut produces GLP-1 
naturally, and releases it into the bloodstream to control the level of sugar in our 
blood, whenever we eat something. GLP-1 acts on a part of the pancreas to 
stimulate the release of insulin. Importantly its effect in the body is ‘switched off’ 
when the blood sugar level returns to normal, thereby preventing dangerously low 
levels of blood sugar occurring. An enzyme called dipeptidyl peptidase-4 (DPP-4) 
breaks down active GLP-1 to an inactive compound within 1-2 minutes of it 
appearing in the bloodstream. We therefore refer to GLP-1 as having a ‘short half-
life’.  
 
In those patients with Type II diabetes, the levels of GLP-1 are abnormally low 
although the potency of the remaining GLP-1 remains the same. This discovery has 
resulted in the production of two specific types of anti-diabetic drug. The first comes 
in tablet form and are called DPP-4 inhibitors. The second comes as an injection 
and are called GLP-1 receptor agonists - these compounds are very similar to 
naturally occurring GLP-1 but have a much longer half-life. Both the DPP-4 
inhibitors and GLP-1 receptor agonists are currently available to treat diabetics. 
 
Recent studies have shown that GLP-1, in addition to the control of blood sugar 
levels, may also protect the heart from the effects of ischaemia (i.e. a lack of blood 
supply) and possibly the damage caused by heart attacks. This has been a very 
exciting discovery and we, here at St Thomas’ Hospital, would like to study this 
promising new effect further. We will be looking specifically at whether GLP-1 can 
alter how the heart function of patients with narrowings in their heart blood vessels 
responds to the changes brought on by exercise performed on a treadmill. 
 
It would be difficult for us to administer naturally occurring GLP-1 to patients 
because of its very short half-life. This would mean a patient having to receive a 
continuous drip of the drug for long periods of time to ensure an adequate amount of 
active GLP-1 was present in the bloodstream. Instead we have elected to use a 
drug called Liraglutide, as a GLP-1 substitute. This drug is 97% identical to natural 
GLP-1 but cannot be broken down by DPP-4. Therefore it can be given as a once 
daily injection just beneath the skin and will be effective for approximately 24 hours. 
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Liraglutide will be compared against a salt-water (saline) placebo that will also be 
administered as an injection just beneath the skin. This way we can ensure the 
effects that we hope to see with Liraglutide are purely down to the drug and not due 
to some play of chance. 
 
Those patients who fit all the selection criteria to participate in this study will be 
asked to perform a series of 4 consecutive exercise treadmill tests spread over a 6-
week period. During each 7-day period leading up to an exercise test, the study 
participant will be taking either Liraglutide or saline placebo once a day. Neither the 
research team nor the patient will know which substance they are injecting. Using 
this method we can ensure that the results we achieve are fully reproducible and not 
open to doubt or questioning.  
 
During each exercise test we will be monitoring heart rate, and in particular the 
maximum heart rate achieved at peak exercise, blood pressure, and any changes 
on the heart tracing. These parameters allow us to determine the effect of the drug 
on how the heart and blood vessels respond to exercise – this is referred to as 
‘haemodynamics’. The duration of exercise achieved and the symptoms patients 
may develop will also be noted. This information will allow us to better understand 
whether GLP-1 can improve the way in which the heart and blood vessels adapt to 
the demands brought on by exercise. 
 
Why have I been invited to participate in this study? 
This patient information sheet will have been presented to you if you fall in to either 
one of these groups: 
 
Group 1 
You would have had a stress test during your referral to the Rapid Access Chest 
Pain Clinic. This test would have been labelled as either ‘abnormal’ or ‘positive’ 
suggesting that there may be a significant narrowing in one or more of your heart’s 
blood vessels causing an obstruction to the flow of blood during exercise. At this 
point you will be referred for a coronary angiogram which is the x-ray dye test that 
allows us to visualise your heart’s blood vessels to determine conclusively whether 
there are any narrowings or not. Until we have the results of your coronary 
angiogram you may not be eligible to enter this study but we have given you this 
information sheet to allow you to familiarise yourself with the study details. 
 
Or you may have already had your coronary angiogram. It has demonstrated a 
significant narrowing in one or more of your 3 main heart blood vessels. The 
Cardiologist who performed the test may have felt that the narrowing(s) was 
sufficiently serious enough to warrant opening the vessel(s), a procedure called an 
angioplasty, which you would have been referred for. At this point in time, and as 




You have furring up of the blood vessels that supply blood to your heart and are 
currently taking medications to protect you from a future heart event. We would 
have approached you to participate in this study during your routine outpatient clinic 
appointment at St Thomas’ Hospital. 
 
Group 3 
You have furring of the blood vessels that supply blood to the heart and because of 
this you are on the waiting list for heart bypass surgery. 
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Do I have to take part? 
No, participation in this study is completely voluntary.  If you do decide to 
participate, you will be given time to read this information sheet and will be asked to 
sign a consent form. You will be free to withdraw from the study at any time, without 
stating your reasons.  If you decide not to take part (or withdraw subsequently), it 
will not, in any way, affect the standard of care you receive. If you withdraw from the 
study, you may still keep in contact with us to let us know your progress. Information 
collected may still be used.  
 
What will happen to me if I take part? 
The routine medical care that you receive will be exactly the same as that given to 
patients who are not participating in the study. You will have had your angiogram as 
scheduled and your cardiologist may have referred you for angioplasty and stenting 
or a bypass operation. There is usually up to a 6-week wait before the angioplasty 
procedure and a longer wait for the bypass operation. It is during this waiting time 
that we would like you to participate in this 6-week study. Your participation in the 
study will not delay you from having your procedure. You will be followed-up as 
routine and your GP will be contacted to inform him/her of your participation in this 
study. 
 
During your first screening visit with the research team you will be asked to sign a 
consent form, a copy of which you will keep, and a copy will be placed in your 
medical notes to alert all potential healthcare providers that you may encounter of 
your enrolment in this study. During your screening visit a member of the research 
team will go through the study protocol with you in complete detail. 
 
What do I have to do?  
 During your screening visit we will ask you to gradually stop taking any 
medication that affects your heart rate. These heart rate limiting medications can 
potentially alter the results of the exercise treadmill tests that you will be 
undertaking. A member of the research team will go through which tablets they 
are and why you have to stop them. Once the 6-week study is over you will be 
restarted on these tablets. We will also let your GP know of these changes. You 
will be asked to continue your heart protection tablets, if you are already taking 
them, such as aspirin, clopidogrel and statins along with your GTN spray which 
you will be able to continue. 
 
 You will be assigned a patient number at the initial screening visit which will 
allow us to randomly allocate you to a specific treatment, i.e. either the study 
agent Liraglutide or the saline placebo. As mentioned previously, neither the 
research team nor you will know which treatment you are receiving since both 
the Liraglutide injection and the saline injection will look identical. 
 
 A member of the research team will give you a tutorial on how to administer the 
injections. We have specifically chosen Liraglutide since it is given as a once 
daily injection and should cause the least inconvenience to your daily activities. 
 
 You will be given a tutorial on Home Blood Glucose (i.e. sugar) Monitoring and 
the signs and symptoms associated with low blood sugars to look out for by a 
member of the research team. We have specifically chosen Liraglutide for this 
study since it is associated with only a very small risk of causing low blood 
sugars. We do, however, want to be as safe as possible and we can achieve this 
by monitoring your blood sugars on a regular basis. 
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 The research team will see you on at least six occasions during the course of 
the study. As such you will be monitored very closely indeed. The initial 
screening visit and the pre-dose visit should last no more than an hour each. 
 
 You will be asked to perform a series of 4 exercise treadmill tests over a 6-week 
period under the supervision of a trained clinical physiologist from the Cardiology 
Department of St Thomas’ Hospital and a trained Cardiologist from the research 
team. Following each treadmill test you will be issued with a different set of study 
medications that you will be asked to self-administer for the next 7 days before 
your next treadmill test. Each of these exercise sessions should last no more 
than 2 hours each. 
 
 Blood samples will be taken at each of the study visits and tests will be 
performed on them by the Pathology Laboratory at St Thomas’ Hospital, where 
they will also be stored. We will use the information to determine whether the 
drug Liraglutide causes any changes to specific markers in the blood. 
 
 We will reimburse both you and your carer travel expenses for each of the visits 
you will need to make during the course of the study. 
 
 You will also be issued contact details of the research team’s main patient 
liaison representative if you have any issues or concerns outside of these study 
visits (please refer to last page). 
 
 If you have Private Medical Insurance, we would advise you to inform your 




What are the possible benefits of taking part? 
The results of this research could potentially improve the future management of 
patients who suffer from coronary heart disease. Patients participating in research 
studies will receive closer monitoring on account of the extra follow-up necessitated 
by the study. Once the study ends the drug Liraglutide will not, however, be 
available to those participants who it may benefit. 
 
What are the possible risks of taking part? 
We are using an established anti-diabetic drug in non-diabetic patients. There is a 
small theoretical risk of causing blood sugars to fall below normal levels. If this were 
to occur you may develop the following signs and symptoms: 
 
 lightheadedness 
 lethargy or tiredness 
 confusion 
 sweating or clamminess 
 fast heart beats or palpitations 
 visual disturbances 
 
If you do develop any of the above, eat something sugary like a biscuit, chocolate or 
cake or drink something sugary like Ribena, Coca Cola, or Lucozade. You will be 
provided with a Home Blood Glucose Monitoring kit which you can then use to 
check what your blood sugar is AFTER you have eaten or drunk something sugary. 
Please contact the Main Patient Liaison member of the research team (you’ll find 
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the details on the last page of this document) if you have had one or more of these 
episodes during the course of your study participation. 
 
Liraglutide, the study drug, has been shown to cause nausea, and in extreme cases 
vomiting and diarrhoea. These effects are transient and pass relatively quickly as 
your body gets used to the drug. We have deliberately structured the study so that 
each participant will receive a very low dose ‘run-in’ phase of the drug, thus allowing 
your body to familiarise itself with Liraglutide and therefore minimising the chances 
of these side effects occurring, before stepping up to low-dose followed by high-
dose Liraglutide. Again please let us know if you suffer any adverse effects 
whatsoever either during each study visit or the periods in-between. It is extremely 
important to the success of the study that you take all the study medications issued 
to you, so please let us know of any concerns you have straight away. 
 
There is a danger of precipitating more severe episodes of angina whilst you are 
completing the exercise tests. We have established very stringent rules on when to 
stop an exercise test before you are put under any undue danger. Trained medical 
practitioners will also supervise each exercise test.  
 
What will happen to any data I give? 
All information collected about you during the course of the research will be kept 
strictly confidential. Personally identifiable information will be collected for the study 
and stored in a secure research office or on computers with access restricted to 
persons authorised by the research team for at least 7 years. After that time it will be 
disposed of securely. In addition to the researchers on this study, authorised 
persons such as sponsors, regulatory authorities & the Research and Development 
Department will have access, if sought, to view identifiable data.  
 
The results of this study are likely be published in medical journals and presented at 
international medical conferences, once the study has been completed and the 
results analysed. For the duration of the study the custodians of the data are 
Professor Michael Marber and Professor Simon Redwood, who will take all 
reasonable steps to protect your privacy. Hard copies of any published results will 
be available to any participants who do not have access to the Internet. 
 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. 
 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with 
the research coordinators who will do their best to answer your questions (Main 
Patient Liaison contact number at the end of this information sheet). If you remain 
unhappy with any aspect of the study and wish to complain formally, you can do this 
through the NHS Complaints Procedure, the details of which can be obtained from 
the hospital. 
Your statutory rights will not be affected by consenting to participate in the study. In 
the event that something does go wrong and you are harmed during the research 
study there are no special compensation arrangements.  If you are harmed and this 
is due to someone’s negligence then you may have grounds for a legal action for 
compensation against the Sponsor Organisation (Kings College London and Guy’s 
and St. Thomas’ NHS Foundation Trust) but you may have to pay your legal costs. 
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Who is organising and funding the research?   
The research is being organised by researchers within King’s College London (KCL) 
and consultants within Guy’s and St Thomas’ NHS Foundation Trust. The research 




Who has reviewed the study?  





Professor Michael Marber (Principal Investigator) 
Professor of Cardiology and Honorary Consultant Cardiologist 
Department of Cardiology, Cardiovascular Division, The Rayne Institute, 4th Floor 
Lambeth Wing, St Thomas’ Hospital, London SE1 7EH 
Tel. No. 0207 188 1008 
Fax No. 0207 188 0970 
 
Professor Simon Redwood (Co-Principal Investigator) 
Professor of Interventional Cardiology and Honorary Consultant Cardiologist 
C/o Suzanne Pattinson, Cardiac Catheterisation Laboratory Office, 4th Floor East 
Wing, St Thomas’ Hospital, London SE1 7EH 
Tel. No. 0207 188 0955 
Fax No. 0207 188 0979 
 
Dr Aung Myat (Research Fellow) 
Specialist Registrar in Cardiology and British Heart Foundation Clinical Research 
Training Fellow 
Department of Cardiology, Cardiovascular Division, The Rayne Institute, 4th Floor 
Lambeth Wing, St Thomas’ Hospital, London SE1 7EH 
Tel. No. 0207 188 7184 
Mobile No. 07968 802363 
Fax No. 0207 188 0970 
Email address: aung.myat@kcl.ac.uk 
 
 
Main Patient Liaison 
Dr Aung Myat (Research Fellow) 
Specialist Registrar in Cardiology and British Heart Foundation Clinical Research 
Training Fellow 
Department of Cardiology, Cardiovascular Division, The Rayne Institute, 4th Floor 
Lambeth Wing, St Thomas’ Hospital, London SE1 7EH 
Tel. No. 0207 188 7184 
Mobile No. 07968 802363 
Fax No. 0207 188 0970 




                   
 
Liraglutide to Improve corONary haemodynamics during 
Exercise streSS 
The LIONESS Trial 
SAFETY INFORMATION CARD 




 sweating or feeling clammy 
 racing heart or palpitations 
 problems with vision 
 
 SYMPTOMS OF ANGINA 
 chest pain 
 shortness of breath 
 sweating and clamminess 









Please make sure to note any of the symptoms above or any other symptom in the 
diary provided along with the date and time they occurred.  
If you are at all concerned about any symptom you may have suffered please 
contact Dr Aung Myat directly or your GP for further advice. 
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GP Information Sheet 
 
Title of Study: The Physiological Effects of GLP-1 on Haemodynamics during 
Exercise in Patients with Ischaemic Heart Disease 
 





Re: Patient Name, Hospital Number, and Date of Birth 
 Patient Address 
 
Trial Start Date: 
Trial End Date: 
 
Patient name has very kindly agreed to participate in a clinical study being carried 
out at St Thomas’ Hospital and which is being co-sponsored by King’s College 
London and Guy’s and St Thomas’ Hospitals NHS Foundation Trust. Patient name 
has signed a consent form for the study. 
 
The patient has fulfilled the following inclusion criteria for the study: 
 
1) Men and women aged 18-65 
2) Patients with a recent abnormal exercise tolerance test demonstrating >0.1 mV of 
planar or down-sloping ST segment depression. 
3) Patients with known coronary artery disease and angiographic evidence of a 
>70% stenosis in a main coronary artery, with or without coronary stenoses 
elsewhere. 
4) Patients must be able to walk confidently on a treadmill. 
5) Patients are non-diabetic. 
6) Patients must have a normal ECG without bundle branch aberration or other 
conduction disturbance. 
7) Patients must have normal left ventricular function. 
 
We are looking at the physiological effects of the incretin hormone, glucagon-like 
peptide-1 (GLP-1), on haemodynamics during exercise in patients with known 
coronary heart disease. Under normal circumstances this hormone is released by 
the gut in response to enteral nutrition and acts primarily to control blood glucose by 
stimulating the release of insulin from the pancreas. In Type II diabetes there is a 
defective incretin effect. Novel anti-diabetic drugs have been developed to 
overcome this such as exenatide, saxagliptin, vildagliptin, sitagliptin, etc. For the 
purposes of this study we will be using Liraglutide as a substitute for endogenous 
GLP-1. Recent studies have shown a potential cardioprotective effect with GLP-1 
and its synthetic analogues both in animal models and latterly in small human 
clinical studies. We aim to investigate these novel findings yet further by performing 
a single-centre, double-blind, randomised, placebo-controlled, cross-over study to 
determine whether GLP-1 has any effect on exercise haemodynamics during 4 
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consecutive treadmill tests over a 6-week period. Patients will be randomly assigned 
to the study agent or matching saline placebo, asked to perform 2 consecutive 
exercise tests during a step-wise increase in their respective therapeutic regimens 
conducted over a 3-week period before crossing over to the opposing regimen and 
repeating the same research protocol for a further 3 weeks. A summary of the study 








We would be grateful if you would take note of the following important points: 
 
 We have asked enrolled patients to discontinue any heart rate-limiting 
medications and nitrates they would have been taking prior to their participation. 
These include: 
o beta-blockers, 
o rate-limiting calcium antagonists, 
o ivabradine, 
o long-acting oral nitrates, and 
o nicorandil. 
 
Patients will be recommenced on these medications once the 6-week study has 
been completed. Patients may suffer breakthrough angina as a result of 
discontinuing these medications and have been asked to seek medical advice if 
this is the case. We would be grateful if you could inform the Main Patient 
Liaison (details below) if this were to occur. This may lead to the patient being 
withdrawn from the study. 
 
 Enrolled patients will be able to continue their remaining cardioprotective 
medications, namely: 
o aspirin, 
o clopidogrel (or prasugrel or ticagrelor), 
o ACE inhibitors, 
o angiotensin receptor blockers, 
o statins and 
o GTN spray. 
 
 All enrolled patients will be non-diabetic. There is a very small risk of 
hypoglycaemia with the use of Liraglutide. Patients will have been educated on 
the signs and symptoms of hypoglycaemia and will be asked to monitor their 
blood glucose 2 times per day, each day they are involved in the study. If they 
do seek medical advice about this, please do let the Main Patient Liaison know. 
 
 Liraglutide can be associated with nausea, vomiting and diarrhoea. Patients 
would have been educated about this and the symptoms are usually transient. 
To guard against this, we have deliberately factored in a ‘run-in’ phase with very 
low dose Liraglutide before a step-wise up-titration of agent at weekly intervals 
(please refer to Study Flowchart illustration) – much like the recommended 
regimen diabetic patients would normally follow when newly commenced on 
Liraglutide. Again please let us know if patients seek your advice about these 
symptoms or any other potential adverse effects of the study agent.  
 
 There is a small but possibly increased risk of pancreatitis associated with drugs 
that act through the GLP-1 pathway. This has been predominantly associated 
with those taking exenatide and sitagliptin but isolated cases associated with 
Liraglutide have been reported in the medical literature. We would therefore 
kindly ask you to take note of this. In particular, any study participants who 
present with persistent, severe nausea and vomiting, rather than the transient 
gastrointestinal upset described above, may well be presenting with an early 
manifestation of pancreatitis and thus warrant further assessment and 
discontinuation of the study agent. 
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 We would like to stress that those patients with a planned coronary angioplasty 
will not be delayed as a result of their enrolment into the study. There is usually 
a 6-week wait, during which time the study can be completed. 
 
 
We thank you for your kind consideration. We do not require any further information 
or action by you at this stage. Please do not hesitate to get in touch with the main 
patient liaison if you have any queries about this study. 
 
 
Main Patient Liaison Contact Details 
 
Dr Aung Myat (Research Fellow) 
Specialist Registrar in Cardiology and British Heart Foundation Clinical Research Training 
Fellow 
Department of Cardiology, Cardiovascular Division, The Rayne Institute, 4th Floor Lambeth 
Wing, St Thomas’ Hospital, London SE1 7EH 
Tel. No. 0207 188 7184 
Mobile No. 07968 802363 
Fax No. 0207 188 0970 










Dr Aung Myat BSc(Hons) MBBS MRCP 
British Heart Foundation Clinical Research Training Fellow 
The Rayne Institute BHF Centre of Research Excellence 
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Further to my conversation with Professor Marber, your revised protocol was discussed at the SCOPE meeting again. 
The proposed study would be classed as a physiological study as long as it does not investigate the efficacy or safety of Liraglutide.
Therefore, any study objectives or design aspects pertaining to evaluate the above should be removed from the protocol. Once you are
convinced such changes have been made to the protocol, you could proceed with the study without re-submitting the protocol.
Yours sincerely, 
Dr. N. Rajakumaraswamy, 
Medical Assessor, 
Clinical Trials Unit,  
MHRA
This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure,
copying or any other action taken in respect of this email is prohibited and may be unlawful.
 
If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what
you have received.Incoming and outgoing email messages are routinely monitored for compliance with the Department of Healths policy
on the use of electronic communications.
 
For more information on the Department of Healths email policy, click
http://www.dh.gov.uk/DHTermsAndConditions/fs/en?CONTENT_ID=4110945&chk=x1C3Zw
The original of this email was scanned for viruses by the Government Secure Intranet virus scanning
service supplied by Cable&Wireless Worldwide in partnership with MessageLabs. (CCTM Certificate
Number 2009/09/0052.) On leaving the GSi this email was certified virus free.
Communications via the GSi may be automatically logged, monitored and/or recorded for legal
purposes.
  




























Dear Professor Marber,  
Re: IRAS Ref: 78543 Study ID 11112 The Effect of GLP-1 on exercise Physiology in patients with IHD   
We are pleased to inform you that the above study has been assessed as eligible for consideration for CRN 
support.  This study has been included on the National Institute for Health Research Clinical Research 
Network (NIHR CRN) Portfolio. The NIHR is committed to providing the CRN support requirements needed 
for your study to be successfully delivered in the NHS, this includes access to a local network of dedicated, 
skilled research support staff including research nurses and other allied health professionals, who can help 
identify eligible patients, arrange consent to participate in the study and monitor patients as they progress 
through the study. Other ways of ensuring the success of the study in the NHS include access to pharmacy, 
imaging and pathology services and the possibility of securing protected time for NHS staff to conduct 
research. 
It is the responsibility of the relevant Local Research Network to consider your study’s requirement for CRN 
support at each site and for multi-centre studies this process will be coordinated by a Lead Network on your 
behalf. 
Your unique Portfolio Study ID number is detailed above and can be used to search for the record for this 
study on the NIHR CRN Portfolio. 
Your study will be categorised within the NIHR Comprehensive Clinical Research Network’s Portfolio of non-
commercial clinical research studies. The NIHR Comprehensive Clinical Research Network (CCRN) is the 
largest of the eight networks that constitute the NIHR CRN. As such, your study will be supported by the 
CCRN and its Specialty Groups, which are here to support you throughout the life of your study and can 
provide you with help and advice if you encounter any problems which adversely affect the start-up and 
subsequent recruitment into the study. 
Your study has been allocated to the Cardiovascular Group and attached is a PDF of the flyer for that 
Group which provides you with an overview of what this CCRN Specialty Group can offer and the contact 
details of the Local Lead in your area who would be happy to speak to you about your study. Further 
information on the CCRN and its Specialty Groups can be found at 
http://www.crncc.nihr.ac.uk/about_us/ccrn 
Recruitment Data 
If your study is accessing CRN support, you are required to upload recruitment data on a monthly basis. 
This is essential to ensuring that the NIHR can report accurately to the Department of Health the number of 
people actively participating in research. Recruitment data is measured against key performance indicators 
which are used to monitor the success of the Clinical Research Network and will feed into the process of 
allocating future funding for NHS infrastructure for research to Comprehensive Local Research Networks 
(CLRNs). This ensures that infrastructure resources are directed to where they are required for the most 
patient benefit. The reporting of recruitment data also helps the Specialty Groups to identify studies which 
are struggling to recruit and to provide support for these studies.  If you are required to upload recruitment 
data you will be sent instructions on how to do this. 









One of the Department of Health’s policies is to encourage transparency and promote public access to 
information about research and research findings affecting health and social care. Accordingly, the 
Department of Health strongly encourages voluntary registration of both interventional and observational 
clinical research studies on its preferred public register, the International Standard Randomised Controlled 
Trial Number (ISRCTN) Register, which is the World Health Organization’s primary registry for the UK and is 
administered by Current Controlled Trials Ltd. 
The NIHR CRN Coordinating Centre has developed a process which enables automatic and seamless 
registration of all new UK Clinical Research Network (UK CRN) Portfolio studies via the UK CRN Portfolio. 
New non-commercial studies with an interventional component included on the National Institute for Health 
Research (NIHR) Clinical Research Network (CRN) Portfolio, which are not currently registered with 
ISRCTN or ClincalTrials.gov, will be registered ‘free’ if they choose to register via the UK CRN Portfolio 
functionality. 
Observational, industry-sponsored and devolved administrations studies (i.e. studies without English sites) 
are encouraged to use the UK CRN Portfolio functionality to register with the ISRCTN; however for these 
studies ISRCTN registration will incur a fee payable by the relevant organisation/company and invoiced 
directly from Current Controlled Trials Ltd. 
To register for an ISRCTN via the UK CRN Portfolio functionality, log onto the Portfolio database via 
https://portal.ukcrn.org.uk/login/ and select ‘yes I wish to register for an ISRCTN’ and complete the extended 
minimum dataset required for ISRCTN registration. The details of your study will be forwarded to Current 
Controlled Trials and the ISRCTN editorial team will contact you in due course. Please do not apply 
directly to Current Controlled Trials if you are registering for an ISRCTN via the UK CRN Portfolio. 
Acknowledgement of Clinical Research Network support 
Acknowledgement of Network support must be made when publishing study findings. 
It is your responsibility to ensure that the following standard text is used to acknowledge the support of the 
Clinical Research Network when publishing your study findings in peer-review journals, or any other form of 
publication: 
[Research team or organisation] acknowledge the support of the National Institute for Health Research, 
through the Comprehensive Clinical Research Network  Please do not hesitate to contact the CCRN 
Portfolio team should you require further information ccrn.portfolio@nihr.ac.uk 
Best Wishes 
Joanna Olliver 
Dr Joanna Olliver 
Portfolio Lead 
NIHR Clinical Research Coordinating Centre (NIHR CRN CC) 
Fairbairn House 
71-75 Clarendon Road 
Leeds 
LS2 9PH 
Tel:   0113 343 5144 
Fax:  0113 343 2300 
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Liraglutide to Improve corONary Haemodynamics During Exercise streSS (LIONESS)
  Purpose
A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1
receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress










Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: The Physiological Effects of GLP-1 on Haemodynamics During Exercise in Patients With Ischaemic Heart Disease
Resource links provided by NLM:
MedlinePlus related topics: Angina Coronary Artery Disease Exercise and Physical Fitness Heart Diseases
Drug Information available for: Liraglutide
U.S. FDA Resources 
Further study details as provided by King's College London:
Primary Outcome Measures:
Change in rate pressure product at 0.1 mV ST-segment depression [ Time Frame: Following consecutive exercise treadmill tests performed at
Week 2, Week3, Week 5 and Week 6 of a 6-week study protocol ] [ Designated as safety issue: No ]
Change in degree of ST-segment depression at peak exercise [ Time Frame: Following consecutive exercise treadmill tests performed at Week
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run-in phase followed by a step-wise increase in Liraglutide therapy over a 3-week period the investigators aim to minimise the occurrence of
adverse reactions and also hope to observe a dose-response effect on exercise haemodynamics. The crossover design will allow study participants
to effectively act as their own controls.
  Eligibility
Ages Eligible for Study:  18 Years to 80 Years
Genders Eligible for Study:  Both
Accepts Healthy Volunteers:  No
Criteria
Inclusion Criteria:
1. Men and women aged 18-80
2. Patients with a recent abnormal exercise tolerance test demonstrating >0.1 mV of planar or down-sloping ST-segment depression.
3. Patients with known coronary artery disease and angiographic evidence of a >70% stenosis in a main epicardial artery, with or without
coronary stenoses elsewhere.
4. Patients must be able to walk confidently on a treadmill.
5. Patients must have a normal resting electrocardiogram (ECG) in sinus rhythm without bundle branch aberration or other conduction
disturbance.
6. Patients must have normal left ventricular function.
Exclusion Criteria:
1. An abnormal resting ECG including atrial fibrillation, bundle branch aberration or other conduction disturbance.
2. Pre-existing left ventricular systolic dysfunction.
3. Pre-existing ischaemic or non-ischaemic cardiomyopathy.
4. Pre-existing valvular heart disease.
5. Inability to safely negotiate an exercise treadmill.
6. Type I diabetes mellitus.
7. Type II diabetes mellitus taking oral or subcutaneous anti diabetic therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a
study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general
information, see Learn About Clinical Studies. 
Please refer to this study by its ClinicalTrials.gov identifier: NCT02315001
Locations
United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, Greater London, United Kingdom, SE17EH
Sponsors and Collaborators
King's College London
Guy's and St Thomas' NHS Foundation Trust
Investigators
Principal Investigator: Michael Marber, PhD FRCP King's College London
Principal Investigator: Simon Redwood, MD FRCP King's College London
  More Information
Additional Information:
Trial rationale and protocol  
Publications:






























































































































Liraglutide-stimulated cardioprotection: is it novel and can it be an anti-anginal 
agent? 
5. Statement: The proposed work does not overlap or duplicate any existing or 
previous work, either scientifically or financially, conducted within the Host 
Department. 
7. Abstract (150 words): The injectable glucagon-like peptide-1 (GLP-1) analogue, 
Liraglutide, is now established as standard of care in Type II diabetes mellitus. Recent 
animal and human studies have demonstrated a potential cardioprotective action of 
endogenous GLP-1 and its synthetic analogues thereof in the context of myocardial 
ischaemia/reperfusion injury and left ventricular systolic dysfunction (LVSD) 
independent of glycaemic control and weight loss. The mechanism of this action 
remains elusive. Through the utilisation of in-vitro and in-vivo murine heart models, we 
aim to elucidate whether Liraglutide-stimulated cardioprotection is direct and follows 
standard signalling pathways involved in post-transcriptional gene modification of 
established pro-survival kinases or indirect, thereby indicating either significant 
alterations in the cardiac protein expression profile or the involvement of extra-cardiac 
receptor pathways. We will also investigate the putative anti-ischaemic action of 
Liraglutide in a cohort of non-diabetic chronic stable angina patients with known 
coronary stenoses awaiting elective percutaneous intervention through serial exercise 
stress testing.     
8. Background  
The “Incretin Concept”: This has evolved from the observation that an oral load of 
glucose can provoke a two to three times more potent insulinotropic stimulus when 
compared to an isoglycaemic intravenous glucose infusion. This effect was attributed to 
the action of specific gut hormones, namely incretins (INtestinal seCRETion of 
INsulin) which form part of the glucagon superfamily and are released from the 
intestine in response to enteral nutrition1. Glucose-dependent insulinotropic polypeptide 
(GIP) was first isolated from purified porcine intestinal extracts2. Glucagon-like peptide-
1 (GLP-1) was next discovered. It is predominantly made by the enteroendocrine L cells 
of the distal ileum and colon. Despite this location, plasma levels of GLP-1 rise within 
minutes of eating pointing to a combination of neural and endocrine signals stimulating 
its secretion. Incretins are essential in maintaining human glucose homeostasis. They act 
via structurally independent G-protein coupled receptors3. The distribution of the GLP-
1 receptor (GLP-1R) is widespread and can be found in islet α and β cells together with 
sites in the central and peripheral nervous systems, alimentary canal, kidney, lung and 
heart4. As a result GLP-1 also strongly inhibits glucagon secretion (pancreatic α cells); 
delays gastric emptying and reduces food intake (stomach); induces satiety (brain); and 
increases glucose uptake (periphery)5,6. Both compounds are rapidly inactivated by the 
enzyme dipeptidyl peptidase-4 (DPP-4) and are cleared mainly by the kidneys. As a 
result of its rapid degradation, GLP-1 has a half-life of <2 minutes which means only 
10-20% of total plasma GLP-1 is biologically active7. 
There is a defective incretin effect in both lean and obese type 2 diabetics8,9. Meal-
stimulated levels of GLP-1 secretion are significantly impaired. This is particularly the 
case in obese type 2 diabetics where the inherent insulin resistance of obesity may well 
be a contributing factor10,11. However, a continuous infusion of exogenous GLP-1 can 
result in near normal insulin responses to a glucose load, suggesting preservation of 
insulinotropic activity12. The clinical relevance of native GLP-1 is profoundly limited, 
however, by its short half-life. Novel treatment strategies for type 2 diabetes (T2DM), 
based on the incretin effect, have been developed to bypass this endogenous cul-de-sac 
through engineering injectable GLP-1R agonists (degradation-resistant peptides with 
improved pharmacokinetic properties that act directly on the human GLP-1R) and oral 
DPP-4 inhibitors (small molecules with clinically useful oral bioavailability that protect 
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the endogenous peptide from degradation and thereby enhance its innate insulinotropic 
activity)4. 
GLP-1 Receptor Agonists: Liraglutide (trade name Victoza), a synthetic analogue that 
shares 97% structural homology to native GLP-1, received FDA approval in January 
2010 to be used as an adjunct to diet, exercise, and in combination with standard oral 
antidiabetic medications, to improve glycaemic control in T2DM. It has a half life of 
approximately 10-14 hours after subcutaneous administration which allows its use as a 
once-daily preparation. Liraglutide binds to albumin in the circulation which protects it 
from DPP-4 degradation and prevents renal elimination. Indeed, since no single-organ 
system is primarily responsible for Liraglutide elimination, those patients with hepatic or 
renal impairment may not require dose adjustment5. Exenatide (a synthetic analogue of 
exendin-4 and a mimetic compound of endogenous GLP-113), on the other hand, is 
predominantly excreted via glomerular filtration and is therefore relatively 
contraindicated in those with renal dysfunction14. GLP-1R agonists mediate significant 
reductions in HBA1c and improve beta cell function in T2DM patients. Unlike the DPP-
4 inhibitors, which are weight-neutral and prevent weight gain, they actively stimulate 
weight reduction. This can in turn enhance insulin sensitivity. In the Liraglutide Effect 
and Action in Diabetes (LEAD) Phase 3 clinical trials, Liraglutide monotherapy or in 
combination with one or two oral agents was associated with a mean weight loss of 1.0-
3.2 kg and HBA1c reductions of 0.6-1.5%
15-20.  Since GLP-1R agonists exclusively 
stimulate insulin secretion only in the presence of elevated glucose levels (GLP-1 
activity ceases at glucose levels <4 mmol/L), they have the added advantage of 
conferring a relatively small risk of hypoglycaemia.  
GLP-1 Receptor Agonists, Cardiovascular Parameters and Myocardial 
Protection: Liraglutide has been associated with decreases in systolic blood pressure 
from -2.1 to -6.7 mmHg which occurs almost immediately, suggesting an independence 
from weight loss15-20. In combination with a thiazolidinedione and metformin, it can 
significantly decrease triglyceride and LDL-C levels relative to placebo18. Liraglutide 
monotherapy has also been shown to positively impact on non-lipid biomarkers of 
cardiovascular risk; namely plasminogen activator inhibitor-1 and brain natriuretic 
peptide21. Recent interest has focussed on the possibility of direct actions on cardiac 
myocytes. The ubiquity of the GLP-1R and, in particular, its presence in the heart has 
been known for some time. It was then discovered that knockout mice lacking the 
GLP-1R suffered increased left ventricular (LV) wall thickness, impaired LV 
contractility, diastolic dysfunction and attenuated cardiac reserve suggesting a possible 
endogenous role for GLP-1 in maintaining normal cardiac structure and function22. 
Moreover, in the failing heart or the myocardium under threat of ischaemia/reperfusion 
(I/R) injury, the potential protective role of GLP-1 has emerged following several 
animal and human studies. This putative, non-glycaemic, mode of action has been made 
all the more plausible by the ability of the heart to utilise a variety of different substrates 
to generate adenosine triphosphate.  
Myocardial Metabolic Modulation during I/R Injury: Under the strain of I/R 
injury, the heart’s metabolic flexibility is significantly compromised. The heart shifts its 
preference from using non-esterified fatty acids (NEFA) to glucose in order to limit the 
production of reactive oxygen species and to obviate the greater need for molecular 
oxygen that comes with NEFA oxidation. Increased glucose uptake during myocardial 
ischaemia helps to: maintain cellular ultrastructure; promote myocardial recovery; reduce 
creatine phosphokinase depletion; slow mitochondrial injury; and sustain electrical and 
mechanical performance. Paradoxically, during an acute myocardial infarction (AMI), 
the circulation of free fatty acids (FFA) and secretion of catecholamines is increased 
thereby leading to acute glucose intolerance23. It follows, therefore, that therapeutic 
agents which can encourage glucose uptake and utilisation and/or minimize NEFA 
uptake and oxidation could prove hugely beneficial in attenuating the deleterious effects 
of I/R injury. Despite an overall acceptance of these rudimentary metabolic principles, 
therapeutic strategies to augment glucose uptake by the injured myocardium have failed 
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to yield the expected clinical benefits. The use of glucose-insulin-potassium (GIK) 
therapy post AMI is a case in point. Hence the focus of attention has recently turned to 
GLP-1, a peptide hormone that could enhance myocardial glucose uptake.  
GLP-1 in Myocardial Ischaemia and Heart Failure: Ex vivo models of isolated 
rodent Langendorff heart perfusion incorporating periods of I/R have all universally 
demonstrated that both GLP-1 and exendin-4 markedly reduce infarct size and enhance 
the recovery of myocardial contractility after transient coronary artery occlusion24-27. 
Furthermore in an experimental conscious canine model, a 24-hour infusion of GLP-1 
was shown to ameliorate the effects of myocardial stunning induced by brief periods of 
coronary occlusion28.  Of note isovolumic LV relaxation, an ATP-dependent process 
specifically influenced by myocardial substrate metabolism, improved significantly 
compared to controls28. A recent in vivo I/R porcine model demonstrated the benefit of 
an extended 3-day period of Exenatide which subsequently reduced infarct size and 
accelerated the recovery of both systolic and diastolic function29. GLP-1 may also confer 
protection to the ischaemic heart in the normoglycaemic setting. A 7-day pre-treatment 
period of Liraglutide given to both non-diabetic and streptozotocin-induced diabetic 
mice was shown to reduce both infarct size and the incidence of cardiac rupture in 
addition to improving cardiac output and ultimately survival after experimental MI30. 
Points of specific interest here are: 1) chronic Liraglutide therapy gave rise to 
cardioprotective and overall survival advantages over and above those observed for 
metformin, despite equivalent effects on glycaemic control; 2) the beneficial effects were 
shown to be independent of weight loss and 3) this could point to the potential use of 
GLP-1R agonists in a non-diabetic population. 
The growing weight of evidence has led to several Phase 2 trials of native GLP-1 in 
humans. In a study of 21 patients presenting with ST-elevation MI and LVSD (ejection 
fraction - EF<40%), a 72-hour GLP-1 infusion was shown to improve LVEF from 
29% to 39% in both diabetic and non-diabetic patients after primary percutaneous 
coronary intervention31. A further study randomised 20 patients to receive either 
standard therapy alone or in addition to a GLP-1 infusion 12 hours prior to coronary 
artery bypass graft surgery. The infusion, which was then continued for 36 hours 
postoperatively, reduced subsequent inotrope and antiarrhythmic drug requirements32. 
Addition of GLP-1 to standard therapy has also demonstrated significant improvements 
in LVEF, maximum myocardial ventilation oxygen consumption, 6-minute walk test 
indices, and quality of life measures in obese patients with LVSD (EF≤40% and NYHA 
class III/IV). The drug, however, had to be administered continuously via a 
subcutaneous infusion over 5 weeks33. The widespread clinical application of 
endogenous GLP-1 is hampered by its short half-life and the need for a continuous 
infusion to maintain therapeutic levels. This is of particular significance in patients 
where strict fluid restrictions may often apply. Nonetheless these proof-of-concept 
studies suggest that GLP-1, independent of its effect on glycaemic control and weight 
loss, can potentially modulate the metabolic and haemodynamic outcomes of patients 
with coronary artery disease (CAD) and LVSD. Of particular interest has been the 
demonstration that sitagliptin, an oral DPP-4 inhibitor, was able to improve myocardial 
response to ischaemia provoked by dobutamine stress and attenuate subsequent post-
ischaemic LVSD (i.e. stunning) in patients with known CAD awaiting elective PCI34. 
Again the effect was seen in both diabetics and non-diabetics and was highly 
reproducible using standard 2D echocardiography and tissue Doppler techniques. 
Furthermore sitagliptin, and by virtue of its action, endogenous GLP-1, displayed a 
significantly greater beneficial effect on ischaemic rather than non-ischaemic LV 
segments.  
GLP-1 Cardioprotective Mechanism of Action: The current evidence base for a 
direct and/or indirect cardioprotective role for endogenous GLP-1 is compelling. The 
mechanisms, however, underlying this beneficial effect remain unknown. Several studies 
have suggested a possible link to pro-survival kinases such as PI3K, Akt, GSK-3β, 
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p70s6K, ERK1/2 and p38-MAPK and activation of cyclic GMP- and cyclic AMP-
dependent pathways24-27,30,35-38. There is also the possibility of positive GLP-1-mediated 
actions on cardiomyocyte apoptosis, endogenous antioxidant defence mechanisms and 
oxidative stress24,29,30,38. None of these studies have thus far been conclusive. Potentially 
GLP-1 and its analogues thereof could well replicate or augment the cardioprotective 
effect of ischaemic preconditioning. The host laboratory has a longstanding and 
established interest in this phenomenon, which describes the cardioprotection 
accumulated against subsequent MI through brief episodes of sub-lethal I/R injury39. 
Bradykinin, angiotensin, endorphins and other short peptides have been shown to pre-
condition the myocardium in the absence of an ischaemic stimulus in animal models40. 
Binding of these ligands triggers an intracellular signalling cascade that eventually 
activates protein kinase C- (PKC-) and mitogen-activated protein kinases (MAPK: 
especially p38-MAPK). This process mediates the opening of K+ATP channels in 
cardiomyocyte and/or mitochondrial membranes which ultimately serves to delay cell 
death by inhibiting the mitochondrial permeability transition pore (mPTP)41-43. Glycogen 
synthase kinase-3 (GSK-3) lies immediately proximal to the mPTP in the signalling 
cascade and is thought to be the point of integration for converging cardioprotective 
signals in preconditioning. Its inactivation is generally considered to be fundamental to 
the prevention of mPTP opening in cardiomyocytes44-48.  
Summary: In addition to promoting weight loss and improving glycaemia, Liraglutide is 
likely to have clinically relevant cardioprotective actions. In particular it offers the 
tantalising prospect of a direct (or indirect) anti-ischaemic action that could reduce 
angina burden; especially in those non-diabetics with established chronic CAD. The 
mechanism of this action is not yet fully understood. 
9. Aims 
Study 1: To determine the concentration of Liraglutide that provides maximum 
protection against infarction using an established ex vivo buffer-perfused isolated 
mouse heart model.  
Study 2: Using this concentration, to determine if Liraglutide-initiated cardioprotection 
depends on the usual preconditioning kinases: PKC-, GSK-3 and p38-MAPK, using 
targeted knock-in or knock-out Langendorff-perfused mouse hearts. 
Study 3: To determine whether Liraglutide-stimulated cardioprotection exhibits the 
tachyphylaxis usually found with agents that mimic ischaemic pre-conditioning. 
Study 4: To determine whether chronic exposure to Liraglutide after coronary artery 
ligation has a beneficial effect on left ventricular remodelling and improves survival. 
Study 5: To examine the potential antianginal action of Liraglutide in non-diabetic 
patients with known chronic CAD awaiting elective PCI using serial exercise stress 
testing to provoke myocardial ischaemia. 
10. Experimental Details and Design of Proposed Investigations:  
Study 1 - Determination of the optimal cardioprotective concentration of 
Liraglutide in an isolated mouse heart model: A recent study has indicated that a 
pre-treatment regime of Liraglutide over 24 hours or 7 days confers a significant benefit 
to the recovery of cardiac function following I/R injury in mice30. These findings 
warrant further investigation since they suggest a possible lack of tachyphylaxis and 
potentially a novel indirect cardioprotective mode of action. The report did not, 
however, include a dose-response relationship to determine the concentration of 
Liraglutide able to promote the maximal reduction in infarct size. We aim to elucidate 
this optimal concentration by using an existing model of infarct volume assessment in 
Langendorff-perfused mouse hearts with which the host laboratory is familiar and has 
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extensive experience48-57. In brief male C57BL/6 mice will be anaesthetised, hearts 
rapidly excised and retrogradely perfused, via aortic cannulation, with ice-cold modified 
Krebs-Henseleit buffer at a constant pressure of 80 mmHg equilibrated with 95% O2 
and 5% CO2. A fluid-filled balloon is then inserted into the left ventricular cavity to 
monitor contractile function with left ventricular end-diastolic pressure (LVEDP) set at 
between 2-8 mmHg. The hearts will be paced atrially at a rate of 580 bpm and coronary 
flow measured by timed collection of the perfusate. After 40 minutes stabilisation, 
hearts fulfilling established criteria, are then exposed to varying, previously documented 
concentrations (75 g/ml, 150 g/ml, 200 g/ml and 250 g/ml), of Liraglutide per ml 
of perfusate for 10 minutes prior to a 5-minute washout period30,58. Immediately after 
this the isolated heart is then subjected to 30 minutes of global ischaemia followed by 2 
hours of reperfusion48-57. At the end of reperfusion hearts are perfused with 5 ml of 1% 
triphenyl tetrazolium chloride (TTC) in phosphate-buffered saline (PBS) for 1 minute 
then placed in an identical solution at 37C for 10 minutes. The atria are then removed, 
remaining myocardium blotted dry and weighed and then stored at -20C. The hearts 
are subsequently thawed, fixed in 2.5% glutaraldehyde and set in 5% agarose before 
short axis sections are taken for risk and infarct volume analysis by an investigator 
blinded to drug assignment. Control mice will be exposed to an equivalent volume of 
PBS (vehicle) added to the perfusate for 10 minutes prior to washout.  Left ventricular 
developed pressure (LVDP), as a function of myocardial recovery, will be monitored 
continuously throughout the stabilisation, ischaemia and reperfusion stages in all 
isolated perfused hearts. TTC-negative infarction volume will be expressed as a 
percentage of total left ventricular volume. 
Study 2 - Determination of the effect of gene-specific pro-survival kinase-
targeted mouse lines on Liraglutide cardioprotection in an ex vivo isolated 
mouse heart model: This series of experiments should allow us to provisionally 
determine whether Liraglutide cardioprotection is novel or adopts standard, firmly 
established, pro-survival kinases. The host laboratory has in-depth experience with 
studying PKC-, GSK-3 and p38-MAPK targeted mouse lines, all of which are 
essential components in the signalling cascade intrinsic to ischaemia-driven myocardial 
necrosis48,50,52. Gene-targeted mice bred on to the C57BL/6 background strain will be 
used. In order to minimise genetic variance within strains heterozygote breeding pairs 
will be used to produce mice homozygous for the wild-type or the targeted allele: wild 
type (PKC-+/+) and PKC- null (PKC--/-); wild type (GSK-3+/+) and inhibition-
resistant GSK-3, where a serine at position 9 crucial to the autoinhibitory motif is 
substituted for alanine, (GSK-39A/9A) and wild type p38 (p38WT/WT) or p38 
rendered resistant to inhibition by SB203580 (p38DR/DR). All these lines have been 
previously described by the host laboratory48,50,52. Each mouse line will undergo the same 
protocol as our first set of experiments using the optimal concentration of Liraglutide in 
the perfusate determined above. We will examine specific mouse lines in a sequential 
fashion starting with PKC- followed by GSK-3 and then p38-MAPK. To the best 
of our knowledge this assessment of the purported cardioprotection afforded by 
Liraglutide in gene-targeted mouse lines has not yet been detailed in the literature. The 
host laboratory has demonstrated that PKC- activation is essential for the reduction in 
infarction that follows early ischaemic preconditioning50. If Liraglutide-stimulated 
cardioprotection works via established pro-survival pathways we would expect to see a 
reduction in infarct size in the wild-type (PKC-+/+) but not the knock-out (PKC--/-) 
mice. It is important to note GSK-3 null mice are not viable, and since it is inactivation 
of this kinase that leads to protection, such mice would not in any case be particularly 
relevant59. GSK-39A/9A mice express a non-inhibitable form of the kinase. According to 
accepted consensus we would expect to find infarct size reduction in the wild type 
GSK-3 mice but not in the non-inhibitable mouse line.  
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The mechanism of p38-MAPK action is perhaps slightly more complex. Work 
emanating from the host laboratory has revealed that activation of p38- and not p38-
MAPK is required for ischaemic preconditioning60. This theory was tested by assessing 
the responses to an inhibitor SB203580 and utilising a chemical genetic approach in 
which either the p38 (DR) or p38 (DR) alleles were targeted to substitute the 
“gatekeeper” threonine residue (T106M), thereby preventing the binding of SB203580 
but not altering kinase activity. We will therefore use 10 µmol/L of SB203580 given for 
10 minutes prior to ischaemia on the Langendorff rig. We would expect to see a 
reduction in infarct size in the p38DR/DR mice after I/R injury following exposure to 
Liraglutide. Wild type p38 mice will not display these positive effects since kinase 
activation will be inhibited by SB203580. A separate cohort of gene-targeted mice for all 
3 pro-survival kinases in question will also be exposed to a PBS vehicle in the perfusate 
and used as negative controls. Table 1 (below) summarises the predicted results if 
Liraglutide were to follow the established signalling cascade widely accepted as central 
to ischaemic pre- and post-conditioning. If these results were to differ from observed 
findings it would suggest GLP-1R agonist-mediated protection differs from the usual 
GPCR-initiated signalling and warrants further detailed biochemical analysis.     
Table 1 Expected results for specific gene-targeted mice pre-treated with 
Liraglutide or PBS. 
















Liraglutide Yes No Yes No No Yes 
PBS vehicle No No No No No No 
 
Study 3 - Verification of the optimal cardioprotective concentration of 
Liraglutide in an in vivo murine model: A pre-treatment regime will be used to 
investigate whether Liraglutide cardioprotection exhibits tachyphylaxis, as befits an 
agent incorporating standard signalling pathways. Intriguingly, recent reports suggest 
protection is still present despite 7 days of Liraglutide exposure30. There are 2 principal 
reasons for this unexpected finding. The first possibility is that during prolonged 
Liraglutide exposure the cardiac protein expression profile is altered and that unlike 
short-term exposure, protection is not reliant on post-translational modification by 
kinases. The other possibility is that protection depends on other GLP-1R-initiated 
pathways present in non-cardiac tissue. As before male C57BL/6 mice will be pre-
treated with the optimal concentration of Liraglutide at an equivalent intraperitoneal 
(IP) dose once daily for 7 days. A parallel control group of mice will be treated with an 
equivalent volume of PBS once daily. Daily weights and blood glucose will be 
monitored. With respect to the literature we would expect to see a cardioprotective 
action independent of weight loss and very little adverse fluctuation in blood glucose 
levels. The in vivo model of acute myocardial I/R injury has been well documented in 
the past24,61,62. In brief on day 8 the mice are anaesthetised by isoflurane inhalation. A 
tracheostomy is performed and an endotracheal tube positioned to allow ventilation. A 
catheter is placed in the right jugular vein for further drug infusion. The left carotid 
artery is cannulated to monitor mean arterial pressure and heart rate. The heart is 
exposed via a left thoracotomy incision and an 8-0 nylon suture is placed around the left 
anterior descending (LAD) artery which is then threaded through a plastic snare to 
allow reversible occlusion of the coronary artery. Liraglutide- and PBS-treated mice will 
then be randomised in a 1:1:1:1 fashion to receive a single IP dose of Liraglutide or PBS 
vehicle 15 minutes prior to ischaemia on day 8. Thirty minutes of ischaemia will then be 
induced by tightening the snare around the LAD artery and confirmed by the 
development of myocardial pallor, hypokinesia, a fall in blood pressure, and ST-segment 
changes on the ECG. After 30 minutes the snare is released to allow 120 minutes of 
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reperfusion to occur. Mice will then be euthanized immediately post reperfusion, hearts 
rapidly excised and, as described above, infarction volume in addition to other 
histochemical and biochemical analyses will be performed along with demarcation of 
the risk zone by retying the coronary snare whilst infusing Evan’s Blue dye. All 
parameters will be measured by an investigator blinded to treatment arm. This regime 
will yield 4 groups, (i) chronic Liraglutide and pre-ischaemic Liraglutide, (ii) chronic 
vehicle and pre-ischaemic vehicle, (iii) chronic Liraglutide and pre-ischaemic vehicle and 
(iv) chronic vehicle and pre-ischaemic Liraglutide. A cohort of mice will be randomised 
to exactly the same protocol followed by a sham procedure to act as “no infarct” 
negative controls. If our findings confirm those of others, suggesting protection is still 
present with chronic exposure, we will determine if cardiac transcriptional change or 
extra-cardiac effects are the cause by excising hearts after 8 days and measuring 
sensitivity to infarction in Langendorff mode. If this suggests alterations intrinsic to the 
heart, experiments will be repeated in-vivo using any targeted mouse lines in which 
acute protection is absent. This may allow the “sensing” kinase to be determined and 
provide greater interrogative power to the transcriptional profiling studies that would 
form the basis of a follow up application. Ultimately these experiments should help to 
delineate whether Liraglutide cardioprotection is direct or indirect.  
Study 4 - To determine whether Liraglutide can positively impact on cardiac 
remodelling post regional myocardial infarction in mice: The clinical validity of 
Liraglutide as a preconditioning agent is limited by the same fundamental constraint that 
has hampered all other postulated agents before it: the inability to predict the moment 
of coronary artery occlusion and therefore the onset of ischaemia. There is, however, 
the possibility that Liraglutide can act in the post-infarct period and have a beneficial 
effect on cardiac remodelling and overall function. This will be tested in vivo with an 
identical protocol to the last set of experiments detailed above. In this case, however, 
mice will not be pre-treated with Liraglutide or vehicle. Instead they will undergo 
permanent LAD artery ligation to induce regional transmural infarction on day 1. Thirty 
minutes after infarction the mice will commence a 14-day course of once-daily IP 
Liraglutide at the optimal concentration established previously. Control mice will be 
given an equal volume of IP PBS vehicle. Daily weight and blood glucose measurements 
will be recorded as before. A separate negative control cohort of mice will have a sham 
procedure and then be randomised to either Liraglutide or PBS vehicle. At day 15 all 
mice will be euthanized and thorough cardiac examinations will be performed. Cardiac 
hypertrophy as a measure of adverse remodelling post I/R injury will be recorded as a 
proportion of heart weight to body weight (HW/BW) in all deceased mice as will 
chamber dimension by post-mortem morphometry. High frequency ultrasound 
biomicroscopy in conjunction with MR imaging and measurement of contractile 
performance by simultaneous recording of pressure and volume will be conducted on all 
hearts regardless of treatment strategy to examine LV function and dimensions in detail. 
These are all techniques with which the host department is familiar63-66.  
Study 5 - Determination of the potential antianginal action of Liraglutide in 
chronic stable angina patients: A series of small animal and human studies have 
indicated a significant cardioprotective role for GLP-1 and its synthetic derivatives, 
independent of glycaemic control and weight loss24-33. What is of particular interest is the 
very real possibility of using these agents in non-diabetic patients30,34. Studies have thus 
far looked predominantly at cardioprotection in the context of acute coronary 
syndromes and LVSD. We aim to study the effects of chronic Liraglutide administration 
in a cohort of non-diabetic stable angina patients with known obstructive lesions 
awaiting elective PCI. The host laboratory has developed an established and 
reproducible exercise protocol for the study of warm-up angina in CHD patients which 
will be adopted for this set of experiments and has been previously documented67,68. In 
brief non-diabetic patients with a positive exercise test (>0.2 mV of planar or down-
sloping ST segment depression) and angiographic evidence of >70% stenosis in the 
LAD artery with or without other stenoses will be enrolled on a consecutive basis. 
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Patients will need to have a normal resting ECG without bundle branch aberration or 
other conduction disturbance, normal LV function and no evidence of LV hypertrophy. 
Patients will be excluded if there is a history of previous MI, LVSD, cardiomyopathy or 
valvular heart disease. Once recruited, patients will have all anti-anginal medication 
withdrawn cautiously but will continue to take aspirin (or clopidogrel) and statins. Both 
investigator and patient will be blinded to the study drug. Patients will receive a once 
daily subcutaneous administration of 1.2 mg of Liraglutide or an equivalent volume of 
placebo for a 3-day period prior to and on the morning of the exercise test. Patients will 
then crossover to the opposite regime after a 4-day washout period and proceed to their 
second exercise test a week later. The primary endpoints will be set as the rate pressure 
product (RPP) at 0.1 mV ST depression (STD) and the time to 0.1mV STD. The 
secondary endpoints will be exercise duration, degree of STD at equivalent workloads 
during peak exercise and recovery time to 0.05 mV STD. Patients will be asked to keep 
an angina burden diary throughout the trial period. Criteria for terminating a stress test 
will be: 1) physical exhaustion, 2) severe chest pain, 3) attaining maximal age-related 
heart rate, 4) STD >0.4mV, or 5) severe dysrhythmia. We would expect the 
administration of Liraglutide to improve both primary and secondary endpoint markers. 
Following placebo administration we would expect tolerance of ischaemia to be similar 
to that of the index study each patient would have had prior to recruitment. This set of 
experiments could help justify the chronic use of Liraglutide as an overall anti-ischaemic 
agent and help prolong the time to or prevent deleterious I/R injury. The previous set 
of experiments could then support the continued use of Liraglutide to improve 
myocardial functionality and recovery after an ischaemic event.        
11. Power Calculations: Please refer to the attached ‘Justification for Funding 
Required’ section for a detailed summary of sample size calculations for each of the 
experiments detailed above. 
12. Expected Value of Results: Despite the improvements in survival mitigated by 
established therapies such as aspirin, ACE inhibitors, and statins, chronic CAD is still 
responsible for 1 in every 5 deaths in the Industrialised World. It is therefore imperative 
that we continue to investigate novel agents that could potentially reduce morbidity and 
mortality. If we demonstrate that Liraglutide mediates cardioprotection via the 
established GPCR intracellular signalling system then clearly this can be regarded as 
direct “run-of-the-mill” post-translational gene modification and therefore likely to 
suffer the same disadvantages seen with other preconditioning mimetics, namely 
tachyphylaxis, which will limit its clinical utility. It is of fundamental importance, 
therefore, that we determine how GLP-1 instigates protection. Indeed if we were to 
elucidate a novel mechanism of action, for instance through the concept of metabolic 
modulation inducing a shift towards increased glucose uptake and utilisation by the 
threatened myocardium, the novelty and clinical application of Liraglutide, outside of its 
established role in T2DM, would be considerably enhanced. Results from the small 
clinical study may also cement the notion that Liraglutide, and therefore GLP-1, has an 
anti-ischaemic action. This could constitute both clinical efficacy and safety proof-of-
concept data to pave the way for a much larger scale randomised controlled trial in a 




Establishing Haemodynamic Stability of an Isolated Murine Heart 
Langendorff Perfusion Model 
The isolated perfused heart system, as first originated by Oscar Langendorff, allows for the 
examination of cardiac inotropic, chronotropic and vascular effects along with responses to 
ischaemia-reperfusion injury without the complications associated with an intact animal 
model. The model has evolved to encompass both constant pressure and constant flow 
derivatives in both recirculating and non-recirculating modes. For the purposes of the 
planned experiment above, we would be using a non-recirculating (single pass), constant 
pressure model in which the coronary arteries are retrogradely perfused with modified 
Krebs-Henseleit (K-H) buffer flowing down the aorta (as opposed to an in vivo blood flow 
from the left ventricle into the aorta). 
 
Objectives 
To ensure the validity of the planned Study 1 experiment, it was first essential to establish 
reproducible haemodynamic stability and infarct volume data from performing isolated 
murine heart Langendorff perfusion using standardised perfusion only and global ischaemia 
and reperfusion protocols. No exogenous substances were tested in this first set of 
experiments. The protocols can be seen in Figure 1 below. As with the main experiments 
the primary endpoint was TTC-negative infarction volume expressed as a percentage of 
total left ventricular volume. For the perfusion only protocol the aim was to demonstrate a 
negligible infarction volume with respect to total left ventricular volume. For the global 
ischaemia-reperfusion protocols the aim was to demonstrate a linear dose-response 
relationship between a stepwise increase in the duration of ischaemia and predicted 
increase in infarction volume. 
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Figure 1 Standard perfusion and ischaemia-reperfusion protocols used to confirm reproducibility of 





Mouse Colony Maintenance and Handling 
All experiments were performed in accordance with the United Kingdom Home Office 
‘Guidance on the Operation of Animals (Scientific Procedures) Act 1986’. Mice were able to 
acclimatize to the animal house conditions for a period of at least one week prior to 
sacrifice. Animals were maintained in box cages at 19°C, on a 12-hour light/dark cycle and 
allowed access to food and water ad libitum. Only C57 Black (C57BL/6) mice were used for 




Mice were anaesthetised with an intraperitoneal (IP) injection of 0.1 ml/g of a 50:50 
mixture of pentobarbitone (Animalcare Ltd, UK) and heparin 1000U/ml (Wockhardt Ltd, 
UK). Once all reflexes were absent, the animal was weighed and transferred to a dissecting 
tray near to the Langendorff perfusion rig. An incision was made immediately beneath the 
xiphisternum to expose the peritoneum and extended laterally along either side of the rib 
cage to expose the diaphragm. The diaphragm was cut off the ribs following the line of the 
anterior costodiaphragmatic junction, exposing the inferior surface of the pericardium and 
lungs. The thorax was then opened with incisions either side lateral of the sternum starting 
at the diaphragm and proceeding cephalad up to the first rib along the costochondral 
junctions parallel to the sternum. The anterior thoracic wall was deflected back over the 
animal’s head and fixed there with tape adhered to the dissecting tray. The mediastinal 
structures were separated from the anterior thoracic wall with scissors. Using blunt 
forceps, the heart was held at its mediastinal structures and the connective tissue severed 
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by scissors. The excised heart and lungs were placed in ice-cold K-H buffer to arrest 
myocardial contraction and transferred to the Langendorff rig. Here the thymus was 
identified and pulled apart along its midline using blunt forceps on either side, to expose 
the intact ascending aorta and arch. A single cut was made just beneath the aortic arch to 
preserve as much ascending aorta as possible. Using two pairs of very fine forceps the heart 
was suspended on opposing sides of the exposed ascending aorta. The aorta was 
cannulated with a 23-guage blunt and grooved stainless steel needle on the Langendorff rig 
while perfusate was flowing from the cannula. Flow of K-H buffer during aortic cannulation 
allowed for perfusion of the excised heart and prevented the accumulation of air 
microbubbles in the cannula. The heart was then held on the needle using a blood vessel 
clamp while securing the aortic cannula with a silk suture. Once cannulated the heart was 
retrogradely perfused with modified K-H buffer at a constant pressure of 80 mmHg. The K-
H buffer had been prefiltered using a 0.5 μM micro-filter (Whatman, Germany) and held in 
a reservoir at the top of the Langendorff rig prior to being warmed to between 36.8–37.2°C 
as it passed through the perfusion apparatus. While doing so, the perfusate was also 
constantly bubbled through with 95% O2/5% CO2 gas. Clearly the period between cessation 
of perfusion after donor heart excision followed by reperfusion upon aortic cannulation is 
time critical, since the organ has only the oxygen and substrate contained within the 
coronary vessels at the time of removal to sustain its high metabolic activity. Temporary 
cardioplegia in ice-cold K-H buffer was used to stave off myocardial damage to some 
extent. 
 
Isolated Heart Perfusion and Monitoring 
Once mounted and secured on the aortic cannula, the left atrium was identified and 
removed with scissors. A deflated balloon fashioned from plastic wrap and secured to a 
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blunt stainless steel needle was inserted into the left ventricle (LV). The balloon had already 
been connected to a pressure transducer, which was coupled to a 4SP Powerlab (AD 
Instruments, UK). Once inside the LV, the balloon was gradually inflated with saline until LV 
end diastolic pressure (LVEDP) stabilised to between 2-5 mmHg. The balloon had been 
constructed so that full inflation size would slightly exceed the maximum expanded volume 
of the LV to avoid the effects of measuring the resistance of the balloon to stretch. Since 
spontaneous heart rate in a perfused heart preparation is usually significantly below that in 
the intact animal, a 0.075 mm silver insulated pacing wire was inserted epicardially into the 
right ventricle near the apex. The stainless steel aortic cannula served as the ground. Both 
wires were attached to a pacing box (SRI Ltd Stimulator, UK). Hearts were paced at 580-600 
beats per minute, during which square wave pulses of 5 ms duration at 1 volt amplitude 
were delivered. Once pacing had been initiated, the perfused heart was immersed in a 
water-jacketed chamber filled with K-H buffer kept at a temperature of 36.8–37.2°C. All 
hearts were initially paced and stabilised for 30 minutes (see Figure 5 above) prior to 
following a perfusion only or ischaemia-reperfusion protocol. Left ventricular developed 
pressure (LVDP – calculated as the difference between systolic and diastolic pressures), 
LVEDP and heart rate (paced and unpaced) were continuously monitored using LabChart 
software (Version 7.3.7, PowerLab, AD Instruments, UK). Coronary flow, defined as the 
volume displaced from the temperature-constant K-H buffer bath in which the perfused 
heart was immersed over 1 minute, was also continuously measured. 
 
Baseline Inclusion Criteria 
For inclusion to this first set of reperfusion studies, hearts had to fulfil the following 
inclusion criteria during the stabilisation period: 
 coronary flow ≥1.5 ml/min; 
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 heart rate >300 beats per minute prior to initiation of pacing; 
 LVDP ≥60 mmHg; 
 time from thoracotomy to aortic cannulation <3-5 minutes; and 
 no persistent dysrhythmia during the 30-minute stabilisation period. 
 
Myocardial Infarct Area Staining 
Following completion of a pre-determined perfusion protocol, the aortic cannula was 
removed from the Langendorff rig and the heart perfused with 10 ml of warmed 1% TTC 
dissolved in K-H buffer at an approximate rate of 2 ml/min. The run-off from the TTC 
perfusate was used to fill an Eppendorff tube in which the heart was placed once the 
perfusion was complete and the heart removed from the cannula. The heart was left to 
stand in the Eppendorff tube for 10 minutes before the TTC fluid was removed and 
replaced with 10% formaldehyde (VWR International Ltd, UK). The tube was left in a 
refrigerator at 2-8°C overnight. On the following day the formaldehyde was removed and 
replaced with double-distilled water. Thereafter the fixated heart was placed on a glass 
block at which point any major vessels and atria were trimmed off. A needle was then used 
to pierce the heart from apex through to base and suspend it in an empty well. The well 
was filled with 3% liquid agarose gel (AGTC Bioproducts Ltd, UK) to fully immerse the heart. 
The heart was allowed to set in agarose for 30 minutes in a refrigerator. The agarose heart 
block was then sectioned transversely from apex to base in 0.7 mm slices using a vibratome 
(Agar Scientific, UK). Each slice was transferred to a 0.7 mm deep glass slide and laid out in 
sequence prior to being covered with a clear slide on top and suspended in double-distilled 
water. The heart sections were digitally scanned before using ImageJ (National Institute of 
Health, USA) image processing and analysis software to determine infarct size (IS) 
expressed as TTC-negative infarction area as a percentage of the area at risk (AAR). 
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Results 
Baseline morphological and haemodynamic characteristics 
There was a significant difference in mouse weight between groups (Table 1). A wide range 
(24-38 g) of mice weight, and hence age, were used for the purposes of these preparatory 
experiments. For the main experiment, we planned to use a narrower range of between 24-
32 g. There were no significant differences in baseline LVEDP and LVDP between hearts 
subjected to the different perfusion protocols. Coronary flow did, however, significantly 
differ between groups. This difference can be attributed to the first three hearts I 
performed Langendorff perfusion on, using the stability (no ischaemia) protocol, in which 
coronary flow measurements were disproportionately high (see Table 1). I would suggest 
this reflects my relative inexperience with the procedure at the time. Moving forward, a 1-
way ANOVA of the hearts exposed to the 3 different ischaemia-reperfusion protocols 
indicated no significant difference (Table 1). I did not measure heart weight during these 
experiments. For the main experiment heart weight will be measured to allow for infarct to 
heart volume comparisons to be made. 
Table 1 Morphological and baseline haemodynamic characteristics of excised murine hearts 
Haemodynamic parameters were obtained after the 30-minute stabilisation period for each experimental protocol. Values 
represent mean ± SD. 








1-WAY ANOVA  
p 
Mouse weight (g) 32.6 ± 4.3 32.7 ± 0.5 27.6 ± 2.9 26.0 ± 2.3 0.03 
LV end diastolic 
pressure (mmHg) 
4.5 ± 2.5 6.3 ± 2.2 3.8 ± 2.6 4.3 ± 1.5 0.56 
LV developed 
pressure (mmHg) 
80.0 ± 17.7 83.0 ± 15.4 87.3 ± 6.1 81.0 ± 16.9 0.93 
Coronary flow 
(ml/min) 
5.17 ± 1.70 3.00 ± 0.50 3.14 ± 0.28 2.85 ± 0.25 0.03 
Coronary flow 
(ml/min) 
- 3.00 ± 0.50 3.14 ± 0.28 2.85 ± 0.25 0.62 
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Haemodynamic function 
The stability protocol demonstrated an approximate 25% decrement in LVDP during the 3-
hour perfusion period, which is expected and represents a degree of pacing-induced 
myocardial fatigue (Figure 2). Consistent with this, coronary flow rate also fell by 
approximately 35%. Following the 30-minute stabilisation period, LVEDP remained virtually 
constant throughout the perfusion protocol indicating maintenance of diastolic function. 
Haemodynamic response to increasing periods of ischaemia followed by reperfusion can be 
seen in Figures 3-5 below. With respect to developed pressure, there was modest recovery 
of myocardial performance following 15 minutes of ischaemia (Figure 3). However, 
following 30- and 45-minute global ischaemia intervals negligible recovery was seen. 
Indeed in 2 of the 4 hearts sampled for the 45-minute ischaemia protocol, ventricular 
contractions did not resume at all. 
 





































































Figure 3 Changes in left ventricular developed pressure during the ischaemia-reperfusion protocols. 
Error bars represent SD. 
 
Figure 4 Changes in left ventricular end diastolic pressure during the ischaemia-reperfusion 
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Figure 5 Changes in coronary flow during the ischaemia-reperfusion protocols. Error bars represent 
SD. 
 
Left ventricular end diastolic pressure could be seen to rise significantly during and 
immediately post ischaemia reflecting a steep rise in intraventricular pressure as a 
consequence of ischaemic contracture (Figure 4). After the 15-minute ischaemia 
protocol, LVEDP did fall again reflecting some degree of myocardial recovery. 
Ultimately, however, LVEDP remained well above baseline in hearts following all 
three ischaemia protocols.  
 
As expected there was a significant difference in recovery of developed pressure in 
response to increasing periods of ischaemia during all three protocols (Table 2). This 
finding was echoed when post ischaemia LVDP was expressed as a percentage of 
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varying degrees of an ischaemic insult but did not differ significantly between 
groups (Figure 5). As such the duration of ischaemia did not appear to influence 
coronary flow during recovery (Table 2). This finding was replicated when coronary 
flows were normalised to pre-ischaemic baseline levels (Figure 7). 
 
Table 2 Comparison of haemodynamic parameters during recovery following different durations of ischaemia. 
Values shown are mean ± SD. LVDP=left ventricular developed pressure. CF=coronary flow. 




1-WAY ANOVA  
p 
LVDP at 30 minutes recovery (mmHg) 47.3 ± 18.8 13.3 ± 11.5 2.3 ± 2.3 0.005 
LVDP at 60 minutes recovery (mmHg) 32.8 ± 11.8 11.0 ± 5.6 2.3 ± 1.5 0.002 
LVDP at 120 minutes recovery (mmHg) 31.0 ± 5.5 6.8 ± 1.9 4.0 ± 3.7 <0.0001 
CF at 30 minutes recovery (ml/min) 1.9 ± 0.7 1.6 ± 0.2 1.2 ± 0.2 0.2 
CF at 60 minutes recovery (ml/min) 1.7 ± 0.6 1.5 ± 0.3 1.1 ± 0.2 0.3 




Figure 6 Changes in left ventricular developed pressure normalised to baseline levels following 
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Figure 7 Changes in coronary flow normalised to baseline levels following different durations of 
ischaemia. Error bars represent SD. 
 
Infarct size 
Histological sections of TTC-stained myocardium for each perfusion protocol can be seen 
below (Figures 8-11). 
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Figure 9 TTC-stained sections of hearts following a 15-minute ischaemia protocol. 
 
 




Figure 11 TTC-stained sections of hearts following a 45-minute ischaemia protocol. 
 
Using ImageJ processing software, IS was calculated by expressing the TTC-negative 
infarction area as a percentage of the AAR. Global ischaemia of 15, 30 and 45 minutes 
duration resulted in an IS/AAR of 30.5±1.4, 44.4±1.9 and 62.7±6.1 respectively (Figure 12). 
An obvious limitation of this process is that mapping areas of TTC-stain digitally is a 
subjective process. For the main experiments, therefore, two investigators blinded to 
treatment arm and perfusion protocol will be asked to kindly estimate infarct sizes. 
Nevertheless, in this particular study there was a clear stepwise increase in IS/AAR 
corresponding to increasing duration of ischaemia (Figure 12). 
 
The IS/AAR in all three ischaemia protocols was significantly greater than obtained after the 
stability protocol (p<0.0001). There was also a significant increase in infarct size between 
15- and 30-minute ischaemia protocols (p<0.0001) and between 30- and 45-minute 
ischaemia protocols (p<0.0001). 
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This set of experiments helped to establish the haemodynamic stability of an isolated 
murine heart Langendorff perfusion technique in my hands. Unfortunately, given the 
significant delays in starting recruitment to the LIONESS Trial a series of planned 
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